var title_f25_9_25744="Impetigo in HIV";
var content_f25_9_25744=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F63238&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F63238&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Impetigo",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Staphylococcus aureus caused this large plaque on the upper lip and cheek.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from The Skin and Infection: A Color Atlas and Text. Sanders CV, Nesbitt LT Jr (Eds) Williams &amp; Wilkins, Baltimore 1995.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_9_25744=[""].join("\n");
var outline_f25_9_25744=null;
var title_f25_9_25745="psoriasiform change in scalp";
var content_f25_9_25745=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F54249&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F54249&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Psoriasiform changes in the scalp of a patient with dermatomyositis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 271px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John H. Stone, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_9_25745=[""].join("\n");
var outline_f25_9_25745=null;
var title_f25_9_25746="Patient information: Gluten-free diet (The Basics)";
var content_f25_9_25746=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/86971\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_table\" href=\"UTD.htm?26/14/26859\">",
"         Gluten-free foods",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_table\" href=\"UTD.htm?39/48/40716\">",
"          Foods that contain gluten",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?13/6/13410\">",
"         Patient information: Celiac disease (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/38/40546\">",
"         Patient information: Vitamin supplements (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?35/31/36339\">",
"         Patient information: Celiac disease in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/14/11492\">",
"         Patient information: Celiac disease in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Gluten-free diet (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H64311477\">",
"      <span class=\"h1\">",
"       What is a gluten-free diet?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A gluten-free diet is a diet that doesn&rsquo;t contain any gluten. Gluten is a protein that is found in wheat, rye, barley, and (sometimes) oats. Many foods, such as breads, pasta, pizza, cereals, and crackers, have gluten in them. People who are on a gluten-free diet should not eat any foods with gluten.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H64311492\">",
"      <span class=\"h1\">",
"       Who should be on a gluten-free diet?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People with a condition called celiac disease should be on a gluten-free diet. Celiac disease is a condition that affects the body&rsquo;s ability to break down certain foods. People with celiac disease get sick if they eat foods with gluten. They need to be on a strict gluten-free diet for their whole life.",
"     </p>",
"     <p>",
"      If you think you have celiac disease, don&rsquo;t start a gluten-free diet until after you are tested for the disease. That&rsquo;s because what you eat can affect your test results.",
"     </p>",
"     <p>",
"      More and more, though, people without celiac disease are eating a gluten-free diet. They might have heard that this diet can help them lose weight or feel better. It&rsquo;s true that a gluten-free diet can be healthy. But it also sometimes keeps people from getting all the nutrition they need. If you are thinking about being on a gluten-free diet, ask your doctor or nurse if it&rsquo;s a good choice for you.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H64311507\">",
"      <span class=\"h1\">",
"       How do I get started?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To get started, you will work with a dietitian (food expert) or other professional who has experience with a gluten-free diet. He or she will:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Teach you which foods are fine to eat and which foods you should avoid",
"       </li>",
"       <li>",
"        Help you plan balanced meals so that you get the nutrition you need",
"       </li>",
"       <li>",
"        Give you gluten-free recipes",
"       </li>",
"       <li>",
"        Help you find gluten-free substitutes for your favorite foods (such as pasta or cookies)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      You can get advice and help from other people, too. Ask your doctor or nurse if there is a local support group for people with celiac disease. Or you can look at Web sites, such as",
"      <a class=\"external\" href=\"file://www.celiac.org/\">",
"       www.celiac.org",
"      </a>",
"      ;",
"      <a class=\"external\" href=\"file://www.celiac.com/\">",
"       www.celiac.com",
"      </a>",
"      ; and",
"      <a class=\"external\" href=\"file://www.csaceliacs.org/\">",
"       www.csaceliacs.org",
"      </a>",
"      .",
"     </p>",
"     <p>",
"      It can be hard to learn how to manage a gluten-free diet, especially at first. But it usually gets easier with practice and over time.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H64311522\">",
"      <span class=\"h1\">",
"       Which foods can I eat?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Foods that are gluten free and fine to eat include the following (",
"      <a class=\"graphic graphic_table graphicRef54353 \" href=\"UTD.htm?26/14/26859\">",
"       table 1",
"      </a>",
"      ):",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Rice, corn, potatoes, quinoa, millet, buckwheat, and soybeans",
"       </li>",
"       <li>",
"        Special flours, pasta, and other products made from these foods and labeled &ldquo;gluten free&rdquo;",
"       </li>",
"       <li>",
"        Fruits and vegetables",
"       </li>",
"       <li>",
"        Meat and eggs",
"       </li>",
"       <li>",
"        Wine and distilled alcoholic drinks, such as rum, tequila, vodka, and whiskey",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Milk, cheese, and other dairy foods are also gluten free. But many people with celiac disease have trouble digesting these foods, especially at first. Doctors usually recommend that people with celiac disease avoid eating dairy products, at least for a short time, while their intestines are healing.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H64311554\">",
"      <span class=\"h1\">",
"       Which foods should I not eat?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You need to avoid all foods made from or with wheat, rye, barley, and (usually) oats (",
"      <a class=\"graphic graphic_table graphicRef86922 \" href=\"UTD.htm?39/48/40716\">",
"       table 2",
"      </a>",
"      ). Ask your doctor or dietitian if you can eat oats.",
"     </p>",
"     <p>",
"      Many types of foods contain or might contain gluten, such as:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Flour, breads, crackers, muffins, and baking mixes",
"       </li>",
"       <li>",
"        Pasta, pastries, and cereals",
"       </li>",
"       <li>",
"        Some sauces, spreads, spices, condiments, and salad dressings",
"       </li>",
"       <li>",
"        Processed meats and meat substitutes (like vegetarian burgers)",
"       </li>",
"       <li>",
"        Beers, ales, lagers, and malt vinegars",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      To know exactly which foods you can eat, you will have to read ingredient labels. Foods that are labeled &ldquo;gluten free&rdquo; or say they are made or processed in a &ldquo;gluten-free facility&rdquo; are fine to eat. Foods that contain wheat are NOT fine to eat. If you are unsure whether a food is gluten free, call the company. Their phone number should be on the package.",
"     </p>",
"     <p>",
"      Some medicines (both prescription and over-the-counter) and vitamin supplements contain a small amount of gluten. But you can still take these medicines if you have celiac disease.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H64311586\">",
"      <span class=\"h1\">",
"       Will I need to take vitamins?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You might. Celiac disease can keep your digestive system from normally absorbing the nutrients in foods. To get all the nutrients you need, your doctor or nurse might recommend that you take a daily vitamin.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H64311601\">",
"      <span class=\"h1\">",
"       Can I eat out?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Many restaurants now have gluten-free menus or foods. But always let the restaurant know you can&rsquo;t have gluten. That way, they can be extra careful when they cook your food.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H64311616\">",
"      <span class=\"h1\">",
"       What if my child is on a gluten-free diet?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your child is on a gluten-free diet, let his or her caregivers, teachers, and school know. Tell them which foods your child can and can&rsquo;t eat. If your child goes to school, you might want to leave a gluten-free treat with the nurse or teacher. That way, your child will have a safe treat when the class has a party.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H64311631\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/6/13410?source=see_link\">",
"       Patient information: Celiac disease (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/38/40546?source=see_link\">",
"       Patient information: Vitamin supplements (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/31/36339?source=see_link\">",
"       Patient information: Celiac disease in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/14/11492?source=see_link\">",
"       Patient information: Celiac disease in children (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?25/9/25746?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86971 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-41.222.196.37-1E842E28B5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_9_25746=[""].join("\n");
var outline_f25_9_25746=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H64311477\">",
"      What is a gluten-free diet?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H64311492\">",
"      Who should be on a gluten-free diet?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H64311507\">",
"      How do I get started?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H64311522\">",
"      Which foods can I eat?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H64311554\">",
"      Which foods should I not eat?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H64311586\">",
"      Will I need to take vitamins?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H64311601\">",
"      Can I eat out?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H64311616\">",
"      What if my child is on a gluten-free diet?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H64311631\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/86971\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/14/26859\">",
"      Gluten-free foods",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_table\" href=\"UTD.htm?39/48/40716\">",
"       Foods that contain gluten",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/6/13410?source=related_link\">",
"      Patient information: Celiac disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/31/36339?source=related_link\">",
"      Patient information: Celiac disease in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/14/11492?source=related_link\">",
"      Patient information: Celiac disease in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/38/40546?source=related_link\">",
"      Patient information: Vitamin supplements (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_9_25747="Colon polyps";
var content_f25_9_25747=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Colon polyps (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?25/9/25747/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/9/25747/contributors\" id=\"au5223\">",
"       Anne Charette, RN, MSN, ANP",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/9/25747/contributors\" id=\"au323\">",
"       Robert H Fletcher, MD, MSc",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?25/9/25747/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/9/25747/contributors\" id=\"se6453\">",
"       J Thomas LaMont, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?25/9/25747/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/9/25747/contributors\" id=\"de8151\">",
"       Shilpa Grover, MD, MPH",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?25/9/25747?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      COLON POLYPS OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     The presence of polyps in the colon or rectum often raises questions for patients and their family. What is the significance of finding a polyp? Does this mean that I have, or will develop, colon or rectal (colorectal) cancer? Will a polyp require surgery?",
"    </p>",
"    <p>",
"     Some types of polyps (called adenomas) have the potential to become cancerous while others (hyperplastic or inflammatory polyps) have virtually no chance of becoming cancerous.",
"    </p>",
"    <p>",
"     When discussing colon polyps, the following points should be considered:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Polyps are common (they occur in 30 to 50 percent of adults)",
"      </li>",
"      <li>",
"       Not all polyps will become cancer",
"      </li>",
"      <li>",
"       It takes many years for a polyp to become cancerous",
"      </li>",
"      <li>",
"       Polyps can be completely and safely removed",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The best course of action when a polyp is found depends upon the number, type, size, and location of the polyp. People who have an adenoma removed will require a follow up examination; new polyps may develop over time that need to be removed.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      COLON POLYP CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     Polyps are very common in men and women of all races who live in industrialized countries, suggesting that dietary and environmental factors play a role in their development.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Lifestyle",
"     </span>",
"     &nbsp;&mdash;&nbsp;Although the exact causes are not completely understood, lifestyle risk factors include the following:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       A high fat diet",
"      </li>",
"      <li>",
"       A diet high in red meat",
"      </li>",
"      <li>",
"       A low fiber diet",
"      </li>",
"      <li>",
"       Cigarette smoking",
"      </li>",
"      <li>",
"       Obesity",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     On the other hand, use of aspirin and other NSAIDs and a high calcium diet may protect against the development of colon cancer. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/23/7541?source=see_link\">",
"      \"Patient information: Colon and rectal cancer screening (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Aging",
"     </span>",
"     &nbsp;&mdash;&nbsp;Colorectal cancer is uncommon before age 40. Ninety percent of cases occur after age 50, with men somewhat more likely to develop polyps than women; therefore, colon cancer screening is usually recommended starting at age 50 for both sexes. It takes approximately 10 years for a small polyp to develop into cancer.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Family history and genetics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Polyps and colon cancer tend to run in families, suggesting that genetic factors are also important in their development.",
"    </p>",
"    <p>",
"     Any history of colon polyps or colon cancer in the family should be discussed with a healthcare provider, particularly if cancer developed at an early age, in close relatives, or in multiple family members. As a general rule, screening for colon cancer begins at an earlier age in people with a family history of cancer or polyps.",
"    </p>",
"    <p>",
"     Rare genetic diseases can cause high rates of colorectal cancer relatively early in adult life. Familial adenomatous polyposis (FAP) and MUTYH-associated polyposis cause multiple colon polyps. Another, hereditary nonpolyposis colon cancer (HNPCC) or Lynch syndrome, increases the risk of colon cancer, but does not cause a large number of polyps. Testing for these genes may be recommended for families with high rates of cancer, but is not generally recommended for other groups.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      TYPES OF COLON POLYPS",
"     </span>",
"    </p>",
"    <p>",
"     The most common types of polyps are hyperplastic and adenomatous polyps. Other types of polyps can also be found in the colon, although these are far less common and are not discussed here.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Hyperplastic polyps",
"     </span>",
"     &nbsp;&mdash;&nbsp;Hyperplastic polyps are usually small, located in the end-portion of the colon (the rectum and sigmoid colon), have",
"     <strong>",
"      no",
"     </strong>",
"     potential to become malignant, and are not worrisome (",
"     <a class=\"graphic graphic_figure graphicRef58531 \" href=\"UTD.htm?12/60/13250\">",
"      figure 1",
"     </a>",
"     ). It is not always possible to distinguish a hyperplastic polyp from an adenomatous polyp based upon appearance during colonoscopy, which means that hyperplastic polyps are often removed or biopsied to allow microscopic examination.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Adenomatous polyps",
"     </span>",
"     &nbsp;&mdash;&nbsp;Two-thirds of colon polyps are adenomas. Most of these polyps do not develop into cancer, although they have the potential to become cancerous. Adenomas are classified by their size, general appearance, and their specific features as seen under the microscope.",
"    </p>",
"    <p>",
"     As a general rule, the larger the adenoma, the more likely it is to eventually become a cancer. As a result, large polyps are usually removed completely to prevent cancer and for microscopic examination to guide follow-up testing.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Malignant polyps",
"     </span>",
"     &nbsp;&mdash;&nbsp;Polyps that contain pre-cancerous or cancerous cells are known as malignant polyps. The optimal treatment for malignant polyps depends upon the extent of the cancer (when examined with a microscope) and other individual factors. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32746?source=see_link\">",
"      \"Approach to the patient with colonic polyps\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      COLON POLYP DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Polyps usually do not cause symptoms but may be detected during a colon cancer screening examination (such as flexible sigmoidoscopy or colonoscopy) (",
"     <a class=\"graphic graphic_picture graphicRef66254 \" href=\"UTD.htm?29/58/30628\">",
"      picture 1",
"     </a>",
"     ) or after a positive fecal occult blood test. Polyps can also be detected on a barium enema x-ray, although small polyps are more difficult to see with x-ray.",
"    </p>",
"    <p>",
"     Colonoscopy is the best way to evaluate the colon because it allows the physician to see the entire lining of the colon and remove any polyps that are found. During colonoscopy, a physician inserts a very thin flexible tube with a light source and small camera into the anus. The tube is advanced through the entire length of the large intestine (colon). (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/30/9698?source=see_link\">",
"      \"Patient information: Colonoscopy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The inside of the colon is a tube-like structure with a flat surface with curved folds. A polyp appears as a lump that protrudes into the inside of the colon (",
"     <a class=\"graphic graphic_picture graphicRef66254 \" href=\"UTD.htm?29/58/30628\">",
"      picture 1",
"     </a>",
"     ). The tissue covering a polyp may look the same as normal colon tissue, or, there may be tissue changes ranging from subtle color changes to ulceration and bleeding. Some polyps are flat (\"sessile\") and others extend out on a stalk (\"pedunculated\").",
"    </p>",
"    <p>",
"     Colonoscopy is also the best test for the follow-up examination of polyps. Virtual colonoscopy using CT technology is another test used to detect polyps in specific circumstances.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      COLON POLYP REMOVAL",
"     </span>",
"    </p>",
"    <p>",
"     Colorectal cancer is the second leading cause of cancer deaths in the United States, accounting for 14 percent of cancer deaths. Colorectal cancer is preventable if precancerous polyps (ie, adenomas) are detected and removed before they become malignant (cancerous). Over time, small polyps can change their structure and become cancerous. Polyps are usually removed when they are found on colonoscopy, which eliminates the chance for that polyp to become cancerous.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Procedure",
"     </span>",
"     &nbsp;&mdash;&nbsp;The medical term for removing polyps is polypectomy. Most polypectomies can be performed through a colonoscope. Small polyps can be removed with an instrument that is inserted through the colonoscope and snips off small pieces of tissue. Larger polyps are usually removed by placing a noose, or snare, around the polyp base and burning through it with electric cautery (",
"     <a class=\"graphic graphic_figure graphicRef63967 \" href=\"UTD.htm?41/4/42063\">",
"      figure 2",
"     </a>",
"     ). The cautery also helps to stop bleeding after the polyp is removed.",
"    </p>",
"    <p>",
"     Polyp removal is not painful because the lining of the colon does not have the ability to feel pain. In addition, a sedative medication is given before the colonoscopy to prevent pain caused by stretching of the colon. Rarely, a polyp will be too large to remove during colonoscopy, which means that a surgical procedure will be needed at a later time.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Complications",
"     </span>",
"     &nbsp;&mdash;&nbsp;Polypectomy is safe although it has a few potential risks and complications. The most common complications are bleeding and perforation (creating a hole in the colon). Fortunately, this occurs infrequently (one in 1000 patients having colonoscopy). Bleeding can usually be controlled during colonoscopy by cauterizing (applying heat) to the bleeding site; surgery is sometimes required for perforation.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      After polyp removal",
"     </span>",
"     &nbsp;&mdash;&nbsp;Medications that can increase bleeding, including aspirin, ibuprofen (Advil&reg;, Motrin&reg;), and naproxen (Aleve&reg;), should be avoided for approximately two weeks after polypectomy. Acetaminophen (Tylenol&reg;) is safe to take. People who require anticoagulant medications such as warfarin (Coumadin&reg;) should discuss how and when to resume this medication with their clinician.",
"    </p>",
"    <p>",
"     A follow up appointment or phone call is usually scheduled after the polyp removal to discuss the results of the tissue analysis and the need for a repeat examination.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      COLON POLYP PREVENTION",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Follow-up examination",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with adenomatous polyps have an increased risk of developing more polyps, which are likely to be adenomatous. There is a 25 to 30 percent chance that adenomas will be present on a repeat colonoscopy done three years after the initial polypectomy. Some of these polyps may have been present during the original examination, but were too small to detect. Other new polyps may also have developed.",
"    </p>",
"    <p>",
"     After polyps are removed, repeat colonoscopy is recommended, usually three to five years after the initial colonoscopy. However, this time interval depends upon several factors:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Microscopic characteristics of the polyp",
"      </li>",
"      <li>",
"       Number and size of the polyps",
"      </li>",
"      <li>",
"       The appearance of the colon during the colonoscopy. A bowel preparation is needed before colonoscopy to remove all traces of feces (stool). If the bowel prep was not completed, feces may remain in the colon, making it more difficult to see small to moderate size polyps. In this situation, follow up colonoscopy may be recommended sooner than three to five years later.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Persons who undergo screening (and re-screening) for colon cancer are much less likely to die from colon cancer. Thus, following screening guidelines is important in the prevention of colon cancer.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Preventing colon cancer",
"     </span>",
"     &nbsp;&mdash;&nbsp;Guidelines issued by one of the major medical societies in the United States (the American College of Gastroenterology) suggest the following to prevent polyps from recurring:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Eat a diet that is low in fat and high in fruits, vegetables, and fiber",
"      </li>",
"      <li>",
"       Maintain a normal body weight",
"      </li>",
"      <li>",
"       Avoid smoking and excessive alcohol use",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/62/28642?source=see_link\">",
"      \"Patient information: Diet and health (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=see_link\">",
"      \"Patient information: Quitting smoking (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      IMPLICATIONS FOR THE FAMILY",
"     </span>",
"    </p>",
"    <p>",
"     First-degree relatives (a parent, brother, sister, or child) of a person who has been diagnosed with an adenomatous polyp (or colorectal cancer) before the age of 60 years have an increased risk of developing adenomatous polyps and colorectal cancer compared to the general population. Thus, family should be made aware if the person is diagnosed with an adenoma or colon cancer.",
"    </p>",
"    <p>",
"     While screening for polyps and cancer is recommended for everyone (typically beginning at age 50), those at increased risk should begin screening earlier. The best test for screening in people with an increased risk of cancer is not known, although a sensitive test (such as colonoscopy) is usually recommended.",
"    </p>",
"    <p>",
"     Relatives can be told the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       People who have one first-degree relative (parent, brother, sister, or child) with colorectal cancer or an advanced type of adenomatous polyps at a young age (before the age of 60 years), or two first-degree relatives diagnosed at any age, should begin screening for colon cancer earlier, typically at age 40, or 10 years younger than the earliest diagnosis in their family, whichever comes first. Screening usually includes colonoscopy, which should be repeated every five years. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?7/23/7541?source=see_link&amp;anchor=H18#H18\">",
"        \"Patient information: Colon and rectal cancer screening (Beyond the Basics)\", section on 'Average risk of colorectal cancer'",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       People with a second-degree relative (grandparent, aunt, or uncle) or third-degree relative (great-grandparent or cousin) with colorectal cancer should be screened for colon cancer similar to a person with an average risk. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?7/23/7541?source=see_link&amp;anchor=H18#H18\">",
"        \"Patient information: Colon and rectal cancer screening (Beyond the Basics)\", section on 'Average risk of colorectal cancer'",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Some conditions, such as hereditary nonpolyposis colorectal cancer (Lynch syndrome), familial adenomatous polyposis, MUTYH- associated polyposis, and inflammatory bowel disease (eg, ulcerative colitis, Crohn's disease) significantly increase the risk of colon polyps or cancer in family members. Colon cancer screening in this group is discussed separately. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?7/23/7541?source=see_link&amp;anchor=H19#H19\">",
"        \"Patient information: Colon and rectal cancer screening (Beyond the Basics)\", section on 'Increased risk of colorectal cancer'",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H19\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10050360\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10050367\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/5/9298?source=see_link\">",
"      Patient information: Colon polyps (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/27/19890?source=see_link\">",
"      Patient information: Colon and rectal cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/11/18611?source=see_link\">",
"      Patient information: Colonoscopy (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/34/25123?source=see_link\">",
"      Patient information: Colon and rectal cancer screening (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/8/40066?source=see_link\">",
"      Patient information: Acromegaly (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/47/21234?source=see_link\">",
"      Patient information: Familial adenomatous polyposis (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10050383\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/23/7541?source=see_link\">",
"      Patient information: Colon and rectal cancer screening (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/30/9698?source=see_link\">",
"      Patient information: Colonoscopy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/62/28642?source=see_link\">",
"      Patient information: Diet and health (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=see_link\">",
"      Patient information: Quitting smoking (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10050398\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32746?source=see_link\">",
"      Approach to the patient with colonic polyps",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/2/11304?source=see_link\">",
"      Bleeding after colonic polypectomy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17016?source=see_link\">",
"      Clinical manifestations and diagnosis of familial adenomatous polyposis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19386?source=see_link\">",
"      Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42394?source=see_link\">",
"      Colorectal cancer: Epidemiology, risk factors, and protective factors",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28968?source=see_link\">",
"      Endoscopic removal of large colonic polyps",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7352?source=see_link\">",
"      Gardner syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/6/37990?source=see_link\">",
"      Overview of Peutz-Jeghers syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37034?source=see_link\">",
"      Screening for colorectal cancer: Strategies in patients at average risk",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/41/9881?source=see_link\">",
"      Screening for colorectal cancer: Strategies in patients with possible increased risk due to family history",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The American Gastroenterological Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.gastro.org/\">",
"      www.gastro.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The American College of Gastroenterology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.acg.gi.org/\">",
"      www.acg.gi.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The American Society of Colon and Rectal Surgeon",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.fascrs.org/\">",
"      www.fascrs.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?25/9/25747/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 7, 2013.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?25/9/25747?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25747/abstract/1\">",
"      Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology 2003; 124:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25747/abstract/2\">",
"      Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 1993; 329:1977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25747/abstract/3\">",
"      Bond JH. Polyp guideline: diagnosis, treatment, and surveillance for patients with colorectal polyps. Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 2000; 95:3053.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f25_9_25747=[""].join("\n");
var outline_f25_9_25747=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           COLON POLYPS OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           COLON POLYP CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           TYPES OF COLON POLYPS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           COLON POLYP DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           COLON POLYP REMOVAL",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           COLON POLYP PREVENTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           IMPLICATIONS FOR THE FAMILY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H19\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/60/13250\" title=\"figure 1\">",
"           Diagram colon rectum PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/4/42063\" title=\"figure 2\">",
"           Polyp removal PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/58/30628\" title=\"picture 1\">",
"           Colonic polyps Endosc",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f25_9_25748="Potassium iodide and iodine: Pediatric drug information";
var content_f25_9_25748=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Potassium iodide and iodine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?34/36/35396?source=see_link\">",
"    see \"Potassium iodide and iodine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?34/6/34916?source=see_link\">",
"    see \"Potassium iodide and iodine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1032396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibacterial, Topical",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antithyroid Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11444787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Graves' disease:",
"     </b>",
"     Oral: Lugol&rsquo;s solution: 1 drop/dose 3 times daily",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1032422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/36/35396?source=see_link\">",
"      see \"Potassium iodide and iodine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Thyroidectomy, preoperative preparation:",
"     </b>",
"     Oral: Lugol&rsquo;s solution: 3-5 drops (0.1-0.3 mL)/dose 3 times daily; administer for 10 days before surgery",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Thyrotoxic crisis:",
"     </b>",
"     Oral: Lugol&rsquo;s solution: 4-8 drops/dose 3 times daily, begin therapy preferably 2 hours following the initial dose of either propylthiouracil or methimazole",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Thyroidectomy, preoperative preparation:",
"     </b>",
"     Oral: Lugol&rsquo;s solution: 5-7 drops (0.25-0.35 mL)/dose 3 times daily; administer for 10 days before surgery; if not euthyroid prior to surgery, consider concurrent beta-blockade (eg, propranolol) in the immediate preoperative period to reduce the risk of thyroid storm (Bahn, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Thyrotoxic crisis:",
"     </b>",
"     Oral: Lugol&rsquo;s solution: 4-8 drops/dose every 6-8 hours; begin administration &ge;1 hour following the initial dose of either propylthiouracil or methimazole (Nayak, 2006)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F802404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: Potassium iodide 100 mg/mL and iodine 50 mg/mL (473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical: Potassium iodide 100 mg/mL and iodine 50 mg/mL (8 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F802365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F4813550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Dilute with a large quantity of water, fruit juice, or milk or administer after meals with food or milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topical: For external use only; apply to area requiring antiseptic",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1032416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral solution: Store at room temperature; excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); protect from light and keep container tightly closed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topical solution: Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); protect from light and keep container tightly closed.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1032397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral solution: Reduce thyroid vascularity prior to thyroidectomy and management of thyrotoxic crisis (FDA approved in adults); has also been used to block thyroidal uptake of radioactive isotopes of iodine in a radiation emergency or after therapeutic/diagnostic use of radioactive iodine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Topical solution: Provide topical antisepsis (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F802787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Potassium iodide and iodine (Strong Iodide Solution or Lugol's solution) may be confused with potassium iodide products, including saturated solution of potassium iodide (SSKI&reg;)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F802381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Irregular heart beat",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Confusion, tiredness, fever",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Skin rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Goiter, salivary gland swelling/tenderness, thyroid adenoma, swelling of neck/throat, myxedema, lymph node swelling, hyper-/hypothyroidism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, gastrointestinal bleeding, metallic taste, nausea, stomach pain, stomach upset, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Numbness, tingling, weakness, joint pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Chronic iodine poisoning (with prolonged treatment/high doses); iodism, hypersensitivity reactions (angioedema, cutaneous and mucosal hemorrhage, serum sickness-like symptoms)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1032402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Hypersensitivity to iodine or any component; active tuberculosis",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F4813544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with cystic fibrosis; may have exaggerated susceptibility to goitrogenic effects. Use with caution in patients with myotonia congenital, Addison&rsquo;s disease, acute bronchitis, or a history of thyroid disease and cardiac disease; avoid use in patients with iodine-induced goiter. Use may cause flare-up of acne and/or dermatitis; avoid use in patients with dermatitis herpetiformis or hypocomplementemic vasculitis.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1032403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Hypersensitivity reactions to iodine have been reported. Prolonged use can lead to hypothyroidism and iodism (chronic iodide intoxication).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F802385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Potassium Salts may enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: Potassium Salts may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antithyroid Agents may increase the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of Potassium Salts. Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Potassium Iodide may enhance the hypothyroid effect of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Potassium Salts may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Iodide I131: Antithyroid Agents may diminish the therapeutic effect of Sodium Iodide I131.  Management: Discontinue antithyroid therapy 3-4 days prior to sodium iodide I-131 administration.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Antithyroid Agents may increase the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antithyroid Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F802371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     D (potassium iodide) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F802372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Iodide crosses the placenta (may cause hypothyroidism and goiter in fetus/newborn). Use for protection against thyroid cancer secondary to radioactive iodine exposure is considered acceptable based upon risk:benefit, keeping in mind the dose and duration. Repeat dosing should be avoided if possible. Refer to Iodine for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1032426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Thyroid function tests, signs/symptoms of hyperthyroidism; thyroid function should be monitored in pregnant women, neonates, and young infants if repeat doses are required following radioactive iodine exposure",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1032418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     In hyperthyroidism, iodine temporarily inhibits thyroid hormone synthesis and secretion into circulation; use also decreases thyroid gland size and vascularity. Serum T",
"     <sub>",
"      4",
"     </sub>",
"     and T",
"     <sub>",
"      3",
"     </sub>",
"     concentrations can be reduced for several weeks with use but effect will not be maintained.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:2em;text-align:justify;\">",
"     Following radioactive iodine exposure, potassium iodide blocks the uptake of radioiodine by the thyroid, reducing the risk of thyroid cancer",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F4813549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antithyroid effects:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 24-48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: 10-15 days after continuous therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: May persist up to 6 weeks",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F14632151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/6/34916?source=see_link\">",
"      see \"Potassium iodide and iodine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Dilute in water, fruit juice, or milk, or take with meals to reduce gastric irritation. May cause metallic taste, nausea, or vomiting; soreness of teeth, gums, or glands; fever, headache, or sore joints; or confusion or tiredness. Discontinue and report to the prescriber any swelling of lips, mouth, or tongue; difficulty swallowing; chest pain or irregular heartbeat; unusual muscle weakness; eye irritation or eyelid swelling; or skin rash.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;American Academy of Pediatrics Committee on Environmental Health. Radiation Disasters and Children,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2003, 111(6 Pt 1):1455-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/9/25748/abstract-text/12777572/pubmed\" id=\"12777572\" target=\"_blank\">",
"        12777572",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hassoun A and Oberfield SE, &ldquo;Renal, Endocrine, and Metabolic Disorders,&rdquo;",
"      <i>",
"       Roger&rsquo;s Textbook of Pediatric Intensive Care",
"      </i>",
"      , 3rd ed, David G Nichols, ed, Philadelphia, PA: Lippincott, Williams, &amp; Wilkins, 2008;1658.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kauffman CA, Hajjeh R, and Chapman SW, &ldquo;Practice Guidelines for the Management of Patients With Sporotrichosis. For the Mycoses Study Group. Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2000, 30(4):684-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/9/25748/abstract-text/10770730/pubmed\" id=\"10770730\" target=\"_blank\">",
"        10770730",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nayak B and Burman K, \"Thyrotoxicosis and Thyroid Storm,\"",
"      <i>",
"       Endocrinol Metab Clin North Am",
"      </i>",
"      , 2006, 35(4):663-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/9/25748/abstract-text/17127140/pubmed\" id=\"17127140\" target=\"_blank\">",
"        17127140",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Potassium Iodide as a Thyroid Blocking Agent in a Radiation Emergency: Final Recommendations on Use,&rdquo; Washington DC, Bureau of Radiological Health and Bureau of Drugs, Food and Drug Administration, 1982.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      U.S. Food and Drug Administration, &ldquo;FDA's Guidance on Protection of Children and Adults Against Thyroid Cancer in Case of Nuclear Accident,&rdquo; FDA Talk Paper. Available at: file://www.fda.gov/bbs/topics/answers/2001/ans01126.html. Accessed January 11, 2002.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13039 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.172.26-18D72DAC39-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_9_25748=[""].join("\n");
var outline_f25_9_25748=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032396\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11444787\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032422\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F802404\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F802365\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4813550\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032416\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032397\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F802787\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F802381\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032402\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4813544\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032403\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299923\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F802385\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F802371\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F802372\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032426\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032418\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4813549\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14632151\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13039\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13039|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/36/35396?source=related_link\">",
"      Potassium iodide and iodine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/6/34916?source=related_link\">",
"      Potassium iodide and iodine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_9_25749="Electrograms dual pathways WPW";
var content_f25_9_25749=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F71684&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F71684&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Electrophysiologic study of orthodromic atrioventricular reentrant tachycardia with two accessory pathways",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 339px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shown are three surface ECG leads (I, 2, V1) and electrograms recorded from the right ventricle (RV); right atrium (RA); bundle of His (HB); and coronary sinus (CS), with electrodes at the proximal (CS4), mid (CS3 and CS2) and distal (CS1) CS. During an othodromic atrioventricular reentrant tachycardia the AA intervals recorded from CS1 and CS4 are identical (270 msec) as a result of simultaneous atrial (A) activation via a posteroseptal (at CS4) and lateral pathway (at CS1), resulting in fusion activation of the left atrium; retrograde left atrial activation via the HB occurs later. A premature ventricular stimulus (arrows), delivered while the HB is refractory, conducts via the posteroseptal pathway (CS4) and advances atrial activation (AA interval 245 msec); however, the stimulus blocks in the lateral pathway, indicated by failure of atrial activation to advance (AA interval remains at 270 msec). This response to a premature ventricular stimulus confirms the presence of two pathways.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_9_25749=[""].join("\n");
var outline_f25_9_25749=null;
var title_f25_9_25750="Telbivudine in the treatment of chronic hepatitis B virus infection";
var content_f25_9_25750=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Telbivudine in the treatment of chronic hepatitis B virus infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/9/25750/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/9/25750/contributors\">",
"     Anna SF Lok, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/9/25750/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/9/25750/contributors\">",
"     Rafael Esteban, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/9/25750/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/9/25750/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/9/25750/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     Telbivudine",
"    </a>",
"    (L-deoxythymidine [LdT or Tyzeka]) is the unmodified beta-L enantiomer of thymidine. It is approved for the treatment of chronic HBV in adults with evidence of viral replication and either persistent elevation in serum aminotransferases or histologically active disease.",
"   </p>",
"   <p>",
"    The treatment of chronic hepatitis B with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    will be reviewed here. A general approach to patients with hepatitis B (including other treatment options) is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24378?source=see_link\">",
"     \"Overview of the management of hepatitis B and case examples\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HBeAg POSITIVE HBV",
"    </span>",
"    &nbsp;&mdash;&nbsp;The available data suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    is slightly more effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    in suppressing HBV DNA in patients who are HBeAg positive but the benefit does not appear to translate into a clinically important advantage for HBeAg seroconversion or histologic improvement.",
"   </p>",
"   <p>",
"    The largest trial (the 007 GLOBE trial) included 1367 patients who were HBsAg positive, HBeAg positive (n = 797) or negative (n = 417), had an ALT level &gt;1.3 times the upper limit of normal, had not previously received nucleoside analogues, and had a liver biopsy compatible with chronic viral hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25750/abstract/1\">",
"     1",
"    </a>",
"    ]. The mean baseline HBV DNA level was 9.5 log",
"    <sub>",
"     10",
"    </sub>",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    in those who were HBeAg positive and 7.7 log",
"    <sub>",
"     10",
"    </sub>",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    in those who were HBeAg negative.",
"   </p>",
"   <p>",
"    The patients were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    (600 mg once daily) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    (100 mg once daily) for up to 104 weeks. The following observations were made in the HBeAg positive group at week 52:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Significantly more patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"       telbivudine",
"      </a>",
"      achieved the primary end point, a composite that included suppression of HBV DNA to &lt;5 log",
"      <sub>",
"       10",
"      </sub>",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      in conjunction with loss of serum HBeAg (75 versus 67 percent).",
"     </li>",
"     <li>",
"      The mean reduction in HBV DNA from baseline was greater than with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      (-6.45 versus -5.54 log",
"      <sub>",
"       10",
"      </sub>",
"      <span class=\"nowrap\">",
"       copies/mL).",
"      </span>",
"     </li>",
"     <li>",
"      The proportion with ALT normalization, HBeAg seroconversion, and HBeAg loss were similar to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      (77 versus 75 percent, 23 versus 22 and 26 versus 23 percent, respectively).",
"     </li>",
"     <li>",
"      The proportion with histologic improvement was similar to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      (69 versus 60 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A follow-up report described outcomes at two years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25750/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Significantly more patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"       telbivudine",
"      </a>",
"      achieved the primary endpoint (63 versus 48 percent).",
"     </li>",
"     <li>",
"      Significantly more patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"       telbivudine",
"      </a>",
"      achieved non-detectable HBV DNA (56 versus 39 percent).",
"     </li>",
"     <li>",
"      HBeAg loss occurred more often with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"       telbivudine",
"      </a>",
"      (35 versus 29 percent), as did HBeAg seroconversion (30 versus 25 percent), although results did not achieve statistical significance. HBeAg seroconversion was significantly more likely in patients with a baseline serum ALT &ge;2 times normal (36 versus 27 percent).",
"     </li>",
"     <li>",
"      The proportion with ALT normalization was significantly greater with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"       telbivudine",
"      </a>",
"      (70 versus 62 percent).",
"     </li>",
"     <li>",
"      Rates of viral resistance were significantly lower with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"       telbivudine",
"      </a>",
"      (25 versus 40 percent).",
"     </li>",
"     <li>",
"      Adverse events occurred at a similar rate between the groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Efficacy data at two years was incrementally proportional to the degree of HBV DNA suppression at week 24 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25750/abstract/3\">",
"     3",
"    </a>",
"    ]. As an example, HBeAg seroconversion was observed in 45 percent of patients who were PCR negative at week 24 compared with only 6 percent in those who had HBV DNA &gt;4 log",
"    <sub>",
"     10",
"    </sub>",
"    <span class=\"nowrap\">",
"     copies/mL.",
"    </span>",
"   </p>",
"   <p>",
"    Approximately 80 percent of patients who achieved a response and discontinued treatment had a sustained response for up to one year. Of 39 patients who stopped therapy after one year (because they achieved an HBV DNA level of &lt;5 log",
"    <sub>",
"     10",
"    </sub>",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    and had HBeAg loss for at least 24 weeks), 84 percent had sustained HBeAg loss and 83 percent had sustained HBeAg seroconversion [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25750/abstract/4\">",
"     4",
"    </a>",
"    ]. Similar rates of sustained response were observed with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    (89 percent sustained HBeAg loss and 88 percent sustained HBeAg seroconversion).",
"   </p>",
"   <p>",
"    Similar results were reported in a study conducted in China [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25750/abstract/5\">",
"     5",
"    </a>",
"    ]. The study included 332 patients (290 HBeAg positive and 42 HBeAg negative) who were randomly assigned to receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    600 mg daily or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    100 mg daily. Responses at week 104 in the telbivudine versus lamivudine group were [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25750/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      HBV DNA reduction by 5.43 log versus 3.97 log",
"     </li>",
"     <li>",
"      Undetectable HBV DNA by PCR in 63 versus 39 percent",
"     </li>",
"     <li>",
"      ALT normalization in 78 versus 63 percent",
"     </li>",
"     <li>",
"      HBeAg loss in 41 versus 28 percent",
"     </li>",
"     <li>",
"      HBeAg seroconversion in 30 versus 20 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All the response parameters were statistically different except for HBeAg seroconversion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     HBeAg NEGATIVE HBV",
"    </span>",
"    &nbsp;&mdash;&nbsp;The available data suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    is slightly more effective in patients who are HBeAg negative in suppressing HBV DNA compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    but the proportion of patients achieving primary endpoint after 52 weeks of treatment was similar.",
"   </p>",
"   <p>",
"    The following observations were made in the GLOBE trial (described above) among HBeAg negative patients after 52 weeks of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25750/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mean reduction in HBV DNA from baseline (-5.23 versus -4.40 log",
"      <sub>",
"       10",
"      </sub>",
"      <span class=\"nowrap\">",
"       copies/mL)",
"      </span>",
"      and the proportion who were HBV DNA negative by PCR was greater than with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      (88 versus 71 percent).",
"     </li>",
"     <li>",
"      The proportions with histologic improvement (69 versus 68 percent) and those with normalization in ALT (74 versus 79 percent) were similar to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following observations were made after two years of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25750/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The primary endpoint was achieved significantly more often with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"       telbivudine",
"      </a>",
"      (78 versus 66 percent)",
"     </li>",
"     <li>",
"      The proportion with undetectable HBV DNA was significantly greater with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"       telbivudine",
"      </a>",
"      (82 versus 57 percent)",
"     </li>",
"     <li>",
"      Genotypic resistance occurred significantly less often with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"       telbivudine",
"      </a>",
"      (11 versus 26 percent)",
"     </li>",
"     <li>",
"      Adverse events occurred at a similar rate between the groups",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As with HBeAg positive chronic HBV, efficacy at two years was incrementally proportional to the degree of HBV DNA suppression at week 24 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25750/abstract/3\">",
"     3",
"    </a>",
"    ]. As an example, ALT normalization was observed in 77 percent of patients who were PCR negative at week 24 compared with only 21 percent in those who had HBV DNA &gt;4 log",
"    <sub>",
"     10",
"    </sub>",
"    <span class=\"nowrap\">",
"     copies/mL.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PREDICTION OF RESPONSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best predictor of treatment outcome in HBeAg positive and HBeAg negative chronic HBV infection treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    appears to be non-detectable serum HBV DNA at treatment week 24.",
"   </p>",
"   <p>",
"    This was illustrated in a follow-up report of the GLOBE trial, which evaluated predictors of response in HBeAg positive and HBeAg negative patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25750/abstract/7\">",
"     7",
"    </a>",
"    ]. HBeAg positive patients who had baseline HBV DNA &lt;9 log",
"    <sub>",
"     10",
"    </sub>",
"    <span class=\"nowrap\">",
"     copies/mL,",
"    </span>",
"    an ALT &ge;2 times the upper limit of normal, and non-detectable HBV DNA at treatment week 24 were more likely to achieve better outcomes than patients without these characteristics. At two years, 89 percent of such patients achieved non-detectable HBV DNA and 52 percent achieved HBeAg seroconversion. However, only 80 (18 percent) patients had baseline HBV DNA &lt;9 log",
"    <sub>",
"     10",
"    </sub>",
"    <span class=\"nowrap\">",
"     copies/mL,",
"    </span>",
"    an ALT &ge;2 times the upper limit of normal and only 57 (71 percent) of those 80 patients (12 percent of all HBeAg-positive patients) had undetectable HBV DNA at week 24.",
"   </p>",
"   <p>",
"    Among HBeAg negative patients, the best outcomes were observed in those with baseline HBV DNA &lt;7 log",
"    <sub>",
"     10",
"    </sub>",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    and non-detectable HBV DNA at treatment week 24. At two years, 91 percent of such patients had non-detectable HBV DNA. However, only 91 (41 percent) patients had baseline HBV DNA &lt;7 log",
"    <sub>",
"     10",
"    </sub>",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    and only 86 (95 percent) of these 91 patients (39 percent) had undetectable HBV DNA at week 24.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only one mutation at the YMDD motif (rtM204I but not rtM204V) has been observed in patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    resistance. Preliminary data indicate that with continued treatment, additional compensatory mutations at positions rt80 and rt180 are selected.",
"   </p>",
"   <p>",
"    Rates of resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    are lower than with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    . In the two-year follow-up of the GLOBE trial described above [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25750/abstract/2\">",
"     2",
"    </a>",
"    ], viral breakthrough was observed significantly more often in the lamivudine groups in both HBeAg positive (47 versus 29 percent) and HBeAg negative (32 versus 12 percent) patients. Viral resistance was also more common with lamivudine in HBeAg positive (40 versus 25 percent) and HBeAg negative (26 versus 11 percent) patients. These resistance rates are substantially higher than with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     LAMIVUDINE OR ADEFOVIR-REFRACTORY PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vitro studies suggest that HBV strains that are resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    will also be resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"   </p>",
"   <p>",
"    HBV with the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    resistance substitution rtA181V had a three- to five-fold reduced susceptibility to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    in cell culture. On the other hand, HBV with the adefovir resistance substitution rtN236T remained susceptible to telbivudine.",
"   </p>",
"   <p>",
"    These data indicate that HBV mutants resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    will be cross-resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    and are likely to be less susceptible to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    . However,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    should be effective in suppressing telbivudine-resistant HBV.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TELBIVUDINE VERSUS ADEFOVIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data directly comparing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    to other nucleoside analogues. The largest trial included 135 patients with HBeAg positive, compensated HBV who were randomly assigned to telbivudine or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    dipivoxil for 24 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25750/abstract/8\">",
"     8",
"    </a>",
"    ]. At 24 weeks, patients in the adefovir arm were re-randomized either to continue adefovir or to switch to telbivudine. The following were the main findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mean HBV DNA reduction from baseline to week 24 was significantly greater with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"       telbivudine",
"      </a>",
"      than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"       adefovir",
"      </a>",
"      (-6.3 versus -4.97 log",
"      <sub>",
"       10",
"      </sub>",
"      <span class=\"nowrap\">",
"       copies/mL).",
"      </span>",
"      At 52 weeks, the mean HBV DNA reduction was significantly greater in the group re-randomized to telbivudine versus those who continued to receive adefovir.",
"     </li>",
"     <li>",
"      Patients randomly assigned or reassigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"       telbivudine",
"      </a>",
"      were more likely to have undetectable HBV DNA by PCR assay at 52 weeks (54 versus 40 percent) and to have loss of HBeAg (26 versus 21 percent) compared to those who continued to receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"       adefovir",
"      </a>",
"      , although these differences did not reach statistical significance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A follow-up report described the viral response among",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    recipients with a persistent suboptimal viral response at week 52 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25750/abstract/9\">",
"     9",
"    </a>",
"    ]. A 2.1 log",
"    <sub>",
"     10",
"    </sub>",
"    decrease in viral load occurred after switching to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    , which was sustained through week 76.",
"   </p>",
"   <p>",
"    A separate report described a benefit of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    salvage therapy (as monotherapy or given in addition to continued",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    ) in 22 patients with virologic breakthrough (a confirmed increase in HBV DNA of &gt;1 log",
"    <sub>",
"     20",
"    </sub>",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    from nadir) while on telbivudine [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25750/abstract/10\">",
"     10",
"    </a>",
"    ]. After 16 weeks of adefovir, HBV DNA levels decreased by a mean of 4.1 log",
"    <sub>",
"     10",
"    </sub>",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    and ALT levels were reduced by 93",
"    <span class=\"nowrap\">",
"     IU/L.",
"    </span>",
"    The degree of HBV DNA decrease was greater in those who received adefovir in combination with telbivudine, although the number of patients studied (n = 5) was small. These data provide in vivo confirmation that adefovir is effective in suppressing telbivudine-resistant HBV.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     HIV COINFECTED PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;No large studies have evaluated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    in HIV coinfected patients. In vitro studies suggest that it has no activity against HIV. However, given that telbivudine can select for mutations in the YMDD motif, it is not a preferred treatment for HIV-HBV coinfected patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16185?source=see_link\">",
"     \"Treatment of hepatitis B in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SAFETY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The GLOBE trial cited above showed that the safety profile of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    is similar to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25750/abstract/2\">",
"     2",
"    </a>",
"    ]. The proportion of patients in whom treatment was stopped or interrupted due to an adverse event was the same in both groups (4 percent). However, elevation in creatinine phosphokinase occurred significantly more often with telbivudine (13 versus 4 percent). In addition, two patients receiving telbivudine developed myopathy (with moderately elevated creatinine phosphokinase levels), which were believed to be due to the drug. Both resolved upon discontinuation. One patient receiving telbivudine developed liver failure due to viral breakthrough during treatment. Myopathy and peripheral neuropathy led to the termination of a clinical trial (unpublished) evaluating combination therapy of peginterferon and telbivudine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/41/26258?source=see_link\">",
"       \"Patient information: Hepatitis B (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/45/31447?source=see_link\">",
"       \"Patient information: Hepatitis B (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"       Telbivudine",
"      </a>",
"      appears to be slightly more effective than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      in reducing HBV DNA in patients with HBeAg positive or HBeAg negative chronic HBV. However, in HBeAg positive patients, this benefit did not translate into improved rates of HBeAg seroconversion or histologic improvement. In HBeAg negative patients, there was a modest benefit compared with lamivudine in suppression of HBV DNA.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"       Telbivudine",
"      </a>",
"      is not effective in patients who developed breakthrough infection while on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Limited data suggest that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"       telbivudine",
"      </a>",
"      may suppress HBV DNA to a greater extent than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"       adefovir",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Telbivudine versus adefovir'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The role of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"       telbivudine",
"      </a>",
"      monotherapy is limited due to its high resistance rate (compared to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"       adefovir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"       entecavir",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      ), cross-resistance with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      and to some extent entecavir, and higher price (compared to lamivudine). Telbivudine should not be used in combination with pegylated interferon because of a high risk of myopathy or peripheral neuropathy.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25750/abstract/1\">",
"      Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357:2576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25750/abstract/2\">",
"      Liaw YF, Gane E, Leung N, et al. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25750/abstract/3\">",
"      DiBisceglie A, Lai CL, Gane E, et al. Telbivudine GLOBE trial: maximal early HBV suppression is predictive of optimal two-year efficacy in nucleoside-treated heaptitis B patients (abstract). Hepatology 2006; 44 (Suppl 1):230A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25750/abstract/4\">",
"      Poynard T, Chutaputti A, Hwang SG, et al. Sustained off-treatment HBeAg response in telbivudine and lamivudine treated HBeAg-positive patients from the GLOBE study (abstract). J Hepatol 2007; 46 (Suppl 1):S27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25750/abstract/5\">",
"      Hou J, Yin YK, Xu D, et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial. Hepatology 2008; 47:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25750/abstract/6\">",
"      Jia JD, Hou YL, Yink YK, et al. Two-year results of a phase III comparative trial of telbivudine vs lamivudine in Chinese patients (abstract). J Hepatol 2007; 46 (Supppl 1): S189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25750/abstract/7\">",
"      Zeuzem S, Gane E, Liaw YF, et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol 2009; 51:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25750/abstract/8\">",
"      Chan HL, Heathcote EJ, Marcellin P, et al. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med 2007; 147:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25750/abstract/9\">",
"      Marcellin P, Chan HLY, Lai CL, et al. 76 weeks follow-up of HBeAg-positive chronic hepatitis B patients treated with telbivudine, adefovir or switched from adefovir to telbivudine (abstract). J Hepatol 2007; 46 (Suppl 1):S55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25750/abstract/10\">",
"      Gane E, Lai CL, Min A, et al. Adefovir salvage therapy for virologic breakthrough in telbivudine-treated patients from the GLOBE study (abstract). J Hepatol 2007; 46 (Suppl 1):S187.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3655 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-00FF42CD0A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_9_25750=[""].join("\n");
var outline_f25_9_25750=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HBeAg POSITIVE HBV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HBeAg NEGATIVE HBV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PREDICTION OF RESPONSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      LAMIVUDINE OR ADEFOVIR-REFRACTORY PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TELBIVUDINE VERSUS ADEFOVIR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      HIV COINFECTED PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SAFETY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24378?source=related_link\">",
"      Overview of the management of hepatitis B and case examples",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/45/31447?source=related_link\">",
"      Patient information: Hepatitis B (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/41/26258?source=related_link\">",
"      Patient information: Hepatitis B (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16185?source=related_link\">",
"      Treatment of hepatitis B in the HIV-infected patient",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_9_25751="Physiology of gastrin";
var content_f25_9_25751=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Physiology of gastrin",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/9/25751/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/9/25751/contributors\">",
"     Rodger A Liddle, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/9/25751/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/9/25751/contributors\">",
"     J Thomas LaMont, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/9/25751/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/9/25751/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/9/25751/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrin is the major hormonal regulator of gastric acid secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25751/abstract/1\">",
"     1",
"    </a>",
"    ]. Its discovery at the turn of the century was based upon its profound effect on meal-stimulated acid secretion, making it one of the first hormones to be described [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25751/abstract/1\">",
"     1",
"    </a>",
"    ]. The study of gastrin accelerated with the isolation and characterization of the peptide in 1964 after which it was found to promote growth of the gastric antrum and have a proliferative effect, which has implicated it as having a possible role in cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25751/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The cloning and characterization of the gastrin receptor in 1992 has provided a valuable tool in the study of gastrointestinal hormones [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25751/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the physiology of gastrin. Zollinger-Ellison syndrome and the physiology of gastric acid secretion are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14504?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Zollinger-Ellison syndrome (gastrinoma)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/51/6968?source=see_link\">",
"     \"Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29160?source=see_link\">",
"     \"Physiology of gastric acid secretion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MOLECULAR FORMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human gastrin is the product of a single gene located on chromosome 17. The active hormone is generated from a precursor peptide \"preprogastrin\" (",
"    <a class=\"graphic graphic_figure graphicRef52877 \" href=\"UTD.htm?34/4/34894\">",
"     figure 1",
"    </a>",
"    ). Human preprogastrin contains 101 amino acids (AA) including a signal peptide (21 AA), spacer sequence (37 AA), gastrin component (34 AA) and a 9 AA extension segment at the carboxyl terminus. The enzymatic processing of preprogastrin produces all of the known physiologically active forms of gastrin.",
"   </p>",
"   <p>",
"    Preprogastrin is processed into progastrin and gastrin peptide fragments of various sizes by sequential enzymatic cleavage (",
"    <a class=\"graphic graphic_figure graphicRef52877 \" href=\"UTD.htm?34/4/34894\">",
"     figure 1",
"    </a>",
"    ). Like other hormones, gastrin is synthesized on rough endoplasmic reticulum, processed in the Golgi apparatus, and packaged in secretory granules, where final modifications occur [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25751/abstract/5\">",
"     5",
"    </a>",
"    ]. In endocrine cells, the glycine residue at the carboxyl terminus is cleaved and the terminus is amidated to form the mature gastrin peptide.",
"   </p>",
"   <p>",
"    Two major forms of gastrin are secreted (G-34 and G-17), although larger G-71 and smaller G-6 forms exist (",
"    <a class=\"graphic graphic_table graphicRef51646 \" href=\"UTD.htm?0/44/715\">",
"     table 1",
"    </a>",
"    ). The common feature of all gastrins is an amidated tetrapeptide (Try-Met-Asp-Phe-NH2) at the carboxyl terminus that imparts full biological activity. Modification by sulfation at tyrosine residues produces alternative gastrin forms. The circulating half-life of gastrin is affected by the size of the various molecular forms. The full physiologic response is determined by the presence of the biologically active moiety and the time available for receptor interaction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22660?source=see_link\">",
"     \"Synthesis, secretion, and regulation of gastrointestinal peptides\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gastrin can be ectopically expressed in non-endocrine cells, such as tumors. However, because these cells lack secretory vesicles, prohormone convertases and amidating enzymes, the main forms of gastrin secreted are progastrins including glycine-extended gastrin. These forms of gastrin may have growth promoting effects on certain tumors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TISSUE DISTRIBUTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vast majority of gastrin is produced in endocrine cells of the gastric antrum [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25751/abstract/6\">",
"     6",
"    </a>",
"    ]. Much smaller amounts of gastrin are produced in other regions of the gastrointestinal tract including the nonantral stomach, duodenum, jejunum, ileum, and pancreas. Gastrin has also been found outside of the gastrointestinal tract including the brain, adrenal glands, respiratory tract, and reproductive organs, although its biological role in these sites is unknown (",
"    <a class=\"graphic graphic_table graphicRef58007 \" href=\"UTD.htm?26/49/27419\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RECEPTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cDNA and the gene for the gastrin receptor have been cloned and sequenced [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25751/abstract/4\">",
"     4",
"    </a>",
"    ]. It is now clear that the receptors for gastrin and cholecystokinin are related and, therefore, constitute the",
"    <span class=\"nowrap\">",
"     \"CCK/Gastrin",
"    </span>",
"    receptor family.\" The CCK-A (alimentary) and CCK-B (brain) receptor cDNAs were cloned from pancreas and brain, respectively, after which it was recognized that the CCK-B receptor was identical to the gastrin receptor of the gastric antrum. The CCK-A and -B receptors have been renamed CCK1 and CCK2 receptors, respectively. The CCK2 receptor is present on parietal cells and enterochromaffin-like cells (ECL cells) of the stomach.",
"   </p>",
"   <p>",
"    The CCK1 receptor is abundant in the pancreas and gallbladder and has a 1000-fold higher affinity for cholecystokinin than for gastrin. In addition to its presence in the stomach, the",
"    <span class=\"nowrap\">",
"     CCK2/gastrin",
"    </span>",
"    receptor is abundant in brain tissue and is also found on pancreatic islet cells. The CCK1 and the",
"    <span class=\"nowrap\">",
"     CCK2/gastrin",
"    </span>",
"    receptors have over 50 percent sequence homology and respond differentially to various receptor antagonists, and to gastrin.",
"   </p>",
"   <p>",
"    Both receptors are classical G protein-coupled receptors containing seven membrane-spanning domains and signal via pertussis toxin-insensitive G proteins (",
"    <a class=\"graphic graphic_figure graphicRef63760 \" href=\"UTD.htm?0/20/324\">",
"     figure 2",
"    </a>",
"    ). Agonist stimulation",
"    <span class=\"nowrap\">",
"     CCK/gastrin",
"    </span>",
"    receptor activates a specific G protein, stimulating the production of second messengers that include inositol phosphate, calcium, and activating protein kinase C. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/49/22293?source=see_link\">",
"     \"Peptide hormone signal transduction and regulation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A CCK2 receptor variant (also referred to as the CCK-C receptor) possessing an extra 69 amino acids in the third intracellular loop has been found in colorectal tumors and Barrett's metaplasia of the esophagus, but not normal adjacent tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25751/abstract/7,8\">",
"     7,8",
"    </a>",
"    ], and in some pancreatic cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25751/abstract/9\">",
"     9",
"    </a>",
"    ]. This receptor has slightly higher affinity for glycine-extended gastrin and increased constitutive activity that may have a role in cancer growth [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25751/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     GASTRIN PHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrin is released from specialized endocrine cells (G cells) into the circulation in response to a meal. The specific components of a meal that stimulate gastrin release include protein, peptides, and amino acids. Gastrin release is profoundly influenced by the pH of the stomach; fasting and increased gastric acid in the stomach inhibit its release, whereas a high gastric pH provides a strong stimulus for its secretion. The G cells are tightly regulated by two counterbalancing hormones, gastrin-releasing peptide and somatostatin, which exert stimulatory and inhibitory effects, respectively.",
"   </p>",
"   <p>",
"    As mentioned above, gastrin is a primary physiologic mediator of gastric acid secretion. The human stomach secretes approximately 2 to 3 liters of acid-rich fluid per day. The regulation of acid secretion is influenced by the central, peripheral, and enteric nervous systems and multiple chemical messengers including gastrin, histamine, somatostatin, and acetylcholine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29160?source=see_link\">",
"     \"Physiology of gastric acid secretion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The major cellular determinants of acid secretion involve the antral gastrin-secreting G cell, the enterochromaffin-like (ECL) cell of the stomach that secretes histamine, and the somatostatin-secreting D cell. The acid-secreting parietal cell possesses receptors for acetylcholine, histamine, and gastrin. Although activation of all three of these receptors can stimulate acid secretion, the most important mechanism of acid release occurs via stimulation of the ECL cell to secrete histamine, which in turn stimulates the parietal cell [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25751/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. The ECL cell receives stimulatory signals from gastrin and inhibitory signals from somatostatin (",
"    <a class=\"graphic graphic_figure graphicRef65068 \" href=\"UTD.htm?18/29/18902\">",
"     figure 3",
"    </a>",
"    ). Somatostatin also provides inhibitory signals to antral G cells.",
"   </p>",
"   <p>",
"    As noted above, the CCK2 receptor can be found on pancreatic islet cells, and hypergastrinemia has been associated with islet cell hyperplasia and enhanced insulin secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25751/abstract/12\">",
"     12",
"    </a>",
"    ]. In animals, coadministration of gastrin and glucagon-like peptide-1 can restore normoglycemia in diabetic mice, suggesting that gastrin may have incretin-like effects [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25751/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38298?source=see_link&amp;anchor=H2#H2\">",
"     \"Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus\", section on 'Glucagon-like peptide-1'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Transgenic and gene deletion animal models",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of gastrin in mammalian physiology has been studied with the use of mouse models that are deficient in the expression of gastrin or the gastrin receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25751/abstract/13\">",
"     13",
"    </a>",
"    ]. Gastrin-deficient mice have reduced numbers of parietal cells and are hypochlorhydric [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25751/abstract/14\">",
"     14",
"    </a>",
"    ]. Interestingly, administration of gastrin and glycine-extended gastrin in combination maintains parietal cell function more effectively than either peptide alone [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25751/abstract/15\">",
"     15",
"    </a>",
"    ]. Gastric acid production cannot be induced by histamine or cholinergic agents, suggesting a significant defect in parietal cell function. Mice in which the gastrin receptor has been knocked out are hypochlorhydric, have reduced parietal cell mass, and decreased numbers of ECL cells [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25751/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Hypochlorhydria is often accompanied by intestinal metaplasia in the stomach and bacterial overgrowth, which have been associated with the eventual appearance of gastric tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25751/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These animal models have also provided insight into the role of gastrin in extragastric locations. Mice lacking the gastrin gene demonstrate decreased proliferation of the colonic mucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25751/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Causes of hypergastrinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypergastrinemia is observed in a number of settings, of which use of acid-suppressive medications and chronic atrophic gastritis are by far the most common. The mechanism of hypergastrinemia in these conditions is related to the stimulation of gastrin production by the alkaline pH environment, explaining the increased plasma gastrin levels often associated with Helicobacter pylori infection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25751/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another important, but far less common, association is the Zollinger-Ellison syndrome, which is caused by a gastrin-producing tumor (",
"    <a class=\"graphic graphic_picture graphicRef78549 \" href=\"UTD.htm?40/38/41577\">",
"     picture 1",
"    </a>",
"    ). Most patients with Zollinger-Ellison syndrome have serum gastrin concentrations between 150 and 1000",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    (71 and 475",
"    <span class=\"nowrap\">",
"     pmol/L).",
"    </span>",
"    This degree of gastrin elevation can also be observed in a variety of other settings, which need to be considered when evaluating a patient found to have hypergastrinemia (",
"    <a class=\"graphic graphic_table graphicRef60819 \" href=\"UTD.htm?9/12/9420\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25751/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14504?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Zollinger-Ellison syndrome (gastrinoma)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The highest gastrin levels (&gt;1000",
"    <span class=\"nowrap\">",
"     pg/mL),",
"    </span>",
"    although rare, are seen with gastrin-secreting tumors or chronic atrophic gastritis accompanying pernicious anemia. Modest elevations in serum gastrin (~200 to 400",
"    <span class=\"nowrap\">",
"     pg/mL)",
"    </span>",
"    are much more common and are often due to acid-suppressive medications (ie, H2 blockers or proton pump inhibitors) or H. pylori-associated gastritis.",
"   </p>",
"   <p>",
"    Other rare causes of achlorhydria-associated hypergastrinemia may occur in the absence of gastritis. For example, impaired potassium secretion into the gastric lumen can reduce hydrogen-potassium proton pump activity on the apical surface of parietal cells, resulting in low acid secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25751/abstract/23\">",
"     23",
"    </a>",
"    ]. Patients with Jervell and Lange-Nielsen syndrome caused by mutations in the potassium channel gene",
"    <em>",
"     KCNQ1",
"    </em>",
"    gene not only have cardiac arrhythmias due to QT prolongation but have gastric achlorhydria, iron deficiency anemia, and hypergastrinemia as a consequence of impaired potassium ion secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25751/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL SIGNIFICANCE OF HYPERGASTRINEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical significance of chronic elevation in serum gastrin levels (as may be seen in patients taking proton pump inhibitors long-term) is uncertain. Gastrin receptors have been detected on a variety of tumor cells, and gastrin has trophic effects on the stomach and intestine, suggesting that it may have a role in the development of gastrointestinal malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25751/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. The degree to which this might contribute to oncogenesis has not been defined. The concern related to hypergastrinemia has focused primarily on two issues: gastric carcinoid tumors, and cancer (particularly colon and pancreatic cancer).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Gastric carcinoid tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypergastrinemia typically causes ECL cell hyperplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25751/abstract/27\">",
"     27",
"    </a>",
"    ]. A major concern was the observation that prolonged hypergastrinemia from potent antisecretory therapy was associated with the development of ECL cell carcinoid tumors in rodents [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25751/abstract/28\">",
"     28",
"    </a>",
"    ]. These data led the Food and Drug Administration to initially restrict the indications for proton-pump inhibitors to short-term use. However, gastric carcinoid tumors have not developed in humans exposed to acid suppression for prolonged periods of time. As a result, these drugs are now commonly used for chronic treatment of a variety of acid-related disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/28/25034?source=see_link&amp;anchor=H59974965#H59974965\">",
"     \"Overview and comparison of the proton pump inhibitors for the treatment of acid-related disorders\", section on 'Hypergastrinemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypergastrinemia and carcinoid tumors occur in two clinical conditions: gastrinoma and pernicious anemia. Carcinoid tumors have been reported in up to 30 percent of patients with multiple endocrine neoplasia type 1 (MEN-1) and 5 percent of patients with atrophic gastritis and pernicious anemia. Interestingly, carcinoid tumors occur in only ~1 percent of patients with sporadic gastrinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25751/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. These findings suggest that carcinoid tumor formation requires not only hypergastrinemia but another cofactor, such as loss of the tumor suppressor gene, menin (the genetic defect in MEN-1), or overexpression of a tumor growth promoter such as BCL-2, which occurs in the setting of chronic inflammation and atrophic gastritis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25751/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Colon cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrin has been implicated in colon cancer based upon laboratory and epidemiologic evidence [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25751/abstract/32-35\">",
"     32-35",
"    </a>",
"    ]. The following observations illustrate some of the laboratory findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gastrin increases the proliferation of colon cancer cell lines and the tumor burden in mice with colon cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?25/9/25751/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Gastrin and glycine-extended gastrin have growth promoting effects on human colon cancer in vivo and in vitro [",
"      <a class=\"abstract\" href=\"UTD.htm?25/9/25751/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A specific inhibitor of glycine-extended gastrin inhibited the growth of human colon cancer, suggesting that receptor blockade may be a strategy for treating patients with colon cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?25/9/25751/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Progastrin, glycine-extended gastrin, and amidated gastrin have been detected in cell extracts of gastrointestinal malignancies, suggesting that gastrin may be an autocrine or paracrine growth regulator [",
"      <a class=\"abstract\" href=\"UTD.htm?25/9/25751/abstract/39-41\">",
"       39-41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In one report, serum gastrin levels were elevated in patients with colon cancer and levels declined following surgical resection [",
"      <a class=\"abstract\" href=\"UTD.htm?25/9/25751/abstract/42\">",
"       42",
"      </a>",
"      ]. Furthermore, serum gastrin levels correlated with cancer stage.",
"     </li>",
"     <li>",
"      Immunostaining reveals that 80 to 90 percent of colon polyps contain gastrin [",
"      <a class=\"abstract\" href=\"UTD.htm?25/9/25751/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Gastrin inhibits apoptosis [",
"      <a class=\"abstract\" href=\"UTD.htm?25/9/25751/abstract/44\">",
"       44",
"      </a>",
"      ] and enhances angiogenesis [",
"      <a class=\"abstract\" href=\"UTD.htm?25/9/25751/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite these observations, it remains controversial whether circulating gastrin has a significant role in the development of human colon cancer. A potential role was supported by a case-control study in which serum gastrin levels from 250 incident cases of colorectal cancer were compared with levels from controls without colorectal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25751/abstract/34\">",
"     34",
"    </a>",
"    ]. After adjusting for some relevant covariates, an elevated serum gastrin concentration was found to be a significant risk factor for colorectal cancer (odds ratio 3.9). These findings support the concept that chronic hypergastrinemia by itself is not carcinogenic, but its proliferative effects may expand the pool of cells that could be at risk for carcinogenesis in susceptible patients. One group of patients at risk may be those infected with H. pylori [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25751/abstract/34\">",
"     34",
"    </a>",
"    ]. An increased rate of colon cancer has not been observed in patients with gastrinoma, pernicious anemia, or in those taking acid-suppressive medications",
"    <span class=\"nowrap\">",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?25/9/25751/abstract/46\">",
"      46",
"     </a>",
"     ].",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pancreatic cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;CCK2/gastrin",
"    receptors have been identified on human pancreatic cancer cells, where they can potentiate cancer growth [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25751/abstract/26\">",
"     26",
"    </a>",
"    ]. This effect is believed to be autocrine or paracrine since gastrin and its messenger RNA has been identified in cancers of the human pancreas [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25751/abstract/47\">",
"     47",
"    </a>",
"    ]. A role for gastrin in the proliferation of pancreatic cancer cells was supported by the observation that growth of cultured human pancreatic cancer cells can be inhibited by antisense oligonucleotides to gastrin [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25751/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Gastric polyps",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term treatment with proton pump inhibitors has been associated with the development of gastric fundic polyps and hyperplasia of the oxyntic mucosa. The clinical significance of these observations is uncertain, and their pathogenesis is incompletely understood [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25751/abstract/49\">",
"     49",
"    </a>",
"    ]. Infection with H. pylori may have a role, since gastrin has a growth promoting effect on the organism [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25751/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CLINICAL USES OF GASTRIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gastrin analog, pentagastrin, has been used clinically to stimulate histamine and gastric acid secretion in diagnostic tests of acid secretory capacity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25751/abstract/51\">",
"     51",
"    </a>",
"    ]. This test has been used to assess the extent of surgical vagotomy. Another clinical use of pentagastrin has been to provoke bioactive neuropeptide secretion in patients with neuroendocrine tumors such as vasoactive intestinal polypeptide secreting tumors (VIPomas) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25751/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/59/16311?source=see_link\">",
"     \"The VIPoma syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gastrin receptor antagonists have the theoretical advantage of blocking gastrin-induced gastric acid secretion, while obviating the concern over the trophic effects related to hypergastrinemia (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Causes of hypergastrinemia'",
"    </a>",
"    above). In addition, they could have a role in the treatment and prevention of gastrointestinal malignancies that express gastrin receptors. A number of potent gastrin receptor inhibitors have been developed and are currently under investigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H68312172\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Human gastrin is the product of a single gene located on chromosome 17. The active hormone is generated from a precursor peptide \"preprogastrin\" (",
"      <a class=\"graphic graphic_figure graphicRef52877 \" href=\"UTD.htm?34/4/34894\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Molecular forms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The vast majority of gastrin is produced in endocrine cells of the gastric antrum (G cells). Much smaller amounts of gastrin are produced in other regions of the gastrointestinal tract including the nonantral stomach, duodenum, jejunum, ileum, and pancreas. Gastrin has also been found outside of the gastrointestinal tract including the brain, adrenal glands, respiratory tract, and reproductive organs, although its biological role in these sites is unknown (",
"      <a class=\"graphic graphic_table graphicRef58007 \" href=\"UTD.htm?26/49/27419\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Tissue distribution'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The receptors for gastrin and cholecystokinin are related and constitute the",
"      <span class=\"nowrap\">",
"       \"CCK/Gastrin",
"      </span>",
"      receptor family.\" The CCK1 receptor is abundant in the pancreas and gallbladder and has a 1000-fold higher affinity for cholecystokinin than for gastrin. The",
"      <span class=\"nowrap\">",
"       CCK2/gastrin",
"      </span>",
"      receptor is found on parietal cells, on enterochromaffin-like (ECL) cells in the stomach, in the brain, and on pancreatic islet cells.",
"     </li>",
"     <li>",
"      Gastrin is released from G cells into the circulation in response to a meal or to a high gastric pH. The G cells are tightly regulated by two counterbalancing hormones, gastrin-releasing peptide and somatostatin, which exert stimulatory and inhibitory effects, respectively. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Gastrin physiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gastrin is a primary physiologic mediator of gastric acid secretion. Gastrin stimulates enterochromaffin-like (ECL) cells, which then secrete histamine, which in turn stimulates parietal cells to secret acid (",
"      <a class=\"graphic graphic_figure graphicRef65068 \" href=\"UTD.htm?18/29/18902\">",
"       figure 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Gastrin physiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical significance of chronic elevation in serum gastrin levels (as may be seen in patients taking proton pump inhibitors long-term) is uncertain. Gastrin receptors have been detected on a variety of tumor cells, and gastrin has trophic effects on the stomach and intestine, suggesting that it may have a role in the development of gastrointestinal malignancies. However, gastric carcinoid tumors have not developed in humans exposed to acid suppression for prolonged periods of time. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical significance of hypergastrinemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypergastrinemia is associated with the development of gastric carcinoid tumors. It has also been implicated in the development of colon and pancreatic cancer. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Gastric carcinoid tumors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Colon cancer'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Pancreatic cancer'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25751/abstract/1\">",
"      Edkins JS. On the chemical mechanism of gastric secretion. Proc R Soc Lond B Biol Sci 1905; 76:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25751/abstract/2\">",
"      GREGORY RA, TRACY HJ. THE CONSTITUTION AND PROPERTIES OF TWO GASTRINS EXTRACTED FROM HOG ANTRAL MUCOSA. Gut 1964; 5:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25751/abstract/3\">",
"      Joshi SN, Gardner JD. Gastrin and colon cancer: a unifying hypothesis. Dig Dis 1996; 14:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25751/abstract/4\">",
"      Kopin AS, Lee YM, McBride EW, et al. Expression cloning and characterization of the canine parietal cell gastrin receptor. Proc Natl Acad Sci U S A 1992; 89:3605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25751/abstract/5\">",
"      Rehfeld JF. Processing of precursors of gastroenteropancreatic hormones: diagnostic significance. J Mol Med (Berl) 1998; 76:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25751/abstract/6\">",
"      Rehfeld JF. The new biology of gastrointestinal hormones. Physiol Rev 1998; 78:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25751/abstract/7\">",
"      Hellmich MR, Rui XL, Hellmich HL, et al. Human colorectal cancers express a constitutively active cholecystokinin-B/gastrin receptor that stimulates cell growth. J Biol Chem 2000; 275:32122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25751/abstract/8\">",
"      Harris JC, Clarke PA, Awan A, et al. An antiapoptotic role for gastrin and the gastrin/CCK-2 receptor in Barrett's esophagus. Cancer Res 2004; 64:1915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25751/abstract/9\">",
"      Smith JP, Verderame MF, McLaughlin P, et al. Characterization of the CCK-C (cancer) receptor in human pancreatic cancer. Int J Mol Med 2002; 10:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25751/abstract/10\">",
"      Hersey SJ, Sachs G. Gastric acid secretion. Physiol Rev 1995; 75:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25751/abstract/11\">",
"      Sachs G, Prinz P. Gastric enterochromaffin-like cells and the regulation of acid secretion. News in Physiological Sci 1996; 11:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25751/abstract/12\">",
"      Rehfeld JF. Incretin physiology beyond glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: cholecystokinin and gastrin peptides. Acta Physiol (Oxf) 2011; 201:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25751/abstract/13\">",
"      Wang TC, Dockray GJ. Lessons from genetically engineered animal models. I. Physiological studies with gastrin in transgenic mice. Am J Physiol 1999; 277:G6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25751/abstract/14\">",
"      Koh TJ, Goldenring JR, Ito S, et al. Gastrin deficiency results in altered gastric differentiation and decreased colonic proliferation in mice. Gastroenterology 1997; 113:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25751/abstract/15\">",
"      Chen D, Zhao CM, Dockray GJ, et al. Glycine-extended gastrin synergizes with gastrin 17 to stimulate acid secretion in gastrin-deficient mice. Gastroenterology 2000; 119:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25751/abstract/16\">",
"      Nagata A, Ito M, Iwata N, et al. G protein-coupled cholecystokinin-B/gastrin receptors are responsible for physiological cell growth of the stomach mucosa in vivo. Proc Natl Acad Sci U S A 1996; 93:11825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25751/abstract/17\">",
"      Langhans N, Rindi G, Chiu M, et al. Abnormal gastric histology and decreased acid production in cholecystokinin-B/gastrin receptor-deficient mice. Gastroenterology 1997; 112:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25751/abstract/18\">",
"      Friis-Hansen L. Lessons from the gastrin knockout mice. Regul Pept 2007; 139:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25751/abstract/19\">",
"      Calam J, Gibbons A, Healey ZV, et al. How does Helicobacter pylori cause mucosal damage? Its effect on acid and gastrin physiology. Gastroenterology 1997; 113:S43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25751/abstract/20\">",
"      Okosdinossian ET, Munshid HA, Wasfi AI, et al. Fasting plasma-gastrin in vitiligo. Lancet 1978; 1:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25751/abstract/21\">",
"      Netter P, Faure G, Brassine A, et al. Hypergastrinemia in rheumatoid arthritis is related to Sj&ouml;gren's syndrome. J Rheumatol 1985; 12:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25751/abstract/22\">",
"      Korman MG, Laver MC, Hansky J. Hypergastrinaemia in chronic renal failure. Br Med J 1972; 1:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25751/abstract/23\">",
"      Song P, Groos S, Riederer B, et al. KCNQ1 is the luminal K+ recycling channel during stimulation of gastric acid secretion. J Physiol 2009; 587:3955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25751/abstract/24\">",
"      Winbo A, Sandstr&ouml;m O, Palmqvist R, Rydberg A. Iron-deficiency anaemia, gastric hyperplasia, and elevated gastrin levels due to potassium channel dysfunction in the Jervell and Lange-Nielsen Syndrome. Cardiol Young 2012; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25751/abstract/25\">",
"      Clerc P, Dufresne M, Saillan C, et al. Differential expression of the CCK-A and CCK-B/gastrin receptor genes in human cancers of the esophagus, stomach and colon. Int J Cancer 1997; 72:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25751/abstract/26\">",
"      de Weerth A, von Schrenck T, L&ouml;hr M, et al. Human pancreatic cancer cell lines express the CCKB receptor. Hepatogastroenterology 1999; 46:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25751/abstract/27\">",
"      Jensen RT. Involvement of cholecystokinin/gastrin-related peptides and their receptors in clinical gastrointestinal disorders. Pharmacol Toxicol 2002; 91:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25751/abstract/28\">",
"      Havu N. Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion. Digestion 1986; 35 Suppl 1:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25751/abstract/29\">",
"      Bordi C, D'Adda T, Azzoni C, et al. Hypergastrinemia and gastric enterochromaffin-like cells. Am J Surg Pathol 1995; 19 Suppl 1:S8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25751/abstract/30\">",
"      Gibril F, Schumann M, Pace A, Jensen RT. Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature. Medicine (Baltimore) 2004; 83:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25751/abstract/31\">",
"      Cadiot G, Laurent-Puig P, Thuille B, et al. Is the multiple endocrine neoplasia type 1 gene a suppressor for fundic argyrophil tumors in the Zollinger-Ellison syndrome? Gastroenterology 1993; 105:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25751/abstract/32\">",
"      Nakata H, Wang SL, Chung DC, et al. Oncogenic ras induces gastrin gene expression in colon cancer. Gastroenterology 1998; 115:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25751/abstract/33\">",
"      Renga M, Brandi G, Paganelli GM, et al. Rectal cell proliferation and colon cancer risk in patients with hypergastrinaemia. Gut 1997; 41:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25751/abstract/34\">",
"      Thorburn CM, Friedman GD, Dickinson CJ, et al. Gastrin and colorectal cancer: a prospective study. Gastroenterology 1998; 115:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25751/abstract/35\">",
"      Grabowska AM, Watson SA. Role of gastrin peptides in carcinogenesis. Cancer Lett 2007; 257:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25751/abstract/36\">",
"      Bold RJ, Ishizuka J, Townsend CM Jr. Progress toward hormonal therapy of gastrointestinal cancer. Ann Surg 1996; 223:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25751/abstract/37\">",
"      Stepan VM, Sawada M, Todisco A, Dickinson CJ. Glycine-extended gastrin exerts growth-promoting effects on human colon cancer cells. Mol Med 1999; 5:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25751/abstract/38\">",
"      Litvak DA, Hellmich MR, Iwase K, et al. JMV1155: a novel inhibitor of glycine-extended progastrin-mediated growth of a human colon cancer in vivo. Anticancer Res 1999; 19:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25751/abstract/39\">",
"      Kelly A, Hollande F, Shulkes A, Baldwin GS. Expression of progastrin-derived peptides and gastrin receptors in a panel of gastrointestinal carcinoma cell lines. J Gastroenterol Hepatol 1998; 13:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25751/abstract/40\">",
"      Van Solinge WW, Nielsen FC, Friis-Hansen L, et al. Expression but incomplete maturation of progastrin in colorectal carcinomas. Gastroenterology 1993; 104:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25751/abstract/41\">",
"      Ciccotosto GD, McLeish A, Hardy KJ, Shulkes A. Expression, processing, and secretion of gastrin in patients with colorectal carcinoma. Gastroenterology 1995; 109:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25751/abstract/42\">",
"      Bombski G, Gasiorowska A, Orszulak-Michalak D, et al. Elevated plasma gastrin, CEA, and CA 19-9 levels decrease after colorectal cancer resection. Int J Colorectal Dis 2003; 18:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25751/abstract/43\">",
"      Smith AM, Watson SA. Gastrin and gastrin receptor activation: an early event in the adenoma-carcinoma sequence. Gut 2000; 47:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25751/abstract/44\">",
"      Ramamoorthy S, Stepan V, Todisco A. Intracellular mechanisms mediating the anti-apoptotic action of gastrin. Biochem Biophys Res Commun 2004; 323:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25751/abstract/45\">",
"      Clarke PA, Dickson JH, Harris JC, et al. Gastrin enhances the angiogenic potential of endothelial cells via modulation of heparin-binding epidermal-like growth factor. Cancer Res 2006; 66:3504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25751/abstract/46\">",
"      Orlando LA, Lenard L, Orlando RC. Chronic hypergastrinemia: causes and consequences. Dig Dis Sci 2007; 52:2482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25751/abstract/47\">",
"      Smith JP, Shih A, Wu Y, et al. Gastrin regulates growth of human pancreatic cancer in a tonic and autocrine fashion. Am J Physiol 1996; 270:R1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25751/abstract/48\">",
"      Smith JP, Verderame MF, Zagon IS. Antisense oligonucleotides to gastrin inhibit growth of human pancreatic cancer. Cancer Lett 1999; 135:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25751/abstract/49\">",
"      el-Zimaity HM, Jackson FW, Graham DY. Fundic gland polyps developing during omeprazole therapy. Am J Gastroenterol 1997; 92:1858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25751/abstract/50\">",
"      Chowers MY, Keller N, Tal R, et al. Human gastrin: a Helicobacter pylori--specific growth factor. Gastroenterology 1999; 117:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25751/abstract/51\">",
"      Payne NA, Gerber JG. Differential effects of somatostatin and prostaglandins on gastric histamine release to pentagastrin. J Pharmacol Exp Ther 1992; 263:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25751/abstract/52\">",
"      Brunt LM, Mazoujian G, O'Dorisio TM, Wells SA Jr. Stimulation of vasoactive intestinal peptide and neurotensin secretion by pentagastrin in a patient with VIPoma syndrome. Surgery 1994; 115:362.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2551 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-2EE9D05621-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_9_25751=[""].join("\n");
var outline_f25_9_25751=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H68312172\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MOLECULAR FORMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TISSUE DISTRIBUTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RECEPTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      GASTRIN PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Transgenic and gene deletion animal models",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Causes of hypergastrinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL SIGNIFICANCE OF HYPERGASTRINEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Gastric carcinoid tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Colon cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Gastric polyps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CLINICAL USES OF GASTRIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H68312172\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2551\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2551|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/4/34894\" title=\"figure 1\">",
"      Synthesis of gastrin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/20/324\" title=\"figure 2\">",
"      G protein structure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/29/18902\" title=\"figure 3\">",
"      Regulation of acid secretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2551|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/38/41577\" title=\"picture 1\">",
"      Zollinger Ellison Light",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2551|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/44/715\" title=\"table 1\">",
"      Secretory products gastrin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/49/27419\" title=\"table 2\">",
"      Mammalian tissues expressing gastrin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/12/9420\" title=\"table 3\">",
"      Causes of hypergastrinemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14504?source=related_link\">",
"      Clinical manifestations and diagnosis of Zollinger-Ellison syndrome (gastrinoma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38298?source=related_link\">",
"      Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/51/6968?source=related_link\">",
"      Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/28/25034?source=related_link\">",
"      Overview and comparison of the proton pump inhibitors for the treatment of acid-related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/49/22293?source=related_link\">",
"      Peptide hormone signal transduction and regulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29160?source=related_link\">",
"      Physiology of gastric acid secretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22660?source=related_link\">",
"      Synthesis, secretion, and regulation of gastrointestinal peptides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/59/16311?source=related_link\">",
"      The VIPoma syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_9_25752="Sarcoid: Muscle, bone, and vascular disease manifestations";
var content_f25_9_25752=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sarcoid: Muscle, bone, and vascular disease manifestations",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/9/25752/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/9/25752/contributors\">",
"     Winston Sequeira, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/9/25752/contributors\">",
"     Rohit Aggarwal, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/9/25752/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/9/25752/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/9/25752/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/9/25752/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/9/25752/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sarcoidosis, a multisystem disorder of unknown etiology, is characterized pathologically by the presence of noncaseating granulomas in affected organs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6376?source=see_link\">",
"     \"Pathogenesis of sarcoidosis\"",
"    </a>",
"    .) It typically affects young adults, and, although any organ may be affected, the disorder commonly presents with one or more of the following three abnormalities:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bilateral hilar adenopathy",
"     </li>",
"     <li>",
"      Pulmonary infiltrates",
"     </li>",
"     <li>",
"      Skin",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      eye lesions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Musculoskeletal disease is a less common problem. However, joint manifestations may be clinically significant in patients with acute disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/1\">",
"     1",
"    </a>",
"    ]. Overall, 4 to 38 percent of patients with sarcoidosis have one or more musculoskeletal manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The bone, muscle, and vascular manifestations of sarcoidosis other than arthritis will be reviewed here. General issues related to sarcoidosis and its pathogenesis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of sarcoidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6376?source=see_link\">",
"     \"Pathogenesis of sarcoidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The American Thoracic Society (ATS) statement on sarcoidosis, as well as other ATS guidelines, can be accessed through the ATS web site at",
"    <a class=\"external\" href=\"file://www.thoracic.org/statements/\">",
"     www.thoracic.org/statements",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SARCOID ARTHROPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The articular manifestations of sarcoidosis and the diagnosis and treatment of sarcoid arthropathy are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11463?source=see_link\">",
"     \"Sarcoid arthropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MYOPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is estimated that skeletal muscle is involved in 50 to 80 percent of individuals with sarcoidosis but is rarely (0.5 to 2.5 percent) symptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Symptoms may result from muscle disease involving the diaphragm, extraocular muscles, and other muscle groups [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/3,6-10\">",
"     3,6-10",
"    </a>",
"    ]. Sarcoidosis should, therefore, be considered in patients presenting with unexplained muscle weakness, pain, or nodular swelling. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26694?source=see_link\">",
"     \"Approach to the patient with muscle weakness\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Three clinical patterns of myopathy have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common form is the insidious onset of proximal muscle weakness with normal or elevated serum levels of muscle enzymes. This myopathy responds poorly to corticosteroids. It should be appreciated, however, that steroid therapy can induce a similar proximal myopathy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23173?source=see_link\">",
"       \"Glucocorticoid-induced myopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An acute myopathy, observed most commonly in women, is associated with elevated muscle enzymes.",
"     </li>",
"     <li>",
"      The least frequent pattern is a nodular myopathy, which can present as single or multiple painful nodules. In one case, the large lesion resembled a tumor [",
"      <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Electromyography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electromyographic studies in patients with sarcoidosis and muscle weakness may reveal a myopathic pattern. In some cases, widespread myotonia can mimic the pattern observed in acid maltase disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/20/17736?source=see_link\">",
"     \"Lysosomal acid maltase deficiency (glycogen storage disease II, Pompe disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging studies may help distinguish and diagnose the different types of myopathy. One study, for example, evaluated the relative utility of magnetic resonance imaging, CT scanning, and gallium scanning in four patients with biopsy-proven lower-extremity myositis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/12\">",
"     12",
"    </a>",
"    ]. Only MRI was positive in all four individuals and could distinguish between atrophic and nodular myopathy. By comparison, gallium scanning (with increased uptake) only identified nodular lesions, and computed tomography failed to provide any additional information. Nodular myopathy produces a characteristic pattern on MRI: a star-shaped area of low-signal intensity centered within the nodule surrounded by areas of high intensity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/13\">",
"     13",
"    </a>",
"    ]. This finding may help direct the location of a muscle biopsy, thereby increasing the yield. It is important to be aware that the central hypointense area persists after steroid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Muscle biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biopsy of affected muscle in patients with sarcoid myopathy reveals a diffuse cellular distribution with macrophages and CD4 positive T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/15\">",
"     15",
"    </a>",
"    ]. In addition, CD8 positive T cells are irregularly distributed within the granulomatous cellular infiltrate in early lesions and surrounding the granulomas in more mature lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Fibronectin and hyaluronidase can be demonstrated in the increased connective tissue with desmin differentiating the myogenic giant cells from Langhans giant cells. Endomysial and perivascular inflammation is present, along with areas of muscle fiber degeneration and regeneration [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/17\">",
"     17",
"    </a>",
"    ]. Fiber destruction in this disease is caused mainly by fiber infiltration rather than by mechanical compression or ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/18\">",
"     18",
"    </a>",
"    ]. On occasion, there may be evidence of a neuromyopathy with granuloma around intramuscular nerve fibers [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Myopathy: Diagnosis and differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to the patient suspected of having sarcoid myopathy depends upon the presence or absence of a diagnosis of sarcoidosis. In the patient with undiagnosed weakness, the evaluation is similar to that of any patient presenting with symptoms suggestive of muscle disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26694?source=see_link\">",
"     \"Approach to the patient with muscle weakness\"",
"    </a>",
"    .) In this setting, a sarcoid myopathy is suspected if a myopathy exists in association with additional manifestations of sarcoidosis.",
"   </p>",
"   <p>",
"    A biopsy showing granulomatous myositis is highly suggestive of, but is not diagnostic of, sarcoidosis. This finding can also occur in a number of other disorders, including granulomatosis with polyangiitis (Wegener&rsquo;s), polymyositis, dermatomyositis, and Crohn's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/9\">",
"     9",
"    </a>",
"    ]. Associated signs and symptoms of sarcoidosis should, therefore, be present before a definite diagnosis can be established. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of sarcoidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Open surgical muscle biopsy has typically been used to assess muscle disease in patients with suspected sarcoid myopathy. Needle biopsy techniques have been used in a few patients with nodular disease; cytologic examination of specimens obtained by fine needle aspiration may provide diagnostically useful material [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although fine needle aspiration has the advantage of being minimally invasive, the sensitivity and specificity of this approach for patients with nodular myopathy are uncertain. However, in the setting of previously diagnosed sarcoidosis and suggestive MRI features (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Imaging studies'",
"    </a>",
"    above), cytologic evidence for granulomatous inflammation and an absence of both neoplasia and pathogenic infectious agents may allow a diagnosis of sarcoid myopathy to be made without open or cutting needle muscle biopsy. However, false negatives may result, in part because of patchy muscle involvement in sarcoid myopathy.",
"   </p>",
"   <p>",
"    Among patients already diagnosed with sarcoidosis, the development of a myopathy is most commonly suspected among those with the insidious development of progressive proximal weakness. Acute presentations may also occur. Abnormal laboratory findings, such as elevated muscle enzymes, specific findings on MRI, and biopsy evidence of granulomatous infiltration further support the diagnosis. Reduced walking capacity and dyspnea may be caused by impaired inspiratory muscle strength, which can only be reliably detected by non-volitional tests of inspiratory muscle strength [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Sarcoid myopathy: Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids may be used to treat symptomatic patients, assuming that the myopathy is not thought to be glucocorticoid-induced. This suggested approach is based upon clinical experience as there have been no placebo-controlled studies of glucocorticoids for sarcoid myopathy. Standard doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    used for other forms of inflammatory myopathies are administered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/22/11626?source=see_link\">",
"     \"Initial treatment of dermatomyositis and polymyositis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For a patient with one or a few painful nodular sarcoid muscle lesions, combined therapy consisting of the intralesional injection of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    , rest, and a nonsteroidal antiinflammatory agent may also be helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     BONE INVOLVEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sarcoidosis of bone occurs in approximately 5 percent of patients (range of 1 to 13 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/23\">",
"     23",
"    </a>",
"    ]. Although bony involvement may be the earliest manifestation of sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/24\">",
"     24",
"    </a>",
"    ], it is usually accompanied by infiltrative skin lesions. When present, the presence of bone lesions generally implies a more chronic and severe disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/23,25\">",
"     23,25",
"    </a>",
"    ]. Almost one-half of affected patients are asymptomatic. Osteoporosis and osteopenia are also noted in patients with sarcoidosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Focal bone lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The proximal and middle phalanges are most frequently involved; however, the skull, vertebrae, ribs, maxilla, and nasal bones also may be affected [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/26-29\">",
"     26-29",
"    </a>",
"    ]. Dactylitis, a sausage-like swelling of a digit, as seen in seronegative spondyloarthropathy and gout, may occur with or without phalangeal bone involvement in patients with sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Cystic bone lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bony lesions are usually cystic; sclerotic lesions are rarely noted. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Sclerotic lesions'",
"    </a>",
"    below.) Multiple cystic lesions sometimes result in a &ldquo;lacy pattern,&rdquo; which is a typical lesion seen in sarcoid bone disease. These changes are typically detected by plain film radiography, but, in some cases, lesions may only be seen on magnetic resonance images [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hand radiographs demonstrate lytic lesions of the heads of the proximal or middle phalanges (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef70918 \" href=\"UTD.htm?13/1/13343\">",
"       image 1",
"      </a>",
"      ) and, less frequently, of the metacarpal bones.",
"     </li>",
"     <li>",
"      Punched out cysts, a fine lattice, or both, in combination with a background of diffuse osteoporosis, may be the only radiographic abnormalities [",
"      <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Permeative defects may involve tunneling with remodeling of the cortex; this process converts the concave shaft into a tubular structure. Destruction of the cortex may then lead to multiple fractures and sequestrum formation [",
"      <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Involvement of the skull may be associated with painless nodules of the scalp.",
"     </li>",
"     <li>",
"      Lupus pernio, nodular skin lesions of the nose and malar areas, may be observed with lesions of the nasal bones and hard palate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Sclerotic lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, sclerotic bone lesions are rare in patients with sarcoidosis; when present, they commonly affect the axial skeleton, with the bones of the pelvis, spine, and ribs being most often involved [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/34\">",
"     34",
"    </a>",
"    ]. These lesions appear to occur exclusively in middle-aged black patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The onset of sclerotic sarcoid bone lesions is insidious and may precede other manifestations of the disease. A bone scan, which is positive, is nonspecific.",
"   </p>",
"   <p>",
"    Sarcoidosis of the long bones may resemble Paget disease since both disorders are associated with increased uptake on bone scans and with lytic and sclerotic lesions on radiography. Unlike Paget disease, however, the serum alkaline phosphatase concentration is usually normal or only mildly elevated in patients with sarcoidosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Spinal involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only a small number of patients with lytic or sclerotic lesions of the spine in association with sarcoidosis have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/36\">",
"     36",
"    </a>",
"    ]. The disease most commonly affects the lower dorsal and upper lumbar vertebrae, but the cervical spine including the atlantoaxial (C1-C2) joint may be involved [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Sternal involvement associated with diffuse spinal sarcoid has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/39\">",
"     39",
"    </a>",
"    ]. Widespread lytic lesions may mimic metastatic disease on radiographs and on bone scintigraphy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Magnetic resonance imaging may be particularly informative with vertebral sarcoidosis. Granulomatous inflammation prolongs T1 and T2 relaxation times [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/36\">",
"     36",
"    </a>",
"    ]. As a result, MRI may demonstrate single or multiple focal lesions that are hypointense on T1 and hyperintense on T2; lesions typically enhance with contrast administration [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A biopsy may be necessary to exclude infection if the disc and spine are concurrently involved [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/43\">",
"     43",
"    </a>",
"    ]. An association between vertebral sarcoidosis and paravertebral ossification simulating ankylosing spondylitis and reactive arthritis has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/44\">",
"     44",
"    </a>",
"    ]. At least 17 patients have had radiographic sacroiliac involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. This coexistence is uncommon (6.6 percent in one study of 61 patients with sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/46\">",
"     46",
"    </a>",
"    ]).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Focal bone lesions: Diagnosis and differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a patient with an established diagnosis of sarcoidosis and radiographic features that are typical for this disease (eg, cystic bone lesions with well defined margins), it may not be necessary to perform any additional studies before making a diagnosis of sarcoid involvement of bone.",
"   </p>",
"   <p>",
"    However, if there are sclerotic lesions or if there is extension of an infiltrative lesion that encroaches on nearby structures (eg, spinal vertebral disease with extradural compression of the spinal cord or spinal nerves) a biopsy is often required to exclude other conditions such as metastatic disease of the breast or prostate, lymphoma, Paget, osteopetrosis, and mastocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Osteopenia and osteoporosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few studies exist evaluating bone mineral density in patients with sarcoidosis. Although bone density may be normal or high in early disease, osteoporosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    osteopenia may eventually develop over time. One study, for example, evaluated bone mineral density using quantitative computed tomography in 36 untreated patients and 190 healthy individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/47\">",
"     47",
"    </a>",
"    ]. Five patients, all with untreated disease of greater than two years, had bone mineral content more than two standard deviations below normal values.",
"   </p>",
"   <p>",
"    Osteopenia in sarcoid may be caused by one or more of the following factors:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diffuse skeletal granulomatosis [",
"      <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/48\">",
"       48",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Calcitriol and osteoclastic activating factor produced by activated T cells [",
"      <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/49\">",
"       49",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Treatment with glucocorticoids, particularly in the postmenopausal patient [",
"      <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/50\">",
"       50",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42855?source=see_link\">",
"       \"Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Bone loss: Prevention and treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevention and treatment of bone loss in patients with sarcoidosis is difficult. Calcium and vitamin D, both commonly administered to patients at risk for osteoporosis, are relatively contraindicated in sarcoidosis because of the propensity toward hypercalcemia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/16/2310?source=see_link\">",
"     \"Hypercalcemia in granulomatous diseases\"",
"    </a>",
"    .) Thus, calcitonin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a bisphosphonate may be preferred in patients with steroid-associated osteopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=see_link\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     VASCULITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rarely, vasculitis involving small, medium, or large arteries occurs in sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/54\">",
"     54",
"    </a>",
"    ]. The vessels may be infiltrated by granulomas, or there may be granulomatous inflammation of the vessel wall [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/55\">",
"     55",
"    </a>",
"    ]. Necrotizing vasculitis may contribute to neurologic injury and peripheral neuropathy in sarcoidosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20616?source=see_link\">",
"     \"Neurologic sarcoidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients with large-vessel vasculitis have early onset sarcoidosis, a sporadic early childhood presentation of Blau syndrome (usually appearing before age four), which is characterized clinically by rash, iritis, and granulomatous arthritis. In some patients, large-vessel involvement may resemble Takayasu arteritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15494?source=see_link&amp;anchor=H9#H9\">",
"     \"Periodic fever syndromes and other autoinflammatory diseases: An overview\", section on 'Blau syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/19/13624?source=see_link\">",
"     \"Clinical features and diagnosis of Takayasu arteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are many similarities between granulomatosis with polyangiitis (Wegener&rsquo;s) and sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/56\">",
"     56",
"    </a>",
"    ]. However, antineutrophil cytoplasmic antibodies are typically present in the former and are absent in the latter. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=see_link\">",
"     \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Vasculitis: Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sarcoid-associated vasculitis is more benign than that observed in granulomatosis with polyangiitis (Wegener&rsquo;s) and usually does not require the use of cytotoxic agents. Oral corticosteroids administered at doses of 40 to 60",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    are quite adequate in most cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     CLUBBING",
"    </span>",
"    &nbsp;&mdash;&nbsp;True clubbing is rare in sarcoidosis, although nail bed thickening is common (",
"    <a class=\"graphic graphic_figure graphicRef52839 \" href=\"UTD.htm?42/58/43951\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/57\">",
"     57",
"    </a>",
"    ]. In one study, for example, clubbing was observed in only 2 of 136 patients at disease presentation and in only two more at follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/58\">",
"     58",
"    </a>",
"    ]. Unilateral clubbing and localized periostitis without clubbing have also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. Dystrophic nails frequently accompany bony abnormalities; however, there are two reports in which the diagnosis was made with nailfold biopsy in patients without bone disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     OTHER ASSOCIATED DISEASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A post-sarcoidosis chronic fatigue-like syndrome has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/23\">",
"     23",
"    </a>",
"    ]. In this setting, there is no evidence of active disease, and all laboratory tests, including serum ACE, are normal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30825?source=see_link\">",
"     \"Clinical features and diagnosis of chronic fatigue syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sarcoidosis has also been described in patients with other autoimmune diseases; these include rheumatoid arthritis, systemic sclerosis, systemic lupus erythematosus, Sj&ouml;gren's syndrome, primary biliary cirrhosis, and myasthenia gravis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/62-64\">",
"     62-64",
"    </a>",
"    ]. Since autoantibodies, circulating immune complexes, and altered lymphocyte function are common to all these diseases, they may all be part of a predisposition to autoimmune disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25752/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Muscle disease",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptomatic muscle disease is a rare manifestation of sarcoidosis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Myopathy'",
"      </a>",
"      above.) Three types of clinical muscle disease are recognized: insidious proximal muscle weakness, acute myopathy with weakness and elevated muscle enzymes, and nodular myopathy.",
"     </li>",
"     <li>",
"      In a patient with sarcoidosis, the presence of muscle weakness, muscle pain, or muscle nodules is suggestive of sarcoid myopathy. The differential diagnosis includes glucocorticoid-induced and other drug-induced myopathies, and, in patients with a muscle biopsy that reveals multiple noncaseating granulomas, other granulomatous diseases must also be considered. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Myopathy: Diagnosis and differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest glucocorticoid treatment for patients with symptomatic acute or chronic myopathy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Considerations regarding agent, dose, and frequency are similar to those for dermatomyositis and polymyositis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/22/11626?source=see_link\">",
"       \"Initial treatment of dermatomyositis and polymyositis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with focal nodular myopathy, we suggest intralesional injection of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"       triamcinolone",
"      </a>",
"      , bed rest, and an NSAID rather than oral glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Bone disease",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bone lesions are uncommonly noted in patients with sarcoidosis. They may be detected by imaging studies in approximately 5 percent of patients but are symptomatic in only one-half.",
"     </li>",
"     <li>",
"      Cystic lesions of the phalanges are the most typical bone lesion but may also be found in the skull, vertebral bodies, and flat bones. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Cystic bone lesions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Spinal involvement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnosis of osseous sarcoidosis may be made in a patient with an established diagnosis of sarcoidosis and with typical cystic bone lesions. We recommend bone biopsy to evaluate sclerotic bone lesions since these are rarely seen in sarcoidosis, and other causes of",
"      <span class=\"nowrap\">",
"       sclerotic/blastic",
"      </span>",
"      bone lesions, such as metastatic cancer, should be excluded. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Sclerotic lesions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Osteopenia and osteoporosis in patients with sarcoidosis may be due to the disease itself or to glucocorticoid treatment. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Osteopenia and osteoporosis'",
"      </a>",
"      above.) We recommend the use of bisphosphonates for prevention and treatment of glucocorticoid-induced bone mineral loss (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=see_link\">",
"       \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Because of a propensity to hypercalcemia in sarcoidosis, we suggest avoiding use of calcium supplements and vitamin D (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Vasculitis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vascular involvement of vessels of any size may occur. Extension of granulomatous inflammation into a blood vessel or granuloma formation within a vessel wall may lead to ischemia or infarction. Distinguishing granulomatous vasculitis due to sarcoidosis from other systemic granulomatous diseases such as granulomatosis with polyangiitis (Wegener&rsquo;s) may be aided by measuring antineutrophil cytoplasmic antibodies (ANCA). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Vasculitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest treating granulomatous vasculitis due to sarcoidosis with oral glucocorticoids (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      40 to 60",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      or equivalent) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Other rheumatic and autoimmune disorders",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clubbing, chronic fatigue, and various diseases of presumed autoimmune pathogenesis (eg, Sj&ouml;gren's syndrome, primary biliary cirrhosis, etc.) have been described in association with sarcoidosis. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Clubbing'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Other associated diseases'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/1\">",
"      Spilberg I, Siltzbach LE, McEwen C. The arthritis of sarcoidosis. Arthritis Rheum 1969; 12:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/2\">",
"      Abril A, Cohen MD. Rheumatologic manifestations of sarcoidosis. Curr Opin Rheumatol 2004; 16:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/3\">",
"      Baydur A, Pandya K, Sharma OP, et al. Control of ventilation, respiratory muscle strength, and granulomatous involvement of skeletal muscle in patients with sarcoidosis. Chest 1993; 103:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/4\">",
"      Zisman DA, Biermann JS, Martinez FJ, et al. Sarcoidosis presenting as a tumorlike muscular lesion. Case report and review of the literature. Medicine (Baltimore) 1999; 78:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/5\">",
"      Fayad F, Liot&eacute; F, Berenbaum F, et al. Muscle involvement in sarcoidosis: a retrospective and followup studies. J Rheumatol 2006; 33:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/6\">",
"      Dewberry RG, Schneider BF, Cale WF, Phillips LH 2nd. Sarcoid myopathy presenting with diaphragm weakness. Muscle Nerve 1993; 16:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/7\">",
"      Cornblath WT, Elner V, Rolfe M. Extraocular muscle involvement in sarcoidosis. Ophthalmology 1993; 100:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/8\">",
"      Janssen M, Dijkmans BA, Eulderink F. Muscle cramps in the calf as presenting symptom of sarcoidosis. Ann Rheum Dis 1991; 50:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/9\">",
"      Simmonds NJ, Hoffbrand BI. Contracturing granulomatous myositis: a separate entity. J Neurol Neurosurg Psychiatry 1990; 53:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/10\">",
"      Gdynia HJ, Osterfeld N, Dorst J, et al. Granulomatous myositis mimicking slowly progressive lower motor neuron disease. Eur J Med Res 2008; 13:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/11\">",
"      Mathur A, Kremer JM. Immunopathology, musculoskeletal features, and treatment of sarcoidosis. Curr Opin Rheumatol 1993; 5:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/12\">",
"      Kurashima K, Shimizu H, Ogawa H, et al. MR and CT in the evaluation of sarcoid myopathy. J Comput Assist Tomogr 1991; 15:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/13\">",
"      Otake S, Banno T, Ohba S, et al. Muscular sarcoidosis: findings at MR imaging. Radiology 1990; 176:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/14\">",
"      Otake S, Imagumbai N, Suzuki M, Ohba S. MR imaging of muscular sarcoidosis after steroid therapy. Eur Radiol 1998; 8:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/15\">",
"      Tews DS, Pongratz DE. Immunohistological analysis of sarcoid myopathy. J Neurol Neurosurg Psychiatry 1995; 59:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/16\">",
"      Takanashi T, Suzuki Y, Yoshino Y, Nonaka I. Granulomatous myositis: pathologic re-evaluation by immunohistochemical analysis of infiltrating mononuclear cells. J Neurol Sci 1997; 145:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/17\">",
"      Prayson RA. Granulomatous myositis. Clinicopathologic study of 12 cases. Am J Clin Pathol 1999; 112:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/18\">",
"      Kumamoto T, Yukishige K, Ito T, et al. Cellular distribution of proteolytic enzymes in the skeletal muscle of sarcoid myopathy. Acta Neuropathol 2002; 104:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/19\">",
"      Gemignani F, Bellanova MF, Salih S, et al. Sarcoid neuromyopathy with selective involvement of the intramuscular nerves. Acta Neuropathol 1998; 95:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/20\">",
"      Guo M, Lemos L, Baliga M. Nodular sarcoid myositis of skeletal muscle diagnosed by fine needle aspiration biopsy. A case report. Acta Cytol 1999; 43:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/21\">",
"      Yamamoto T, Nagira K, Akisue T, et al. Aspiration biopsy of nodular sarcoidosis of the muscle. Diagn Cytopathol 2002; 26:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/22\">",
"      Kabitz HJ, Lang F, Walterspacher S, et al. Impact of impaired inspiratory muscle strength on dyspnea and walking capacity in sarcoidosis. Chest 2006; 130:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/23\">",
"      James DG, Neville E, Carstairs LS. Bone and joint sarcoidosis. Semin Arthritis Rheum 1976; 6:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/24\">",
"      Chang JC, Sakurai H, Jagirdar J. Symptomatic rib lesions as the primary presentation of sarcoidosis. Report of two cases and review of literature. Sarcoidosis 1992; 9:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/25\">",
"      Neville E, Carstairs LS, James DG. Sarcoidosis of bone. Q J Med 1977; 46:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/26\">",
"      BERK RN, BROWER TD. VERTEBRAL SARCOIDOSIS. Radiology 1964; 82:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/27\">",
"      Young DA, Laman ML. Radiodense skeletal lesions in Boeck's sarcoid. Am J Roentgenol Radium Ther Nucl Med 1972; 114:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/28\">",
"      Rubin MM, Sanfilippo RJ, Pliskin A. Maxillary alveolar bone loss in a patient with sarcoidosis. J Oral Maxillofac Surg 1991; 49:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/29\">",
"      CURTIS GT. SARCOIDOSIS OF THE NASAL BONES. Br J Radiol 1964; 37:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/30\">",
"      Rothschild BM, Pingitore C, Eaton M. Dactylitis: implications for clinical practice. Semin Arthritis Rheum 1998; 28:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/31\">",
"      Blacksin MF, Acello AN, Kowalec J, Lyons MM. Osseous sarcoidosis of the foot: detection by MR imaging. AJR Am J Roentgenol 1994; 163:1444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/32\">",
"      Le Breton C, Ferroir JP, Cadranel J, et al. Case report 825. Leptomeningeal and spinal-pelvic osseous sarcoidosis. Skeletal Radiol 1994; 23:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/33\">",
"      Posner MA, Melendez E, Steiner G. Solitary osseous sarcoidosis in a finger. J Hand Surg Am 1991; 16:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/34\">",
"      De Bardt M, Grossin M, Smadja M, Kahn MF. Vertebral osteosclerotic sarcoidosis. AJR Am J Roentgenol 1991; 157:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/35\">",
"      Vinnicombe S, Heron C, Wansbrough-Jones M. Dense bones. Br J Radiol 1992; 65:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/36\">",
"      Shaikh S, Soubani AO, Rumore P, et al. Lytic osseous destruction in vertebral sarcoidosis. N Y State J Med 1992; 92:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/37\">",
"      Cutler SS, Sankaranarayanan G. Vertebral sarcoidosis. JAMA 1978; 240:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/38\">",
"      Sundaram M, Place H, Shaffer WO, Martin DS. Progressive destructive vertebral sarcoid leading to surgical fusion. Skeletal Radiol 1999; 28:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/39\">",
"      Claren&ccedil;on F, Silbermann-Hoffman O, Lebreton C, et al. Diffuse spine involvement in sarcoidosis with sternal lytic lesions: two case reports. Spine (Phila Pa 1976) 2007; 32:E594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/40\">",
"      Talmi D, Smith S, Mulligan ME. Central skeletal sarcoidosis mimicking metastatic disease. Skeletal Radiol 2008; 37:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/41\">",
"      Nijjar SS, Leslie WD. A case of skeletal sarcoidosis imitating skeletal metastases on bone scintigraphy. CMAJ 2008; 178:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/42\">",
"      Ginsberg LE, Williams DW 3rd, Stanton C. MRI of vertebral sarcoidosis. J Comput Assist Tomogr 1993; 17:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/43\">",
"      Kenney CM 3rd, Goldstein SJ. MRI of sarcoid spondylodiskitis. J Comput Assist Tomogr 1992; 16:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/44\">",
"      Perlman SG, Damergis J, Witorsch P, et al. Vertebral sarcoidosis with paravertebral ossification. Arthritis Rheum 1978; 21:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/45\">",
"      Franco M, Passeron C, Tieulie N, et al. Long-term radiographic follow-up in a patient with osteosclerotic sarcoidosis of the spine and pelvis. Rev Rhum Engl Ed 1998; 65:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/46\">",
"      Erb N, Cushley MJ, Kassimos DG, et al. An assessment of back pain and the prevalence of sacroiliitis in sarcoidosis. Chest 2005; 127:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/47\">",
"      Montemurro L, Fraioli P, Rizzato G. Bone loss in untreated longstanding sarcoidosis. Sarcoidosis 1991; 8:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/48\">",
"      Fallon MD, Perry HM 3rd, Teitelbaum SL. Skeletal sarcoidosis with osteopenia. Metab Bone Dis Relat Res 1981; 3:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/49\">",
"      Reichel H, Koeffler HP, Norman AW. The role of the vitamin D endocrine system in health and disease. N Engl J Med 1989; 320:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/50\">",
"      Montemurro L, Fraioli P, Riboldi A, et al. Bone loss in prednisone treated sarcoidosis: a two-year follow-up. Ann Ital Med Int 1990; 5:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/51\">",
"      Rizzato G, Fraioli P. Natural and corticosteroid-induced osteoporosis in sarcoidosis: prevention, treatment, follow up and reversibility. Sarcoidosis 1990; 7:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/52\">",
"      Montemurro L, Schiraldi G, Fraioli P, et al. Prevention of corticosteroid-induced osteoporosis with salmon calcitonin in sarcoid patients. Calcif Tissue Int 1991; 49:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/53\">",
"      Gallacher SJ, Fenner JA, Anderson K, et al. Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid dependent lung disease: an open pilot study. Thorax 1992; 47:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/54\">",
"      Fernandes SR, Singsen BH, Hoffman GS. Sarcoidosis and systemic vasculitis. Semin Arthritis Rheum 2000; 30:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/55\">",
"      Kwong T, Valderrama E, Paley C, Ilowite N. Systemic necrotizing vasculitis associated with childhood sarcoidosis. Semin Arthritis Rheum 1994; 23:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/56\">",
"      DeRemee RA. Sarcoidosis and Wegener's granulomatosis: a comparative analysis. Sarcoidosis 1994; 11:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/57\">",
"      Tariq S, McConnochie K, Mahy NJ, Williams WJ. Silent sarcoidosis and clubbing. Sarcoidosis 1990; 7:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/58\">",
"      Yancey J, Luxford W, Sharma OP. Clubbing of the fingers in sarcoidosis. JAMA 1972; 222:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/59\">",
"      Hashmi S, Kaplan D. Asymmetric clubbing as a manifestation of sarcoid bone disease. Am J Med 1992; 93:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/60\">",
"      Alloway JA, Nashel DJ, Rohatgi PK. Sarcoidosis and hypertrophic osteoarthropathy. J Rheumatol 1992; 19:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/61\">",
"      Wakelin SH, James MP. Sarcoidosis: nail dystrophy without underlying bone changes. Cutis 1995; 55:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/62\">",
"      Needleman SW, Silber RA, Von Brecht JH, Goeken JA. Systemic lupus erythematosus complicated by disseminated sarcoidosis. Report of a case associated with circulating immune complexes. Am J Clin Pathol 1982; 78:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/63\">",
"      Akama H, Yoshida T, Kawai S. Primary biliary cirrhosis coexisting with sarcoidosis--or possibly Sj&ouml;gren's syndrome? West J Med 1991; 154:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/64\">",
"      Andonopoulos AP, Papathanasopoulos PG, Karatza C, et al. Sarcoidosis in a patient with myasthenia gravis. Case report and review of the literature. Clin Rheumatol 1991; 10:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25752/abstract/65\">",
"      Hunter T, Arnott JE, McCarthy DS. Features of systemic lupus erythematosus and sarcoidosis occurring together. Arthritis Rheum 1980; 23:364.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5586 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-89.32.226.102-D86B8ADF8C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_9_25752=[""].join("\n");
var outline_f25_9_25752=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SARCOID ARTHROPATHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MYOPATHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Electromyography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Muscle biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Myopathy: Diagnosis and differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Sarcoid myopathy: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      BONE INVOLVEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Focal bone lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Cystic bone lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Sclerotic lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Spinal involvement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Focal bone lesions: Diagnosis and differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Osteopenia and osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Bone loss: Prevention and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      VASCULITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Vasculitis: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      CLUBBING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      OTHER ASSOCIATED DISEASES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Muscle disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Bone disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Vasculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Other rheumatic and autoimmune disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/5586\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5586|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?13/1/13343\" title=\"diagnostic image 1\">",
"      Sarcoid arthropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5586|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/58/43951\" title=\"figure 1\">",
"      Clubbing of the fingers",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26694?source=related_link\">",
"      Approach to the patient with muscle weakness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/19/13624?source=related_link\">",
"      Clinical features and diagnosis of Takayasu arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30825?source=related_link\">",
"      Clinical features and diagnosis of chronic fatigue syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=related_link\">",
"      Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=related_link\">",
"      Clinical manifestations and diagnosis of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23173?source=related_link\">",
"      Glucocorticoid-induced myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/16/2310?source=related_link\">",
"      Hypercalcemia in granulomatous diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/22/11626?source=related_link\">",
"      Initial treatment of dermatomyositis and polymyositis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/20/17736?source=related_link\">",
"      Lysosomal acid maltase deficiency (glycogen storage disease II, Pompe disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20616?source=related_link\">",
"      Neurologic sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6376?source=related_link\">",
"      Pathogenesis of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42855?source=related_link\">",
"      Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15494?source=related_link\">",
"      Periodic fever syndromes and other autoinflammatory diseases: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=related_link\">",
"      Prevention and treatment of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11463?source=related_link\">",
"      Sarcoid arthropathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_9_25753="Evaluation of the first seizure in adults";
var content_f25_9_25753=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of the first seizure in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/9/25753/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/9/25753/contributors\">",
"     Steven C Schachter, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/9/25753/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/9/25753/contributors\">",
"     Timothy A Pedley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/9/25753/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/9/25753/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/9/25753/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 6, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A seizure is a sudden change in behavior that is the consequence of brain dysfunction:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Epileptic seizures result from electrical hypersynchronization of neuronal networks in the cerebral cortex. Epilepsy is characterized by recurrent epileptic seizures due to a genetically determined or acquired brain disorder [",
"      <a class=\"abstract\" href=\"UTD.htm?25/9/25753/abstract/1\">",
"       1",
"      </a>",
"      ]. Approximately 0.5 to 1 percent of the population has epilepsy.",
"     </li>",
"     <li>",
"      Some seizures are provoked, that is, they occur in the setting of metabolic derangement, drug or alcohol withdrawal, and acute neurologic disorders such as stroke or encephalitis. Such patients are not considered to have epilepsy, because the presumption is that these seizures would not recur in the absence of the provocation.",
"     </li>",
"     <li>",
"      Nonepileptic seizures (NES) are sudden changes in behavior that resemble epileptic seizures but are not associated with the typical neurophysiological changes that characterize epileptic seizures [",
"      <a class=\"abstract\" href=\"UTD.htm?25/9/25753/abstract/2-4\">",
"       2-4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pharmacological treatment of epileptic seizures is directed at restoring neuronal function to normal, while the treatment of NES is specific to the disorder that triggered the seizure. Thus, the primary goal in evaluating a patient's first seizure is to resolve whether the seizure resulted from a treatable systemic process or intrinsic dysfunction of the central nervous system and, if the latter, the nature of the underlying brain pathology. This evaluation will determine the likelihood that a patient will have additional seizures, assist in the decision whether to begin anticonvulsant therapy, and direct appropriate treatment to the underlying cause, if known [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25753/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The differential diagnosis and clinical features of seizures and the diagnostic evaluation of the first seizure in adults are reviewed here. While convulsive and nonconvulsive status epilepticus may be the initial presentation of epilepsy, they are not specifically discussed because clinical recognition is straightforward [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25753/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19642?source=see_link\">",
"     \"Status epilepticus in adults\"",
"    </a>",
"    .) The treatment of chronic epilepsy is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=see_link\">",
"     \"Overview of the management of epilepsy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Epilepsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Less than one-half of epilepsy cases have an identifiable cause. It is presumed that epilepsy in most of these other patients is genetically determined. In the remainder of patients in whom an etiology can be determined, the causes of epileptic seizures include [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25753/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Head trauma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/52/4935?source=see_link\">",
"       \"Post-traumatic seizures and epilepsy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Brain tumors",
"     </li>",
"     <li>",
"      Stroke",
"     </li>",
"     <li>",
"      Intracranial infection",
"     </li>",
"     <li>",
"      Cerebral degeneration",
"     </li>",
"     <li>",
"      Congenital brain malformations",
"     </li>",
"     <li>",
"      Inborn errors of metabolism",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the elderly, vascular, degenerative, and neoplastic etiologies are more common than in younger adults and children [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25753/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40841?source=see_link\">",
"     \"Seizures and epilepsy in the elderly patient: Etiology, clinical presentation, and diagnosis\"",
"    </a>",
"    .) A higher proportion of epilepsy in children is due to congenital brain malformations than in other age groups. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33769?source=see_link\">",
"     \"Epilepsy syndromes in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These general principles were illustrated in a population-based cohort study of 1195 patients with newly diagnosed or suspected epileptic seizures, 564 of whom had definite epileptic seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25753/abstract/10\">",
"     10",
"    </a>",
"    ]. The proportions of males and females were similar, 25 percent were under the age of 15, and 24 percent were 60 years or older. The majority (62 percent) of epileptic seizures were idiopathic. In the remainder, the cause was vascular disease in 15 percent and tumor in 6 percent. The proportion with an identifiable cause was much higher in older patients; 49 percent were due to vascular disease and 11 percent to tumor.",
"   </p>",
"   <p>",
"    Onset of seizures in late life may be a risk factor for stroke, possibly because covert cerebrovascular disease can often be the mechanism of new onset epilepsy in older patients. This point is illustrated by a study of 4,709 people with idiopathic epilepsy beginning at or after the age of 60 years, but no history of stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25753/abstract/11\">",
"     11",
"    </a>",
"    ]. Subjects were matched to the same number of controls with no history of epilepsy or stroke. In longitudinal follow-up, the epilepsy group had a significantly higher risk of stroke at any time point compared with controls (hazard ratio 2.9, 95% CI 2.45-3.41). This finding suggests that new onset of seizures in older patients should prompt evaluation and treatment for stroke risk factors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40841?source=see_link\">",
"     \"Seizures and epilepsy in the elderly patient: Etiology, clinical presentation, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=see_link&amp;anchor=H21#H21\">",
"     \"Overview of the management of epilepsy in adults\", section on 'Post-stroke seizures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Head injury accounts for a relatively small proportion of epilepsy overall. The risk to an individual who suffers head trauma varies widely from minimal risk in people who have a concussive head injury in which the loss of consciousness or amnesia is less than 30 minutes, to at least a 12-fold increased risk over 10 years in people who suffer trauma-induced prolonged amnesia, subdural hematoma, or brain contusion [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25753/abstract/12\">",
"     12",
"    </a>",
"    ]. Antiepileptic drugs prevent seizures in the first week after head injury, but do not prevent the development of epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25753/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/52/4935?source=see_link\">",
"     \"Post-traumatic seizures and epilepsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Acute symptomatic seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients often experience seizures in the setting of acute medical or neurologic illness or injury (eg, stroke, traumatic brain injury, meningitis, anoxic encephalopathy) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25753/abstract/14\">",
"     14",
"    </a>",
"    ]. Such patients are not necessarily considered to have epilepsy. While this occurrence places them at risk for future epilepsy, a seizure in the acute setting does not carry the same risk for seizure recurrence as does an unprovoked seizure that occurs after recovery from the acute illness - so-called remote symptomatic seizure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25753/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A subset of acute symptomatic seizures is those that occur in the setting of an acute medical illness or metabolic disturbance (",
"    <a class=\"graphic graphic_table graphicRef61807 \" href=\"UTD.htm?5/14/5355\">",
"     table 1",
"    </a>",
"    ). In contrast to the setting of an acute stroke or traumatic brain injury, patients with seizures provoked by metabolic derangements are not felt to be at risk for future epilepsy or recurrent seizures in the absence of recurrence of the medical condition. Another feature of these provoked seizures is that the risk of seizures is felt to occur in proportion to the rapidity of the onset, rather than to the severity of the underlying metabolic disturbance [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25753/abstract/14,16\">",
"     14,16",
"    </a>",
"    ]. These conditions include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypoglycemic seizures are most common in diabetic patients who take excessive amounts of insulin or oral hypoglycemics; islet cell tumors are much less common, but seizures may be the initial presentation. Prodromal symptoms of hypoglycemic seizures include diaphoresis, tachycardia, anxiety, and confusion.",
"     </li>",
"     <li>",
"      Nonketotic hyperglycemia most commonly occurs in elderly diabetics and can cause focal motor seizures.",
"     </li>",
"     <li>",
"      Precipitous falls in serum sodium concentrations can trigger generalized tonic-clonic seizures (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Generalized seizures'",
"      </a>",
"      below), usually in association with a prodrome of confusion and depressed level of consciousness. These convulsions are associated with a high risk of mortality and must be treated urgently. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=see_link\">",
"       \"Manifestations of hyponatremia and hypernatremia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypocalcemia is a rare cause of seizures and most often occurs in neonates. In adults, hypocalcemia may occur after thyroid or parathyroid surgery or in association with renal failure, hypoparathyroidism, or pancreatitis. Typical prodromic symptoms and signs are mental status changes and tetany. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36646?source=see_link\">",
"       \"Clinical manifestations of hypocalcemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Magnesium levels below 0.8",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      may result in irritability, agitation, confusion, myoclonus, tetany, and convulsions, and may be accompanied by hypocalcemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/37/42580?source=see_link\">",
"       \"Signs and symptoms of magnesium depletion\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Renal failure and uremia are often associated with seizures, particularly myoclonic seizures (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Generalized seizures'",
"      </a>",
"      below). Generalized tonic-clonic seizures occur in approximately 10 percent of patients with chronic renal failure, usually late in the course. Seizures may also occur in patients undergoing dialysis as part of the dialysis disequilibrium syndrome; associated symptoms are headache, nausea, muscle cramps, irritability, confusion, and depressed level of consciousness. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/58/22440?source=see_link\">",
"       \"Seizures in patients undergoing hemodialysis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hyperthyroidism can cause seizures and can exacerbate seizures in patients with epilepsy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30057?source=see_link\">",
"       \"Neurologic manifestations of hyperthyroidism and Graves' disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Disorders of porphyrin metabolism may cause seizures. Acute intermittent porphyria (AIP) is due to a partial deficiency of porphobilinogen deaminase, which results in excess delta-aminolevulinic acid and porphobilinogen in the urine. Seizures occur in approximately 15 percent of AIP attacks and are usually generalized tonic-clonic seizures, although partial seizures may occur (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Auras (simple partial seizures)'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H11\">",
"       'Complex partial seizures'",
"      </a>",
"      below). Other symptoms of AIP include abdominal pain and behavioral changes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10439?source=see_link\">",
"       \"Clinical manifestations and diagnosis of acute intermittent porphyria\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cerebral anoxia as a complication of cardiac or respiratory arrest, carbon monoxide poisoning, drowning, or anesthetic complication can cause myoclonic and generalized tonic-clonic seizures. Cerebral anoxia due to syncope can result in very brief tonic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      clonic movements without a prolonged postictal state, which is why syncope frequently results in an evaluation for seizures. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18682?source=see_link&amp;anchor=H17#H17\">",
"       \"Evaluation of syncope in adults\", section on 'Distinction of syncope from seizures'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Withdrawal states (particularly alcohol and benzodiazepine withdrawal) are associated with seizures. Alcohol withdrawal seizures typically occur within 7 to 48 hours of the last drink. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20441?source=see_link\">",
"       \"Management of moderate and severe alcohol withdrawal syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Drug",
"      <span class=\"nowrap\">",
"       toxicity/intoxication",
"      </span>",
"      is also reported to cause seizures (",
"      <a class=\"graphic graphic_table graphicRef78226 \" href=\"UTD.htm?16/47/17148\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     IMITATORS OF EPILEPSY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several conditions must be differentiated from epileptic seizures. The most prevalent of the nonepileptic paroxysmal events that can be mistaken for epilepsy differ significantly by age group (",
"    <a class=\"graphic graphic_table graphicRef81289 \" href=\"UTD.htm?31/38/32364\">",
"     table 3",
"    </a>",
"    ). In adolescents and young adults, these diagnoses can be classified into six broad categories:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Syncope",
"     </li>",
"     <li>",
"      Psychological disorders",
"     </li>",
"     <li>",
"      Sleep disorders",
"     </li>",
"     <li>",
"      Paroxysmal movement disorders",
"     </li>",
"     <li>",
"      Migraine",
"     </li>",
"     <li>",
"      Miscellaneous neurologic events",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    More common in the elderly are",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Transient ischemic attack",
"     </li>",
"     <li>",
"      Transient global amnesia",
"     </li>",
"     <li>",
"      Drop attacks",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These disorders and their differentiation from epileptic seizures are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18074?source=see_link\">",
"     \"Nonepileptic paroxysmal disorders in adolescents and adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40841?source=see_link&amp;anchor=H16#H16\">",
"     \"Seizures and epilepsy in the elderly patient: Etiology, clinical presentation, and diagnosis\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic evaluation of a first seizure begins with the history. An accurate description of the seizure may be difficult to obtain from the patient and witnesses; it is usually necessary to ask pointed questions about the circumstances leading up to the seizure, the ictal behaviors, and the postictal state. It is also worthwhile to inquire specifically whether the patient has had prior seizures, including febrile seizures in infancy, or other episodes that were not evaluated by a physician or that were labeled as something other than seizures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Seizure precipitants or triggers",
"    </span>",
"    &nbsp;&mdash;&nbsp;A key element in the history is whether a particular environmental or physiological precipitant or trigger immediately preceded the seizure. Some patients with epilepsy tend to have seizures under particular conditions, and their first seizure may provide a clue to their so-called seizure trigger. Triggers include (but are not limited to) strong emotions, intense exercise, loud music, and flashing lights [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25753/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Photic-induced seizures'",
"    </a>",
"    below.) These triggers are often experienced immediately before the seizure.",
"   </p>",
"   <p>",
"    Other physiological conditions such as fever, the menstrual period, lack of sleep, and stress can also precipitate seizures, probably by lowering seizure threshold rather than directly causing a seizure. As a result, the temporal relationship to the presenting seizure is often less clear. Triggers may also precipitate nonepileptic paroxysmal disorders, especially syncope.",
"   </p>",
"   <p>",
"    However, the majority of patients with epilepsy have no identifiable or consistent trigger to their seizures. In addition, triggers are the sole cause of epileptic seizures in only a very small percentage of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Photic-induced seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Photosensitivity has received considerable attention as a seizure trigger. The light stimulation may come from a natural or artificial source, in particular television shows and video games. The most famous incident occurred in relation to a Pok&eacute;mon cartoon aired in 1997 in Japan in which 685 children (from an estimated 7 million viewers) sought medical attention for neurologic symptoms; most (about 80 percent) were felt to be seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25753/abstract/17,19\">",
"     17,19",
"    </a>",
"    ]. Three-fourths of the children had not experienced seizures previously.",
"   </p>",
"   <p>",
"    A review of photic-induced seizures made the following epidemiologic observations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25753/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children are more susceptible to photic-induced seizures and photoparoxysmal electroencephalogram (EEG) changes than adults; and photosensitivity may decline in individuals with photic-induced seizures",
"     </li>",
"     <li>",
"      A tendency for photic-induced seizures may be inherited",
"     </li>",
"     <li>",
"      Photoconvulsive seizures are usually generalized, but they may be partial",
"     </li>",
"     <li>",
"      Individuals may be sensitive to certain light triggers but not others",
"     </li>",
"     <li>",
"      Women appear more susceptible, but males dominate in reports of video game-induced seizures, probably because they play them more",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The stimuli that are most likely to induce seizures appear to be identifiable. Guidelines for restricting use of specific signals on television broadcasts exist in Japan and Great Britain, and a working group has developed draft consensus guidelines in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25753/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While photosensitivity suggests seizures, it may not be specific to epilepsy. In one case report, a child with presumed photosensitive epilepsy was found to have visually-induced syncope with bradycardia followed by cardiac arrest, documented by EKG and normal EEG activity during the event [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25753/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Seizure symptoms and signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The next step in the history is to identify the symptoms and signs (observed behaviors) that occurred throughout the seizure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Auras (simple partial seizures)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms that a patient experiences at the beginning of the seizure are referred to as the warning or aura. Auras are seizures that affect enough of the brain to cause symptoms, but not enough to interfere with consciousness. In the seizure classification system established by the International League Against Epilepsy, auras are called simple partial seizures (",
"    <a class=\"graphic graphic_table graphicRef53661 \" href=\"UTD.htm?0/60/973\">",
"     table 4",
"    </a>",
"    ); \"simple\" means that consciousness is not impaired and \"partial\" means that only part of the cortex is disrupted by the seizure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25753/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The symptoms of simple partial seizures vary from one patient to another and depend entirely on where the seizure originates in the brain, that is, the part of the cortex that is disrupted at the onset of the seizure. A seizure that begins in the occipital cortex may result in flashing lights, while a seizure that affects the motor cortex will result in rhythmic jerking movements of the face, arm, or leg on the side of the body opposite to the involved cortex (Jacksonian seizure).",
"   </p>",
"   <p>",
"    Auras that commonly occur in patients with epilepsy are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef55996 \" href=\"UTD.htm?18/45/19165\">",
"     table 5",
"    </a>",
"    ). These symptoms can also be experienced under other circumstances, but do not typically precede provoked seizures. Thus, the occurrence of an aura supports the diagnosis of an epileptic seizure.",
"   </p>",
"   <p>",
"    When a patient's first seizure was not preceded by a simple partial seizure, it is more difficult to distinguish whether it was an epileptic seizure or a nonepileptic seizure (NES). Many epileptic patients do not have a warning when their seizures start. Instead, they abruptly lose consciousness, which they may describe as blacking out, when the part of the cortex that controls memory is disrupted by the seizure. However, this process is not specific for epileptic seizures and therefore does not allow differentiation from NES.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Complex partial seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classification system for epileptic seizures includes several seizure types that are characterized by an abrupt loss of consciousness: complex partial seizures (\"complex\" means that consciousness and awareness of the surroundings are lost), absence seizures, and generalized tonic-clonic seizures (also known as convulsions; \"tonic\" refers to muscle stiffening and \"clonic\" refers to muscle jerking) (",
"    <a class=\"graphic graphic_table graphicRef53661 \" href=\"UTD.htm?0/60/973\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Complex partial seizures (previously called temporal lobe seizures or psychomotor seizures) are the most common type of seizure in epileptic adults. During the seizure patients appear to be awake but are not in contact with others in their environment and do not respond normally to instructions or questions. They often seem to stare into space and either remain motionless or engage in repetitive behaviors, called automatisms, such as facial grimacing, gesturing, chewing, lip smacking, snapping fingers, repeating words or phrases, walking, running, or undressing. Patients may become hostile or aggressive if physically restrained during complex partial seizures.",
"   </p>",
"   <p>",
"    Complex partial seizures typically last less than three minutes and may be immediately preceded by a simple partial seizure. Afterward, the patient enters the postictal phase, often characterized by somnolence, confusion, and headache for up to several hours (",
"    <a class=\"graphic graphic_table graphicRef59341 \" href=\"UTD.htm?12/4/12363\">",
"     table 6",
"    </a>",
"    ). The patient has no memory of what took place during the seizure other than, perhaps, the aura.",
"   </p>",
"   <p>",
"    The behaviors that typify complex partial seizures are not specific for epileptic seizures and may be observed in association with NES.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Generalized seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to partial seizures, generalized seizures appear to originate in all regions of the cortex simultaneously. Absence seizures and generalized tonic-clonic seizures are types of generalized seizures. Other subtypes of generalized seizures are clonic, myoclonic, tonic, and atonic seizures.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Absence seizures (also called petit mal) usually occur during childhood and typically last between 5 and 10 seconds. They frequently occur in clusters and may take place dozens or even hundreds of times a day. Absence seizures cause sudden staring with impaired consciousness. If an absence seizure lasts for 10 seconds or more, there may also be eye blinking and lip smacking. Absence seizures are discussed in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33769?source=see_link&amp;anchor=H7#H7\">",
"       \"Epilepsy syndromes in children\", section on 'Absence seizures'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A generalized tonic-clonic seizure (also called grand mal seizure, major motor seizure, or convulsion) is the most dramatic type of seizure (",
"      <a class=\"graphic graphic_table graphicRef54942 \" href=\"UTD.htm?13/61/14300\">",
"       table 7",
"      </a>",
"      ). It begins with an abrupt loss of consciousness, often in association with a scream or shriek. All of the muscles of the arms and legs as well as the chest and back then become stiff. The patient may begin to appear cyanotic during this tonic phase. After approximately one minute, the muscles begin to jerk and twitch for an additional one to two minutes. During this clonic phase the tongue can be bitten, and frothy and bloody sputum may be seen coming out of the mouth. The postictal phase begins once the twitching movements end. The patient is initially in a deep sleep, breathing deeply, and then gradually wakes up, often complaining of a headache.",
"     </li>",
"     <li>",
"      Clonic seizures cause rhythmical jerking muscle contractions that usually involve the arms, neck, and face.",
"     </li>",
"     <li>",
"      Myoclonic seizures consist of sudden, brief muscle contractions that may occur singly or in clusters and that can affect any group of muscles, although typically the arms are affected. Consciousness is usually not impaired.",
"     </li>",
"     <li>",
"      Tonic seizures cause sudden muscle stiffening, often associated with impaired consciousness and falling to the ground.",
"     </li>",
"     <li>",
"      Atonic seizures (also known as drop seizures) produce the opposite effect of tonic seizures &mdash; a sudden loss of control of the muscles, particularly of the legs, that results in collapsing to the ground and possible injuries.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The behaviors that typify absence seizures and generalized tonic-clonic seizures are not specific for epileptic seizures and may be observed in association with NES.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Postictal state",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the end of a seizure, there is a period of transition from the ictal state back to the individual's normal level of awareness and function. This interval is referred to as the \"postictal period\" and signifies the recovery period for the brain. Manifestations typically include confusion and suppressed alertness; focal neurologic deficits may also be present. The postictal state may last from seconds to minutes to hours, depending upon several factors including which part(s) of the brain were affected by the seizure, the length of the seizure, whether the individual was on AEDs, and age.",
"   </p>",
"   <p>",
"    As an example, young adults with partial seizures of frontal lobe origin may have postictal states that last only several seconds, while elderly patients with secondarily generalized seizures may have postictal confusion and sleepiness that persists for as long as several days to a week, particularly if there is underlying brain dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25753/abstract/23\">",
"     23",
"    </a>",
"    ]. If a person had a CPS or a convulsion, his or her level of awareness gradually improves during the postictal period, much like a person waking up from anesthesia after an operation.",
"   </p>",
"   <p>",
"    In some cases, the postictal symptoms may be the presenting clinical feature, when the seizure itself is very brief",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    unwitnessed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Postictal paresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postictal paresis (also called Todd's paralysis) is a transient neurologic deficit that lasts for hours or rarely days after an epileptic seizure. As the name implies, the classical deficit is weakness of a hand, arm, or leg that appears following focal motor seizure activity involving one limb or side of the body. The degree of weakness is usually moderate but occasionally can be severe. The cause of postictal paresis is unknown but may involve prolonged neuronal hyperpolarization due to activation of metabolic pumps or transient inactivation caused by NMDA receptor activation and excessive calcium influx.",
"   </p>",
"   <p>",
"    Postictal paresis (PP), although familiar to neurologists, has not been well-studied. One retrospective observational study evaluated 328 selected patients from ages 16 to 57 years who had prolonged video-electroencephalogram (EEG) monitoring for medically intractable epilepsy and focal seizure onset; those with nonepileptic seizures, status epilepticus, and Lennox-Gastaut syndrome were excluded [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25753/abstract/24\">",
"     24",
"    </a>",
"    ]. The following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      PP occurred in 44 patients (13.4 percent)",
"     </li>",
"     <li>",
"      PP was always unilateral and always contralateral to the seizure focus",
"     </li>",
"     <li>",
"      The mean duration of PP was 174 seconds (range 11 seconds to 22 minutes)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of all seizures followed by PP, the following features were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Obvious ictal motor activity was seen in 78 percent",
"     </li>",
"     <li>",
"      Very slight ictal motor activity was seen in 10 percent",
"     </li>",
"     <li>",
"      No ictal motor activity was seen in nearly 10 percent",
"     </li>",
"     <li>",
"      The most common ictal lateralizing sign was unilateral clonic activity in 56 percent",
"     </li>",
"     <li>",
"      Ictal dystonic posturing occurred in 48 percent",
"     </li>",
"     <li>",
"      Ictal limb immobility occurred in 25 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The results of this study are valuable because few other data exist on the frequency, duration, and seizure characteristics associated with PP. However, the study is likely biased by the inclusion only of patients with medically intractable seizures who had undergone video-EEG monitoring, and the results may not extrapolate to a general epilepsy population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4993294\">",
"    <span class=\"h3\">",
"     Other postictal symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other postictal deficits, analogous to the classic Todd's paralysis, can occur when focal ictal discharges involve other brain regions. Examples include transient aphasia, amaurosis, hemianopsia, and sensory loss. Some patients manifest psychosis and aggression [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25753/abstract/25\">",
"     25",
"    </a>",
"    ]. These are discussed in somewhat more detail in relation to specific partial epilepsy syndromes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/1/23578?source=see_link&amp;anchor=H7#H7\">",
"     \"Localization-related (partial) epilepsy: Causes and clinical features\", section on 'Clinical and EEG features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Other aspects of the patient history",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Medication history",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of medications that have been associated with iatrogenic seizures (",
"    <a class=\"graphic graphic_table graphicRef78226 \" href=\"UTD.htm?16/47/17148\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25753/abstract/8,26\">",
"     8,26",
"    </a>",
"    ]. Partial-onset seizures are less likely to be drug-induced than generalized tonic-clonic seizures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Past medical history",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of risk factors for epileptic seizures that should be addressed, including head injury, stroke, Alzheimer disease, history of intracranial infection, and alcohol or drug abuse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Family history",
"    </span>",
"    &nbsp;&mdash;&nbsp;A positive family history of seizures is highly suggestive that the patient has epilepsy. In particular, absence seizures and myoclonic seizures may be inherited. Occasionally, a family member does not have seizures but has an abnormal electroencephalogram. One genetic epidemiology study suggests that while family history of seizures in siblings is reasonably accurate, seizures and epilepsy in parents are underreported [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25753/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Physical and neurologic examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination is generally unrevealing in patients with epileptic seizures, but is important when central nervous system infection or hemorrhage are diagnostic possibilities. The neurologic examination should evaluate for lateralizing abnormalities, such as weakness, hyperreflexia, or a positive Babinski sign, that may point to a contralateral structural brain lesion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC STUDIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Laboratory screening",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H109884887\">",
"    <span class=\"h3\">",
"     Causative metabolic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;A patient with a first epileptic seizure typically has screening laboratory studies to exclude a metabolic or toxic cause for an acute symptomatic seizure. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Acute symptomatic seizures'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Laboratory evaluations that are appropriate for the evaluation of a first seizure include electrolytes, glucose, calcium, magnesium, hematology studies, renal function tests, liver function tests, and toxicology screens, although the likelihood of finding a relevant abnormality in unselected patients is low [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25753/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Acute symptomatic seizures'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Prolactin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum prolactin assessment has limited utility as a diagnostic test for epileptic seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25753/abstract/29\">",
"     29",
"    </a>",
"    ]. The serum prolactin concentration may rise shortly after generalized tonic-clonic seizures and some partial seizures. Typically, a level is drawn 10 to 20 minutes after the event and compared with a baseline level drawn six hours later. Criteria for abnormality are not well established; many investigators use twice the baseline level.",
"   </p>",
"   <p>",
"    A systematic review made the following conclusions regarding prolactin as a diagnostic test for epileptic seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25753/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pooled sensitivity was higher for generalized tonic-clonic seizures than for partial complex seizures (60 versus 46 percent).",
"     </li>",
"     <li>",
"      An elevated serum prolactin level can be useful in differentiating generalized tonic-clonic and partial complex seizures from psychogenic seizures in adults and older children. The positive predictive value is greater than 93 percent, if the pretest probability is 50 percent or higher. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33226?source=see_link&amp;anchor=H21#H21\">",
"       \"Psychogenic nonepileptic seizures\", section on 'Serum testing'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Because of low sensitivity, a normal prolactin level is insufficient to exclude epileptic seizures or support a psychogenic diagnosis.",
"     </li>",
"     <li>",
"      Some studies suggest that prolactin rises after syncope. Prolactin levels cannot be used to differentiate seizure from syncope.",
"     </li>",
"     <li>",
"      Insufficient data preclude conclusions regarding the utility of prolactin levels after simple partial seizures, repetitive seizures, status epilepticus, and in neonates.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H109884894\">",
"    <span class=\"h3\">",
"     Other seizure biomarkers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other serum markers have been used to help distinguish epileptic seizures from syncope, psychogenic nonepileptic seizures, and other physiologic events. These include: creatine phosphokinase (CPK), cortisol, white blood cell count, lactate dehydrogenase, pCO2, ammonia, and neuron specific enolase [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25753/abstract/31-34\">",
"     31-34",
"    </a>",
"    ]. CPK levels in particular are often elevated after generalized tonic-clonic seizures, but not after partial seizures. The later rise and prolonged elevation, up to 24 hours postictally, makes this test somewhat more useful in the outpatient setting. However, a defined threshold level for abnormality, sensitivity, and specificity remain to be determined for CPK, as for other serum markers [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25753/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Lumbar puncture",
"    </span>",
"    &nbsp;&mdash;&nbsp;A lumbar puncture is essential if the clinical presentation is suggestive of an acute infectious process that involves the central nervous system or the patient has a history of a cancer-type that is known to metastasize to the meninges [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25753/abstract/28\">",
"     28",
"    </a>",
"    ]. In other circumstances the test is not likely to be helpful and may be misleading since a prolonged seizure itself can cause cerebrospinal fluid pleocytosis.",
"   </p>",
"   <p>",
"    Lumbar puncture should only be performed after a space occupying brain lesion has been excluded by appropriate neuroimaging studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Electroencephalography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The electroencephalogram (EEG) is an essential study in the diagnostic evaluation of epileptic seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25753/abstract/28,37\">",
"     28,37",
"    </a>",
"    ]. If abnormal, the routine, interictal EEG may aid in supporting the diagnosis of epileptic seizures and may also suggest whether a patient has generalized or partial seizures. Among adults presenting with a first seizure, an EEG demonstrates epileptiform abnormalities in 23 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25753/abstract/28\">",
"     28",
"    </a>",
"    ]. This finding substantially increases the likelihood that the patient will experience a second seizure over the next two years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25753/abstract/28,38\">",
"     28,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of sleep deprivation and provocative measures during the test, such as hyperventilation and intermittent photic stimulation, increase the yield [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25753/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, a normal EEG does not rule out epilepsy, and many EEG abnormalities are nonspecific. As an example, diffuse slowing may also occur with a wide variety of encephalopathies or in association with some medications, especially at high dosages. Epileptiform abnormalities are usually more informative than less specific changes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32425?source=see_link\">",
"     \"Electroencephalography (EEG) in the diagnosis of seizures and epilepsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;A neuroimaging study should be done to exclude a structural brain abnormality if the patient's first seizure was clearly not a provoked seizure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25753/abstract/28,37\">",
"     28,37",
"    </a>",
"    ]. Brain magnetic resonance imaging (MRI) is preferred over computed tomography (CT) to identify specific lesions such as cortical dysplasias, infarcts, or tumors.",
"   </p>",
"   <p>",
"    Nevertheless, a brain CT scan is suitable to exclude a mass lesion, hemorrhage, or large stroke under emergency situations or if an MRI is unavailable or contraindicated (eg, in patients with pacemakers, non-compatible aneurysm clips, or severe claustrophobia). A systematic literature review of 15 published reports concluded that a noncontrast CT scan performed in the emergency room changed acute management in 9 to 17 percent of adult patients presenting with a first seizure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25753/abstract/41\">",
"     41",
"    </a>",
"    ]. Relevant findings included intracranial hemorrhage, brain abscess, and tumor.",
"   </p>",
"   <p>",
"    In young to middle-aged adults, common MRI findings are mesial temporal sclerosis, sequelae of head injury, congenital anomalies, brain tumors, cysticercosis, and vascular lesions. In the elderly, MRIs often reveal strokes, cerebral degeneration, or neoplasms. However, up to 50 percent of patients, regardless of age, have normal neuroimaging studies. Also, while structural abnormalities on brain MRI or CT usually suggest a symptomatic, focal-onset epilepsy syndrome, these findings should not be interpreted in isolation. Many MRI findings are nonspecific and may be incidental [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25753/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The utility of brain MRI individuals presenting with a seizure is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/49/13082?source=see_link\">",
"     \"Neuroimaging in the evaluation of seizures and epilepsy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/4/14409?source=see_link&amp;anchor=H17#H17\">",
"     \"Clinical and laboratory diagnosis of seizures in infants and children\", section on 'Neuroimaging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     WHEN TO START ANTIEPILEPTIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to initiate therapy with antiepileptic drugs is often difficult. This topic is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31818?source=see_link&amp;anchor=H2#H2\">",
"     \"Initial treatment of epilepsy in adults\", section on 'When to start AED therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     PSYCHOSOCIAL CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newly diagnosed patients with epilepsy may suffer a number of losses, including loss of independence, employment, insurance, ability to drive, and self-esteem. As the treatment plan is formulated, these psychosocial issues should be explored with patients so that appropriate referrals for additional help and counseling can be initiated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Driving",
"    </span>",
"    &nbsp;&mdash;&nbsp;States vary widely in driver licensing requirements for patients with epilepsy as well as the responsibilities of physicians to notify state authorities [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25753/abstract/44\">",
"     44",
"    </a>",
"    ]. This topic is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/51/32568?source=see_link\">",
"     \"Driving restrictions for patients with seizures and epilepsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     HOSPITALIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hospitalization may be required for patients who have a first seizure associated with a prolonged postictal state or incomplete recovery. Other indications for hospitalization include status epilepticus, the presence of a systemic illness that may require treatment, a history of head trauma, or questions regarding compliance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/56/28546?source=see_link\">",
"       \"Patient information: Seizures (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/0/18434?source=see_link\">",
"       \"Patient information: EEG (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/27/34229?source=see_link\">",
"       \"Patient information: Seizures in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7965526\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The primary objectives of the medical evaluation of the first seizure are to establish whether the event was a seizure, and if so, whether it resulted from a correctable systemic process or whether the patient is at risk for developing further unprovoked seizures (epilepsy). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Imitators of epilepsy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Epilepsy is characterized by recurrent epileptic seizures due to a genetically determined or acquired brain disorder. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epilepsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute symptomatic seizures are those that occur in the setting of acute medical (eg, hypoglycemia, hyponatremia) or neurologic illness or injury (eg, stroke, traumatic brain injury, meningitis, anoxic encephalopathy). Such patients are not necessarily considered to have epilepsy. Although in the latter category their risk of developing epilepsy may be higher than if such seizures had not occurred. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Acute symptomatic seizures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several conditions can cause nonepileptic events that can be mistaken for epilepsy; these conditions include syncope, psychological disorders, and transient ischemic attacks. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Imitators of epilepsy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18074?source=see_link\">",
"       \"Nonepileptic paroxysmal disorders in adolescents and adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A careful history, physical and neurologic examinations, and laboratory evaluation are usually helpful in making an accurate diagnosis:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A detailed description of the seizure should be obtained from the patient and witnesses and should include the circumstances leading up to the seizure, the ictal behaviors, and the postictal state. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other items in the past medical history and a physical and neurological examination are also important in the evaluation of a first seizure. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Other aspects of the patient history'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Physical and neurologic examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnostic studies should include laboratory studies (electrolytes, glucose, calcium, magnesium, hematology studies, renal function tests, liver function tests, and toxicology screens), an electroencephalogram, and a neuroimaging study. Depending on the clinical situation, a lumbar puncture may also be indicated. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Diagnostic studies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hospitalization may be required for patients who have a first seizure associated with a prolonged postictal state or incomplete recovery. Other indications for hospitalization include status epilepticus, the presence of a systemic illness that may require treatment, a history of head trauma, or questions regarding compliance. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Hospitalization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antiepileptic drugs are not always indicated after a first seizure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31818?source=see_link&amp;anchor=H2#H2\">",
"       \"Initial treatment of epilepsy in adults\", section on 'When to start AED therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If the patient is felt to have had an unprovoked (ie, not an acute symptomatic seizure), epileptic seizure then driving may need to be restricted. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/51/32568?source=see_link\">",
"       \"Driving restrictions for patients with seizures and epilepsy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25753/abstract/1\">",
"      Chang BS, Lowenstein DH. Epilepsy. N Engl J Med 2003; 349:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25753/abstract/2\">",
"      Vossler, DG. Nonepileptic seizures of physiologic origin. J Epilepsy 1995; 8:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25753/abstract/3\">",
"      Alper K, Devinsky O, Perrine K, et al. Psychiatric classification of nonconversion nonepileptic seizures. Arch Neurol 1995; 52:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25753/abstract/4\">",
"      Bortz, JJ. Nonepileptic seizures: issues in differential diagnosis and treatment. CNS Spectrums 1997; 2:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25753/abstract/5\">",
"      Berg AT, Shinnar S. The risk of seizure recurrence following a first unprovoked seizure: a quantitative review. Neurology 1991; 41:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25753/abstract/6\">",
"      Camfield PR, Camfield CS, Dooley JM, et al. Epilepsy after a first unprovoked seizure in childhood. Neurology 1985; 35:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25753/abstract/7\">",
"      Willmore LJ. Epilepsy emergencies: the first seizure and status epilepticus. Neurology 1998; 51:S34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25753/abstract/8\">",
"      Schachter SC. Iatrogenic seizures. Neurol Clin 1998; 16:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25753/abstract/9\">",
"      Schold C, Yarnell PR, Earnest MP. Origin of seizures in elderly patients. JAMA 1977; 238:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25753/abstract/10\">",
"      Sander JW, Hart YM, Johnson AL, Shorvon SD. National General Practice Study of Epilepsy: newly diagnosed epileptic seizures in a general population. Lancet 1990; 336:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25753/abstract/11\">",
"      Cleary P, Shorvon S, Tallis R. Late-onset seizures as a predictor of subsequent stroke. Lancet 2004; 363:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25753/abstract/12\">",
"      Annegers JF, Hauser WA, Coan SP, Rocca WA. A population-based study of seizures after traumatic brain injuries. N Engl J Med 1998; 338:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25753/abstract/13\">",
"      Temkin NR. Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials. Epilepsia 2001; 42:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25753/abstract/14\">",
"      Beghi E, Carpio A, Forsgren L, et al. Recommendation for a definition of acute symptomatic seizure. Epilepsia 2010; 51:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25753/abstract/15\">",
"      Hesdorffer DC, Benn EK, Cascino GD, Hauser WA. Is a first acute symptomatic seizure epilepsy? Mortality and risk for recurrent seizure. Epilepsia 2009; 50:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25753/abstract/16\">",
"      Riggs JE. Neurologic manifestations of electrolyte disturbances. Neurol Clin 2002; 20:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25753/abstract/17\">",
"      Fisher RS, Harding G, Erba G, et al. Photic- and pattern-induced seizures: a review for the Epilepsy Foundation of America Working Group. Epilepsia 2005; 46:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25753/abstract/18\">",
"      Pittau F, Tinuper P, Bisulli F, et al. Videopolygraphic and functional MRI study of musicogenic epilepsy. A case report and literature review. Epilepsy Behav 2008; 13:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25753/abstract/19\">",
"      Takada H, Aso K, Watanabe K, et al. Epileptic seizures induced by animated cartoon, \"Pocket Monster\". Epilepsia 1999; 40:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25753/abstract/20\">",
"      Harding G, Wilkins AJ, Erba G, et al. Photic- and pattern-induced seizures: expert consensus of the Epilepsy Foundation of America Working Group. Epilepsia 2005; 46:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25753/abstract/21\">",
"      Seri S, Cerquiglini A, Harding GF. Visually induced syncope: a nonepileptic manifestation of visual sensitivity? Neurology 2006; 67:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25753/abstract/22\">",
"      Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 1989; 30:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25753/abstract/23\">",
"      Theodore WH. The postictal state: effects of age and underlying brain dysfunction. Epilepsy Behav 2010; 19:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25753/abstract/24\">",
"      Gallmetzer P, Leutmezer F, Serles W, et al. Postictal paresis in focal epilepsies--incidence, duration, and causes: a video-EEG monitoring study. Neurology 2004; 62:2160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25753/abstract/25\">",
"      Ito M. Neuropsychiatric evaluations of postictal behavioral changes. Epilepsy Behav 2010; 19:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25753/abstract/26\">",
"      Dallos V, Heathfield K. Iatrogenic epilepsy due to antidepressant drugs. Br Med J 1969; 4:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25753/abstract/27\">",
"      Ottman R, Barker-Cummings C, Leibson CL, et al. Accuracy of family history information on epilepsy and other seizure disorders. Neurology 2011; 76:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25753/abstract/28\">",
"      Krumholz A, Wiebe S, Gronseth G, et al. Practice Parameter: evaluating an apparent unprovoked first seizure in adults (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2007; 69:1996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25753/abstract/29\">",
"      Shukla G, Bhatia M, Vivekanandhan S, et al. Serum prolactin levels for differentiation of nonepileptic versus true seizures: limited utility. Epilepsy Behav 2004; 5:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25753/abstract/30\">",
"      Chen DK, So YT, Fisher RS, Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Use of serum prolactin in diagnosing epileptic seizures: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2005; 65:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25753/abstract/31\">",
"      Willert C, Spitzer C, Kusserow S, Runge U. Serum neuron-specific enolase, prolactin, and creatine kinase after epileptic and psychogenic non-epileptic seizures. Acta Neurol Scand 2004; 109:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25753/abstract/32\">",
"      Pritchard PB 3rd, Wannamaker BB, Sagel J, Daniel CM. Serum prolactin and cortisol levels in evaluation of pseudoepileptic seizures. Ann Neurol 1985; 18:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25753/abstract/33\">",
"      Shah AK, Shein N, Fuerst D, et al. Peripheral WBC count and serum prolactin level in various seizure types and nonepileptic events. Epilepsia 2001; 42:1472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25753/abstract/34\">",
"      Hung TY, Chen CC, Wang TL, et al. Transient hyperammonemia in seizures: a prospective study. Epilepsia 2011; 52:2043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25753/abstract/35\">",
"      Wyllie E, Lueders H, Pippenger C, VanLente F. Postictal serum creatine kinase in the diagnosis of seizure disorders. Arch Neurol 1985; 42:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25753/abstract/36\">",
"      Petramfar P, Yaghoobi E, Nemati R, Asadi-Pooya AA. Serum creatine phosphokinase is helpful in distinguishing generalized tonic-clonic seizures from psychogenic nonepileptic seizures and vasovagal syncope. Epilepsy Behav 2009; 15:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25753/abstract/37\">",
"      Fountain NB, Van Ness PC, Swain-Eng R, et al. Quality improvement in neurology: AAN epilepsy quality measures: Report of the Quality Measurement and Reporting Subcommittee of the American Academy of Neurology. Neurology 2011; 76:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25753/abstract/38\">",
"      van Donselaar CA, Schimsheimer RJ, Geerts AT, Declerck AC. Value of the electroencephalogram in adult patients with untreated idiopathic first seizures. Arch Neurol 1992; 49:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25753/abstract/39\">",
"      Shinnar S, Kang H, Berg AT, et al. EEG abnormalities in children with a first unprovoked seizure. Epilepsia 1994; 35:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25753/abstract/40\">",
"      Leach JP, Stephen LJ, Salveta C, Brodie MJ. Which electroencephalography (EEG) for epilepsy? The relative usefulness of different EEG protocols in patients with possible epilepsy. J Neurol Neurosurg Psychiatry 2006; 77:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25753/abstract/41\">",
"      Harden CL, Huff JS, Schwartz TH, et al. Reassessment: neuroimaging in the emergency patient presenting with seizure (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2007; 69:1772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25753/abstract/42\">",
"      Ramirez-Lassepas M, Cipolle RJ, Morillo LR, Gumnit RJ. Value of computed tomographic scan in the evaluation of adult patients after their first seizure. Ann Neurol 1984; 15:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25753/abstract/43\">",
"      Betting LE, Mory SB, Lopes-Cendes I, et al. MRI reveals structural abnormalities in patients with idiopathic generalized epilepsy. Neurology 2006; 67:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25753/abstract/44\">",
"      Krauss GL, Ampaw L, Krumholz A. Individual state driving restrictions for people with epilepsy in the US. Neurology 2001; 57:1780.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2219 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-528937E1C1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_9_25753=[""].join("\n");
var outline_f25_9_25753=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7965526\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Epilepsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Acute symptomatic seizures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      IMITATORS OF EPILEPSY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Seizure precipitants or triggers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Photic-induced seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Seizure symptoms and signs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Auras (simple partial seizures)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Complex partial seizures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Generalized seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Postictal state",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Postictal paresis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4993294\">",
"      - Other postictal symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Other aspects of the patient history",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Medication history",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Past medical history",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Family history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Physical and neurologic examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DIAGNOSTIC STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Laboratory screening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H109884887\">",
"      - Causative metabolic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Prolactin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H109884894\">",
"      - Other seizure biomarkers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Lumbar puncture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Electroencephalography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      WHEN TO START ANTIEPILEPTIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      PSYCHOSOCIAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Driving",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      HOSPITALIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7965526\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/2219\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/2219|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/14/5355\" title=\"table 1\">",
"      Causes of acute symptomatic seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/47/17148\" title=\"table 2\">",
"      Drugs that induce seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/38/32364\" title=\"table 3\">",
"      Differential diagnosis of seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/60/973\" title=\"table 4\">",
"      Classification of epileptic seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/45/19165\" title=\"table 5\">",
"      Symptoms of simple partial seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/4/12363\" title=\"table 6\">",
"      Postictal symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/61/14300\" title=\"table 7\">",
"      Phases of tonic clonic seizures",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/4/14409?source=related_link\">",
"      Clinical and laboratory diagnosis of seizures in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10439?source=related_link\">",
"      Clinical manifestations and diagnosis of acute intermittent porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36646?source=related_link\">",
"      Clinical manifestations of hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/51/32568?source=related_link\">",
"      Driving restrictions for patients with seizures and epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32425?source=related_link\">",
"      Electroencephalography (EEG) in the diagnosis of seizures and epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33769?source=related_link\">",
"      Epilepsy syndromes in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18682?source=related_link\">",
"      Evaluation of syncope in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31818?source=related_link\">",
"      Initial treatment of epilepsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/1/23578?source=related_link\">",
"      Localization-related (partial) epilepsy: Causes and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20441?source=related_link\">",
"      Management of moderate and severe alcohol withdrawal syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=related_link\">",
"      Manifestations of hyponatremia and hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/49/13082?source=related_link\">",
"      Neuroimaging in the evaluation of seizures and epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30057?source=related_link\">",
"      Neurologic manifestations of hyperthyroidism and Graves' disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18074?source=related_link\">",
"      Nonepileptic paroxysmal disorders in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=related_link\">",
"      Overview of the management of epilepsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/0/18434?source=related_link\">",
"      Patient information: EEG (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/56/28546?source=related_link\">",
"      Patient information: Seizures (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/27/34229?source=related_link\">",
"      Patient information: Seizures in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/52/4935?source=related_link\">",
"      Post-traumatic seizures and epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33226?source=related_link\">",
"      Psychogenic nonepileptic seizures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40841?source=related_link\">",
"      Seizures and epilepsy in the elderly patient: Etiology, clinical presentation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/58/22440?source=related_link\">",
"      Seizures in patients undergoing hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/37/42580?source=related_link\">",
"      Signs and symptoms of magnesium depletion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19642?source=related_link\">",
"      Status epilepticus in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_9_25754="Risk factors for adverse outcomes after unstable angina or non-ST elevation myocardial infarction";
var content_f25_9_25754=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Risk factors for adverse outcomes after unstable angina or non-ST elevation myocardial infarction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/9/25754/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/9/25754/contributors\">",
"     Jeffrey A Breall, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/9/25754/contributors\">",
"     Michael Simons, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/9/25754/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/9/25754/contributors\">",
"     Christopher P Cannon, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/9/25754/contributors\">",
"     Allan S Jaffe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/9/25754/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/9/25754/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/9/25754/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk stratification of patients with an acute coronary syndrome (ACS) begins upon presentation and is then a continuous process to predict those who are at high risk for further ischemic events or adverse outcomes. Among patients with",
"    <span class=\"nowrap\">",
"     UA/NSTEMI,",
"    </span>",
"    risk stratification begins with initial assessment to detect patients at immediate high risk. Subsequent evaluation is aimed at identifying patients who will benefit from an early invasive strategy at 4 to 48 hours and, finally, at predicting which patients are at increased risk after discharge.",
"   </p>",
"   <p>",
"    The individual risk factors that influence prognosis will be discussed here. The general approach to risk stratification for patients with",
"    <span class=\"nowrap\">",
"     UA/NSTEMI",
"    </span>",
"    and the major ri",
"1ff8",
"sk prediction models are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/43/2746?source=see_link\">",
"     \"Risk stratification after unstable angina or non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RISK PREDICTORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8883788\">",
"    <span class=\"h2\">",
"     Number of CHD risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The four modifiable coronary heart disease (CHD) risk factors (hypertension, smoking, dyslipidemia, and diabetes), as well as a family history of premature CHD, predict the development of atherosclerosis and its clinical consequences in a high percentage of patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\", section on 'Established risk factors for atherosclerotic CVD'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The relationship between the number of these risk factors and in-hospital mortality was evaluated in a study of 542,008 patients with first myocardial infarction (MI) and without prior cardiovascular disease from the National (United States) Registry of Myocardial Infarction (NRMI) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/1\">",
"     1",
"    </a>",
"    ]. Over 85 percent of patients had at least one CHD risk factor. After adjustment for age and other clinical risk factors, there was a significant inverse increase in risk between the number of CHD risk factors and in-hospital mortality (odds ratios of 1.54, 1.39, 1.30, 1.10, 1.09, and 1.00 with 0, 1, 2, 3, 4, and 5 risk factors, respectively). The explanation for this surprising finding is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Older age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Age is an important risk factor for diffuse coronary disease and for a poorer outcome in hospitalized patients with UA or NSTEMI [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In the TIMI III registry, patients over the age of 75 with",
"    <span class=\"nowrap\">",
"     UA/NSTEMI",
"    </span>",
"    had more diffuse and severe coronary disease and more adverse outcomes both in hospital and within the first six weeks after discharge than those less than 75 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Type of unstable angina",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Braunwald classification of UA attempts to assign patients to a particular risk group based upon the severity, clinical circumstances, and the intensity of and response to therapy (",
"    <a class=\"graphic graphic_table graphicRef74808 \" href=\"UTD.htm?21/46/22251\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28505?source=see_link\">",
"     \"Classification of unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prospective studies have validated the predictive value of this classification [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. In one, recurrence of chest pain increased with higher severity class (28, 45, and 64 percent for classes I [accelerated angina], II [subacute angina at rest], and III [acute angina at rest]) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/5\">",
"     5",
"    </a>",
"    ]. At six months, patient and infarct-free survival were not different in the severity classes but were significantly lower for class C (post-MI angina) than class B (primary UA): 89 versus 97 percent for patient survival and 80 versus 89 percent for infarct-free survival. Other predictors of death or nonfatal MI were age, male sex, and maximal intravenous antiischemic therapy.",
"   </p>",
"   <p>",
"    The classification also correlates with angiographic findings. Patients with class III or class C are significantly more likely to have complex lesions and reduced TIMI flow grade [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/7\">",
"     7",
"    </a>",
"    ]. Patients with angina refractory to maximal medical therapy are more likely to have intracoronary thrombus.",
"   </p>",
"   <p>",
"    An important limitation of the original Braunwald classification is that it did not take into account the prognostic importance of ECG changes and serum troponins, which are discussed in the following sections. Subsequent versions of this classification included the ECG and physical findings (",
"    <a class=\"graphic graphic_table graphicRef55745 \" href=\"UTD.htm?6/60/7117\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/8\">",
"     8",
"    </a>",
"    ] and serum troponins (",
"    <a class=\"graphic graphic_figure graphicRef57088 \" href=\"UTD.htm?15/44/16078\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/9\">",
"     9",
"    </a>",
"    ]. However, the applicability of this approach to current practice is uncertain, since almost all high or intermediate risk patients and many low risk patients would undergo revascularization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=see_link\">",
"     \"Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overt heart failure (HF) or severe left ventricular dysfunction is features that identify patients at particularly high risk, in whom coronary angiography should be performed without delay. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/43/2746?source=see_link&amp;anchor=H3#H3\">",
"     \"Risk stratification after unstable angina or non-ST elevation myocardial infarction\", section on 'Immediate high-risk patients'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evidence of even lesser degrees of HF on physical examination or chest x-ray indicates extensive LV systolic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diastolic dysfunction and is associated with a worse prognosis compared to those with no pulmonary congestion [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Killip class",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Killip classification, published in 1967, categorizes patients with an acute MI based upon the presence or absence of simple physical examination findings that suggest LV dysfunction (",
"    <a class=\"graphic graphic_table graphicRef65592 \" href=\"UTD.htm?3/59/4027\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Class I - no evidence of HF",
"     </li>",
"     <li>",
"      Class II - findings consistent with mild to moderate HF ",
"1ff8",
"(S3, lung rales less than one-half way up the posterior lung fields, or jugular venous distension)",
"     </li>",
"     <li>",
"      Class III - overt pulmonary edema",
"     </li>",
"     <li>",
"      Class IV - cardiogenic shock",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients presenting with Killip class II or III HF complicating an acute MI tend to be older and are more often female; they also have higher rates of comorbidities, including hypertension and diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/12\">",
"     12",
"    </a>",
"    ]. Patients with HF are also less likely to receive therapies of known efficacy in acute MI, including beta blockers and statins [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The higher the Killip class on presentation, the greater the subsequent mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. While most studies of the Killip classification have evaluated its prognostic value in STEMI, this scoring system also predicts risk in patients with a non-ST elevation ACS. This was illustrated in an analysis of data from 26,090 patients enrolled in GUSTO IIb, PURSUIT, PARAGON A, and PARAGON B [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/13\">",
"     13",
"    </a>",
"    ]. Survival was analyzed by Killip class; those in classes III and IV were combined into a single category. Compared to those in Killip class I, those in class II and",
"    <span class=\"nowrap\">",
"     III/IV",
"    </span>",
"    had significantly higher mortality rates at 30 days (3 versus 9 and 14 percent) and six months (5 versus 15 and 23 percent).",
"   </p>",
"   <p>",
"    Similar findings were noted in an analysis of international data on 3917 patients with NSTEMI and 4960 patients with UA from the GRACE registry [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/12\">",
"     12",
"    </a>",
"    ]. Sixteen percent of those with NSTEMI and 8 percent of those with UA had Killip class II or III HF on admission. Patients with HF, compared to those without HF, had increased mortality in-hospital (10 versus 3 percent for NSTEMI and 7 versus 2 percent for UA). Mortality was also increased for those with an NSTEMI presenting with HF from discharge to six months (11 versus 4 percent). In this report, HF developing after admission was associated with an even higher in-hospital mortality (18 percent for NSTEMI and 16 percent for UA).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both sustained ventricular arrhythmias and atrial fibrillation are adverse risk factors in patients with a non-ST elevation ACS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Sustained ventricular arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Older studies, performed before the routine use of early revascularization, aggressive antithrombotic therapy, and secondary preventative measures (including statin use), found that the development of ventricular tachycardia (VT) or ventricular fibrillation (VF) after a non-ST elevation ACS (NSTE ACS) was a predictor of increased mortality at both 30 days and six months in the 2.1 percent of patients who developed these arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More contemporary rates of all-cause death after these arrhythmias were evaluated using data from 9211 patients enrolled in the EARLY ACS trial, which compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/24/32135?source=see_link\">",
"     eptifibatide",
"    </a>",
"    to placebo in high-risk patients scheduled to undergo an invasive strategy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=see_link&amp;anchor=H32#H32\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'Timing'",
"    </a>",
"    .) The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The cumulative incidence of",
"      <span class=\"nowrap\">",
"       VT/VF",
"      </span>",
"      was 1.5 percent, with 0.6 percent occurring &le;48 hours after enrollment. Predictors of sustained",
"      <span class=\"nowrap\">",
"       VT/VF,",
"      </span>",
"      irrespective of time of onset, were prior heart failure, ejection fraction &lt;30 percent, and triple-vessel coronary artery disease.",
"     </li>",
"     <li>",
"      Approximately 40 percent of the episodes of",
"      <span class=\"nowrap\">",
"       VT/VF",
"      </span>",
"      occurred in patients with a left ventricular ejection fraction &gt;50 percent; in these patients the mean time to",
"      <span class=\"nowrap\">",
"       VT/VF",
"      </span>",
"      was five days.&nbsp;",
"     </li>",
"     <li>",
"      The incidence of all-cause death from 48 hours to 30 days was greater in those with",
"      <span class=\"nowrap\">",
"       VT/VF",
"      </span>",
"      within 48 hours of randomization than in those without (13.0 versus 2.2 percent; adjusted odds ratio 6.73, 95% CI 2.68-16.90).",
"     </li>",
"     <li>",
"      When compared to patients without",
"      <span class=\"nowrap\">",
"       VT/VF,",
"      </span>",
"      those with",
"      <span class=\"nowrap\">",
"       VT/VF",
"      </span>",
"      &gt;48 hours had a higher risk of death at one year than was seen for those with",
"      <span class=\"nowrap\">",
"       VT/VF",
"      </span>",
"      &le;48 hours (hazard ratios 20.70 versus 7.45).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Larger discussions of sustained ventricular arrhythmias in the setting of acute MI are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29193?source=see_link&amp;anchor=H287278073#H287278073\">",
"     \"Sustained monomorphic ventricular tachycardia in patients with a prior myocardial infarction: Treatment and prognosis\", section on 'VT in the setting of acute MI (AMI)'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=see_link\">",
"     \"Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Atrial fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The occurrence of atrial fibrillation (AF) in patients with a non-ST elevation ACS is associated with increased mortality, similar to observations in ST elevation MI. In an analysis from the PURSUIT trial, 6.4 percent of patients with a non-ST elevation ACS developed AF during hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/16\">",
"     16",
"    </a>",
"    ]. These patients had a higher mortality at 30 days (adjusted hazard ratio 4.4) and at six months (adjusted hazard ratio 3). Similar findings were noted in a study of more than 2300 patients with ACS (73 percent unstable angina or non-ST elevation MI; 19 percent with AF) cared for between 1995 and 2001 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/17\">",
"     17",
"    </a>",
"    ]. The risk of all-cause mortality was significantly increased at 30 days and 10 years. A large part of this association is probably related to the presence of concurrent heart failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16615?source=see_link\">",
"     \"Supraventricular arrhythmias after myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     ECG features",
"    </span>",
"    &nbsp;&mdash;&nbsp;ST segment elevation is the hallmark of acute myocardial injury. The following findings were noted in the PURSUIT trial of 9461 patients with an ACS who did not have persistent ST elevation [",
"    <a class=\"abstract\" href=\"./risk-factors-for-adverse-outcomes-after-unstable-angina-or-non-st-elevation-myocard",
"1ff8",
"ial-infarction/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The highest rate of mortality and morbidity occurred in patients with transient ST elevation and substantial myocardial damage.",
"     </li>",
"     <li>",
"      Intermediate risk was seen in those without ST elevation but with a rise in cardiac enzymes.",
"     </li>",
"     <li>",
"      The lowest risk occurred in those with neither ST elevation nor a typical enzyme rise.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     ST segment depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ECG can provide prognostic information. This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/26/4521?source=see_link\">",
"     \"Electrocardiogram in the prognosis of myocardial infarction or unstable angina\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Summarized briefly, the prognosis is worse in patients with ST segment depression compared to those with T wave inversion alone or a normal ECG [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/19\">",
"     19",
"    </a>",
"    ]. The importance of ST depression was illustrated in an analysis from GUSTO IIb of over 12,000 patients presenting with symptoms of cardiac ischemia at rest that was confirmed by ECG [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/20\">",
"     20",
"    </a>",
"    ]. The 30 day incidence of death or MI was significantly higher in patients with ST depression (10.5 versus 5.5 percent in those with T wave inversion alone, adjusted odds ratio 1.62). This difference in mortality persisted at six months (15.4 versus 8.1 percent).",
"   </p>",
"   <p>",
"    The magnitude, location, and extent of ST segment depression and recurrent or persistent ST segment depression are also predictive of worse outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5702489\">",
"    <span class=\"h3\">",
"     Left bundle branch block",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a study of over 5000 patients in a patient-pooled data set (from the FRISC II, ICTUS, and RITA-3 databases), the presence of left bundle branch block on the admission electrocardiogram was independently associated with a significantly increased rate of long-term cardiovascular death or myocardial infarction (adjusted hazard ratio 1.64, 95% CI 1.18-2.28) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/19\">",
"     19",
"    </a>",
"    ]. This finding appeared due in part to increased age and increased frequency and severity of left ventricular dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Infarct location",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infarct location is an important determinant of prognosis in patients with NSTEMI. Patients with anterior infarcts are at a greater risk for recurrent cardiac events compared to patients with an inferior wall infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. This was illustrated in a report from the SPRINT registry in which patients with an anterior NSTEMI had, after adjustment for other risk factors, a significant increase in one-year cardiac event rate (odds ratio 3.15) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/21\">",
"     21",
"    </a>",
"    ]. Anterior infarction is associated with larger infarct size and a lower LVEF [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/23\">",
"     23",
"    </a>",
"    ]. As a result of these and other observations, an anterior location is considered an adverse risk factor in the TIMI risk score (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?5/34/5665?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/43/2746?source=see_link&amp;anchor=H7#H7\">",
"     \"Risk stratification after unstable angina or non-ST elevation myocardial infarction\", section on 'TIMI risk score'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Continuous ST segment monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuous ST segment monitoring can identify patients with silent ischemia after an MI or an episode of UA; silent ischemia has been associated with an adverse clinical outcome in such patients. A meta-analysis of 995 patients from three randomized trials detected ischemic episodes in 27 percent using computer-assisted 12-lead or a vectorcardiographic ECG-ischemia monitoring device [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/25\">",
"     25",
"    </a>",
"    ]. There was a direct relationship between the number of ischemic episodes per 24 hours and the risk of a cardiac event (death or MI) at five or 30 days. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/35/4665?source=see_link\">",
"     \"Silent myocardial ischemia: Prognosis and therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of silent ischemia on continuous monitoring early after NSTEMI also adversely affects long-term prognosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/43/2746?source=see_link&amp;anchor=H21#H21\">",
"     \"Risk stratification after unstable angina or non-ST elevation myocardial infarction\", section on 'Continuous electrocardiography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Silent ischemia also may be detected at stress testing performed prior to discharge in patients who have not undergone revascularization (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/43/2746?source=see_link&amp;anchor=H16#H16\">",
"     \"Risk stratification after unstable angina or non-ST elevation myocardial infarction\", section on 'Stress testing'",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     QRS duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with an NSTEMI who have a QRS duration &ge;100 ms in the absence of bundle branch block may have significant increases in mortality in-hospital and at one and five years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/26\">",
"     26",
"    </a>",
"    ]. This may be partially explained by an association with a greater degree of left ventricular dysfunction, ischemia and multivessel coronary disease, and an increased vulnerability to reentrant ventricular tachyarrhythmias and sudden death. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/11/4282?source=see_link\">",
"     \"Conduction abnormalities after myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Serum biomarkers",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of serum biomarkers can be measured to assist in risk stratification of patients with",
"    <span class=\"nowrap\">",
"     UA/NSTEMI.",
"    </span>",
"    The two most commonly used are serum troponins and CK-MB. Other biomarkers, such as myoglobin, C-reactive protein (CRP), and brain natriuretic peptide (BNP), also have prognostic significance; their role, alone or in combination, in clinical decision making is not yet clearly established.",
"   </p>",
"   <p>",
"    Before reviewing the data supporting these relationships, several points deserve emphasis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the past, patients with an ACS and normal serum CK-MB were considered to have UA even if serum troponins were elevated. Such patients are now considered to have an NSTEMI [",
"      <a class=\"abstract\" href=\"./risk-factors-for-adverse-outco",
"1ff8",
"mes-after-unstable-angina-or-non-st-elevation-myocardial-infarction/abstract/27\">",
"       27",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=see_link&amp;anchor=H2#H2\">",
"       \"Criteria for the diagnosis of acute myocardial infarction\", section on 'Definitions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      As mentioned above, elevations in serum troponins are considered indications for an early invasive strategy [",
"      <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/28\">",
"       28",
"      </a>",
"      ]. Ensuing revascularization in many of these patients may alter the adverse predictive value of elevated cardiac enzymes noted in many of the studies mentioned below. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=see_link\">",
"       \"Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Small elevations in cardiac enzymes in ACS are thought to reflect localized areas of infarction [",
"      <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/29\">",
"       29",
"      </a>",
"      ], while more pronounced elevations reflect larger size. The adverse prognosis associated with enzyme elevations may also be related to worse underlying disease. In the FRISC II trial, any elevation in serum cardiac troponin T (cTnT) in the noninvasive arm of the study increased the likelihood of severe three vessel disease, an unstable plaque with thrombus and downstream microembolization, and impairment of coronary flow; these factors are all associated with an increased risk for reinfarction and death [",
"      <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Data from TACTICS-TIMI 18 suggest that women with a non-ST elevation ACS are more likely to have elevations of CRP and BNP, and less likely to have elevations of troponins and CK-MB, than men, despite similar levels of risk. As a result, a multimarker approach that incorporates CRP and BNP as well as troponins may more accurately predict risk for both genders (see",
"      <a class=\"local\" href=\"#H22\">",
"       'Markers in women'",
"      </a>",
"      below).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Serum troponins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac troponin I (cTnI) and cTnT are sensitive and specific markers of myocardial necrosis. Elevations in serum troponins are associated with a graded adverse effect early, mid-term, and long-term prognosis in men and women with a non-ST elevation MI. The data supporting this relationship are described in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39530?source=see_link\">",
"     \"Troponins and creatine kinase as biomarkers of cardiac injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The largest experience on the magnitude of the predictive value of serum troponin T comes from the GUSTO IV ACS trial of over 7000 patients who did not undergo early revascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/31\">",
"     31",
"    </a>",
"    ]. The patients were stratified by quartiles of troponin T (&le;0.01, 0.01 to 0.12, 0.12 to 0.47, and 0.47). The 30 day mortality rate increased from 1.1 to 7.4 percent from the first to fourth quartiles of cTnT. There was also a significant increase in the 30 day rate of MI from the first to second quartiles of cTnT (2.5 versus 6.7 percent), but no further increase between the upper three quartiles. Serum troponin T and serum CRP had independent and complementary prognostic significance (see",
"    <a class=\"local\" href=\"#H20\">",
"     'C-reactive protein'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Serum CK-MB",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is also a graded relationship between serum CK-MB elevations and prognosis in ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. The relationship between peak CK-MB level and outcome in patients with a non-ST elevation ACS was evaluated in the PURSUIT trial of 8250 patients from whom at least one CK-MB sample was obtained [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/32\">",
"     32",
"    </a>",
"    ]. Mortality was related to the presence of an elevated CK-MB level and the degree of elevation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The 30 day and six month mortality was 1.8 and 4 percent, respectively, when peak CK-MB levels were normal; these patients were considered to have UA.",
"     </li>",
"     <li>",
"      Mortality increased progressively to 8.3 and 11 percent at 30 days and six months when peak CK-MB levels were more than 10 times normal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39530?source=see_link&amp;anchor=H22#H22\">",
"     \"Troponins and creatine kinase as biomarkers of cardiac injury\", section on 'CK-MB fraction for prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Serum myoglobin",
"    </span>",
"    &nbsp;&mdash;&nbsp;An analysis from the TIMI 11B and TACTIC-TIMI 18 trials of patients with a non-ST elevation ACS found predictive value from the baseline serum concentration of myoglobin, another biomarker of cardiac injury [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/34\">",
"     34",
"    </a>",
"    ]. A serum myoglobin above 110",
"    <span class=\"nowrap\">",
"     &micro;g/L",
"    </span>",
"    was associated with the following significant changes: a lower incidence of TIMI grade III flow (indicating a patent infarct-related artery), a greater likelihood of thrombus in the infarct-related artery, and an increase in six month mortality (adjusted odds ratio 3.0) but not nonfatal MI. These effects were independent of other prognostic variables such as ECG changes and serum cTnI and CK-MB.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Plasma BNP and N-pro-BNP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain natriuretic peptide (BNP) is a neurohormone synthesized in the left ventricular myocardium and released into circulation in response to ventricular dilatation and pressure overload. Elevated plasma concentrations of BNP, which can be measured by a rapid bedside assay, are of prognostic importance for both early and late outcomes in patients with a non-ST elevation ACS, a presumed reflection of left ventricular dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/35-41\">",
"     35-41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=see_link\">",
"     \"Natriuretic peptide measurement in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The predictive value of plasma BNP was best illustrated in a study of 2525 such patients in whom plasma BNP was measured at a mean of 40 hours after the onset of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/35\">",
"     35",
"    </a>",
"    ]. After adjusting for other predictors of risk, the odds ratios for death at 10 months were 3.8, 4, and 5.8 for concentrations in the second, third, or fourth quartiles compared to those in the lowest quartile; higher plasma BNP was also associated with an increased risk of new or recurrent myocardial infarction and new or worsening heart failure (",
"    <a class=\"graphic graphic_figure graphicRef62159 graphicRef72910 \" href=\"UTD.htm?36/26/37295\">",
"     figure 2A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Plasma N-terminal pro-BNP (N-pro-BNP) has similar predictive valu",
"1ff8",
"e [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/36,42-47\">",
"     36,42-47",
"    </a>",
"    ]. The largest study of this issue is an analysis of data on 6809 patients from the GUSTO IV ACS trial [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/42\">",
"     42",
"    </a>",
"    ]. Blood samples obtained within 24 hours of symptom onset in patients with a non-ST elevation ACS were retrospectively assayed for N-pro-BNP. Patients in the lowest decile of N-pro-BNP (&le;98",
"    <span class=\"nowrap\">",
"     ng/L)",
"    </span>",
"    had a significantly lower mortality rate at one year than those in the highest decile (&gt;4634",
"    <span class=\"nowrap\">",
"     ng/L)",
"    </span>",
"    (0.4 versus 27.1 percent). N-pro-BNP had a stronger correlation with mortality than any other marker studied, including cTnT and CRP.",
"   </p>",
"   <p>",
"    Serial measurements may permit an on-going assessment of risk. Both failure of initially elevated N-pro-BNP levels to rapidly decline (to &le;250",
"    <span class=\"nowrap\">",
"     ng/L)",
"    </span>",
"    and a late rise over 72 hours to above 250",
"    <span class=\"nowrap\">",
"     ng/L",
"    </span>",
"    in patients with initially low levels may be associated with a marked increase in risk of mortality at 30 days [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/47\">",
"     47",
"    </a>",
"    ]. Plasma N-pro-BNP is highest during the acute phase and then gradually falls over six months [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/48\">",
"     48",
"    </a>",
"    ]. Elevated values at any time period are associated with increased risk. Late persistent elevations presumably reflect chronic left ventricular dysfunction.",
"   </p>",
"   <p>",
"    The prognostic value of serial testing during follow-up was illustrated in a review of patients who were enrolled in Phase Z of the A to Z trial of statin therapy in non-ST elevation ACS in which plasma BNP was measured in 4266 patients at baseline, 3618 at four months, and 2966 at one year [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/39\">",
"     39",
"    </a>",
"    ]. Plasma BNP values above 80",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    were considered elevated. The following findings were noted during two year follow-up:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with measurements at both baseline and four months, plasma BNP was elevated in 13.5 percent at baseline and 4.0 percent at four months. Among patients with a normal plasma BNP at baseline, 2.5 percent had a new elevation at four months.",
"     </li>",
"     <li>",
"      Among patients with measurements at both four and 12 months, half of the 6 percent of patients with elevated plasma BNP at four months had a persistent elevation at 12 months. On the other hand, 4.6 percent had a new elevation at 12 months.",
"     </li>",
"     <li>",
"      The risk of death or new heart failure was significantly increased in patients with elevated plasma BNP at baseline (21 versus 7 percent with a normal plasma BNP, adjusted hazard ratio [HR] 2.5), four months (19 versus 4 percent, adjusted HR 3.9), and 12 months (11 versus 1 percent, adjusted HR 4.7).",
"     </li>",
"     <li>",
"      The risk of death or new heart failure was significantly increased in patients with a new elevation in plasma BNP at four months (15 versus 3.5 percent with a persistent normal plasma BNP, adjusted HR 4.5).",
"     </li>",
"     <li>",
"      The risk of death or new heart failure was only modestly increased in patients with a plasma BNP that was elevated at baseline but normal at four months (adjusted HR 1.5 compared to those with normal values at both times).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The role of plasma BNP or N-pro-BNP monitoring in patients with a non-ST elevation ACS remains to be determined. Although assessment of plasma BNP or N-pro BNP may provide a more complete risk assessment, true value from such measurements will be provided only if there is evidence of benefit from therapeutic interventions directed at lowering hormone levels [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/39-41\">",
"     39-41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     C-reactive protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevations in serum CRP, an acute phase reactant, are associated with a worse short- and long-term prognosis in patients with a non-ST elevation ACS. Data from several large trials show a correlation between the level of serum CRP and rates of subsequent cardiovascular death or MI. Serum CRP also predicts short- and long-term mortality in patients with an ACS who undergo early revascularization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/0/27658?source=see_link\">",
"     \"C-reactive protein in cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The largest experience on the magnitude of the predictive value of serum CRP and its interaction with serum troponin T comes from the GUSTO IV ACS trial of over 7000 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/31\">",
"     31",
"    </a>",
"    ]. The patients were stratified by quartiles of CRP and troponin T at enrollment. The 30 day mortality rate increased from 2 to 6.3 percent from the first to fourth quartiles of CRP; there was no correlation between quartile of CRP and rate of MI at 30 days. Serum CRP and troponin T had independent and complementary prognostic significance; the mortality rate at 30 days ranged from 0.3 to 9.1 percent for patients in the lowest to the highest quartile of both markers.",
"   </p>",
"   <p>",
"    Similar relationships have been noted in smaller trials [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. Serum CRP may remain elevated for a prolonged period after symptoms abate [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/51\">",
"     51",
"    </a>",
"    ]. Patients with elevated serum CRP at discharge are at greater risk for recurrent symptoms or a new MI (in one report, 69 versus 15 percent in patients with normal serum CRP at discharge) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Heart-type fatty acid binding protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart-type fatty acid binding protein (H-FABP) is a small cytosolic protein that functions as the principle transporter of long chain fatty acids in cardiac muscle cells [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/52\">",
"     52",
"    </a>",
"    ]. It is released into the circulation in response to myocardial injury, and may provide added value to other cardiac biomarkers for the early diagnosis of myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/28/28101?source=see_link&amp;anchor=H7#H7\">",
"     \"Biomarkers of cardiac injury other than troponins and creatine kinase\", section on 'Heart-type fatty acid binding protein'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ability of H-FABP to predict cardiovascular outcomes was evaluated in 2287 patients with ACS enrolled in the OPUS-TIMI 16 trial [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/54\">",
"     54",
"    </a>",
"    ]. H-FABP was elevated (&gt;8 ng per mL) in 332 patients (15 percent). These patients had, at 10 month follow-up, a significant increase in the rate of the composite end point of death, recurrent MI, or heart failure (multivariable adjusted HR 1.9).",
"1ff8",
" H-FABP elevation provided incremental information for risk stratification to troponins or BNP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Markers in women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from TACTICS-TIMI 18 suggest that women with a non-ST elevation ACS are more likely to have elevations of CRP and BNP, and less likely to have elevations of troponins and CK-MB, than men, despite similar levels of risk [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/55\">",
"     55",
"    </a>",
"    ]. As a result, a multimarker approach that incorporates CRP and BNP as well as troponins may more accurately predict risk for both genders. In TACTICS-TIMI 18, risk of death or MI at six months was similar for men and women when the total number of elevated biomarkers was 0 (4.4 versus 2.9 percent), 1 (6.5 versus 6.2 percent) or 2 to 3 (13.3 versus 12.1 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Multimarker approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of multiple markers appears to have additive prognostic value. This was demonstrated in the CHECKMATE study in which combined bedside multimarker testing (serum CK-MB, cTnI, and myoglobin) were compared to local laboratory testing of a single marker measured at baseline and multiple times in the next 16 to 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/56\">",
"     56",
"    </a>",
"    ]. Patients with either all three tests positive or only CK-MB and cTnI positive had a higher rate of death or infarction at 30 days compared to positive single marker testing in the local laboratory (18.8 and 21.9 versus 5.5 percent). It is possible that the value of the multimarker approach reflects somewhat different mechanisms of enzyme release from ischemic myocardial cells or, with myoglobin, with hypoperfusion-induced release from skeletal muscle cells [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted above, elevations in serum CRP and BNP are also of prognostic importance and assess different pathophysiologic mechanisms than cardiac enzymes in myocardial ischemia. Risk stratification based upon an additive effect of cTnI, CRP, and BNP was evaluated in a study of 450 patients with ACS without ST segment elevation in the OPUS-TIMI 16 trial and validated in 1635 patients in the TACTICS-TIMI 18 trial [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/57\">",
"     57",
"    </a>",
"    ]. The number of elevated markers was a significant predictor of the composite end point of death, MI, or heart failure in both trials. In TACTICS-TIMI 18, the end point at six months was increased 2.1-, 3.1-, and 3.7-fold in those with one, two, or three elevated biomarkers compared to no biomarker elevations.",
"   </p>",
"   <p>",
"    In a similar analysis of data on 6809 patients from the GUSTO IV ACS trial, independent predictors of mortality at one year included N-pro-BNP, cTnT, CRP, heart rate, and creatinine clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/42\">",
"     42",
"    </a>",
"    ]. The two-marker combination of N-pro-BNP in the top quartile (&gt;1869",
"    <span class=\"nowrap\">",
"     ng/L)",
"    </span>",
"    plus any of the other markers in their top quartiles (cTnT &gt;0.47",
"    <span class=\"nowrap\">",
"     microg/L,",
"    </span>",
"    CRP &gt;9.62",
"    <span class=\"nowrap\">",
"     mg/L,",
"    </span>",
"    heart rate &gt;79 bpm, or creatinine clearance &le;51",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    predicted a one-year mortality of 22 to 26 percent, while N-pro-BNP in the bottom quartile plus any other marker in the bottom quartile predicted a one-year mortality of less than 2 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57154531\">",
"    <span class=\"h2\">",
"     Incomplete revascularization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relationship between incomplete angiographic revascularization and outcome after percutaneous coronary intervention in patients with non-ST elevation ACS is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=see_link&amp;anchor=H22#H22\">",
"     \"Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction\", section on 'Multivessel versus culprit only PCI'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H458463926\">",
"    <span class=\"h2\">",
"     Serum potassium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies performed before the routine use of beta blockers, statins, and aggressive antithrombotic therapy in addition to urgent reperfusion in many patients, demonstrated a relationship between low serum potassium levels and the risk of ventricular arrhythmias. These early studies led to specific recommendations for the serum potassium level in patients with acute MI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=see_link&amp;anchor=H26#H26\">",
"     \"Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction\", section on 'VF Predictors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The relationship between serum potassium level and in-hospital mortality in patients with biomarker confirmed acute MI and managed with more recent recommended therapies was evaluated in a study of nearly 40,000 patients enrolled in a United States database between 2000 and 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/58\">",
"     58",
"    </a>",
"    ]. After multivariate analysis, a U-shaped relationship between mean postadmission serum potassium level and in-hospital mortality was found. Using a mean postadmission serum potassium level of 3.5 to &lt;4.0",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    as the reference, the adjusted odds ratios (all of which were significantly increased) for mortality in those with serum potassium levels of &lt;3.0, 3.0 to &lt;3.5, 4.0 to &lt;4.5, 4.5 to &lt;5.0, 5.0 to &lt;5.5, and &ge;5.5",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    were 8.11, 1.45, 1.25, 1.96, 3.27, and 6.44, respectively. It is important to note that patients with a serum potassium between 4.5 and 5.0",
"    <span class=\"nowrap\">",
"     mEq/L,",
"    </span>",
"    a range that has previously considered &ldquo;within normal limits&rdquo;, had a nearly two-fold greater risk of death compared to those with levels between 3.5 to &lt;4.0",
"    <span class=\"nowrap\">",
"     mEq/L.",
"    </span>",
"    The findings of this study pertaining to the secondary composite outcome of ventricular fibrillation or cardiac arrest are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=see_link&amp;anchor=H26#H26\">",
"     \"Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction\", section on 'VF Predictors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Glycemic control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetic patients have a worse long-term outcome after a non-ST elevation ACS than those without diabetes (",
"    <a class=\"graphic graphic_figure graphicRef81567 \" href=\"UTD.htm?23/59/24509\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/59\">",
"     59",
"    </a>",
"    ]. In addition, there is increasing evidence that suboptimal glycemic control in diabetic patients and stress hyperglycemia in nondiabetic patients are associated with worse in-hospital outcomes after acute MI and that strict glycemic control may be beneficial.",
"   </p>",
"   <p>",
"    The 2007",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines on non-ST elevation ACS considered it reasonable in patients with diabetes mellitus to administer insulin to achieve a goal serum glucose of less than 150",
"    <spa 1ff8 class=\"nowrap\" n>",
"     mg/dL",
"     (8.3",
"     <span class=\"nowrap\">",
"      mmol/L)",
"     </span>",
"     during the first three hospital days [",
"     <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/28\">",
"      28",
"     </a>",
"     ]. The long-term goal of strict glycemic control is similar to those in other diabetic patients.",
"    </spa>",
"   </p>",
"   <p>",
"    The data supporting these conclusions are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44567?source=see_link\">",
"     \"Glycemic control for acute myocardial infarction in patients with and without diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=see_link&amp;anchor=H3#H3\">",
"     \"Initial management of blood glucose in type 2 diabetes mellitus\", section on 'Degree of glycemic control'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Claudication",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of intermittent claudication appears to predict worse outcomes in patients with an NSTEMI [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/60-62\">",
"     60-62",
"    </a>",
"    ]. This was illustrated in a study of 1045 patients (35 percent with a known NSTEMI) evaluated two months after an acute MI in which 78 (7 percent) had intermittent claudication [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/60\">",
"     60",
"    </a>",
"    ]. At 26 months of follow-up, those with claudication were five times more likely to have a fatal cardiac event than those without claudication (19.2 versus 3.6 percent). The patients with claudication were older and more likely to have a history of diabetes, a prior MI, a stroke, or diminished left ventricular function. Even when these comorbidities were taken into account, patients with claudication had a significantly higher incidence of cardiac death (hazard ratio 6.57).",
"   </p>",
"   <p>",
"    A similar increase in risk and in underlying comorbidities in patients with peripheral artery disease has been noted in other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. Nevertheless, these patients still appear to benefit from an early invasive strategy. This was illustrated in a post hoc analysis from the TACTICS-TIMI 18 trial in which 166 patients (7.5 percent) had concomitant peripheral artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/62\">",
"     62",
"    </a>",
"    ]. These patients had, with an early invasive strategy, significant reductions in mortality at 30 days (2.3 versus 11.4 percent with conservative therapy) and six months and in MI at six months (3.5 versus 12.7 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     White blood cell count",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a higher white blood cell (WBC) count, which is a marker of inflammation, have an increased risk for an adverse event, in-hospital mortality, and short- and long-term mortality after a non-ST elevation ACS as well as an acute ST elevation MI [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/63-68\">",
"     63-68",
"    </a>",
"    ]. In a report from the Cooperative Cardiovascular Project of over 150,000 patients &ge;65 years of age with an acute MI (60 percent without ST elevation or left bundle branch block), patients in the highest quintile of WBC were significantly more likely to die at 30 days than those in the lowest quintile (10.3 versus 30.2 percent, adjusted odds ratio 2.37) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The specific predictive value of the baseline WBC in patients with non-ST elevation MI or unstable angina was best evaluated in a substudy report from the TACTICS-TIMI 18 trial [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/66\">",
"     66",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Higher WBC were associated with significantly lower TIMI flow grades and myocardial perfusion grades and more extensive coronary disease",
"     </li>",
"     <li>",
"      Higher WBC were associated with a higher six month mortality, which ranged from 1.5 percent at a WBC",
"      <span class=\"nowrap\">",
"       &lt;6,700/&micro;L",
"      </span>",
"      to 3.6 percent at a WBC of 6,700 to",
"      <span class=\"nowrap\">",
"       10,100/&micro;L",
"      </span>",
"      to 5.1 percent at a WBC above",
"      <span class=\"nowrap\">",
"       10,100/&micro;L",
"      </span>",
"     </li>",
"     <li>",
"      Six month mortality ranged from 0.8 percent in patients with a WBC",
"      <span class=\"nowrap\">",
"       &lt;6700/&micro;L",
"      </span>",
"      and a low serum CRP to 2.2 percent in those with a high WBC (above",
"      <span class=\"nowrap\">",
"       10,100/&micro;L)",
"      </span>",
"      and a low serum CRP to 7.1 percent in those with a high WBC and a high serum CRP.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Elevated plasma levels of the leukocyte enzyme myeloperoxidase, which is secreted during acute inflammation, have also been correlated with prognosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of anemia appears to be an adverse predictor of prognosis in patients with a non-ST elevation ACS. In a review of clinical trials that included over 14,500 patients with a non-ST elevation ACS, the likelihood of cardiovascular mortality, nonfatal MI, or recurrent ischemia at 30 days was increased in patients with a hemoglobin below 11",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    compared to those with a hemoglobin of 15 to 16",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/69\">",
"     69",
"    </a>",
"    ]. After adjustment for baseline characteristics, a hemoglobin below 11",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    was an independent predictor of the combined end point (adjusted odds ratio 1.45 per each 1",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    decrement in hemoglobin).",
"   </p>",
"   <p>",
"    There also may be a graded increase in late (up to 24 months) mortality in patients with anemia on admission or at discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The value of blood transfusion in anemic patients for the sole purpose of raising the hemoglobin concentration with a non-ST elevation ACS is unproven in the absence of a clear indication for such therapy. The available data are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=see_link\">",
"     \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Major bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the patients with anemia described above have had major bleeding during their hospitalization. The relationship between major bleeding and long-term death or ischemic events was evaluated in a study of over 34,000 patients with non-ST elevation ACS enrolled in the OASIS registry and the OASIS-2 and CURE trials [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/71\">",
"     71",
"    </a>",
"    ]. The likelihood of death in patients who bled compared to those who did not was significantly increased at 30 days and between 30 days and six months (adjusted HR 5.37; 95% CI 3.97-7.26 and 1.54; 95% CI 1.01-2.36 respectively). A similar significant association existed between bleeding and myocardial infarction.",
"   </p>",
"   <p>",
"    One possible explanation for these observations is that patients wh",
"1ff8",
"o have significant bleeding during their hospitalization are not discharged on guideline recommended antiplatelet therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/72\">",
"     72",
"    </a>",
"    ]. In addition there may be a delay in starting dual antiplatelet therapy long after the major bleed has come under control.",
"   </p>",
"   <p>",
"    This theory was evaluated using data in the PREMIER registry of 2498 patients with acute MI [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/72\">",
"     72",
"    </a>",
"    ]. Patients with in-hospital bleeding (n = 301) were significantly less likely to be receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or thienopyridine at discharge (adjusted odds ratio [OR] 0.45; 05% CI 0.31-0.54 and 0.62 95% CI 0.52-0.91 respectively). At one month patients were significantly less likely to be receiving aspirin (OR 0.68; 95% CI 0.50-0.92) and there was a non-significant decreased likelihood of receiving thienopyridine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Decreased renal function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with end-stage renal disease have a higher risk for and a worse outcome after myocardial infarction. However, lesser degrees of renal dysfunction also predict an adverse prognosis in patients with an acute MI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=see_link\">",
"     \"Chronic kidney disease and coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/0/29703?source=see_link\">",
"     \"Risk factors and epidemiology of coronary artery disease in end-stage renal disease (dialysis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The magnitude of this effect has been examined in several studies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/73-75\">",
"     73-75",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an analysis of three major trials of over 19,000 patients with a non-ST elevation ACS, the patients with impaired renal function (estimated baseline creatinine clearance below 70",
"      <span class=\"nowrap\">",
"       mL/min)",
"      </span>",
"      had increased mortality at both 30 days and six months (approximately 10.5 versus 3.4 percent at six months) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/73\">",
"       73",
"      </a>",
"      ]. They were also older and had more baseline risk factors. After accounting for these differences, the adjusted hazard ratio for death and for death or MI at six months was significantly increased in patients with reduced renal function (1.23 and 1.08, respectively, for each 10",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      decrement in creatinine clearance). The increase in risk was most pronounced in patients the lowest creatinine clearances (median 45",
"      <span class=\"nowrap\">",
"       mL/min).",
"      </span>",
"     </li>",
"     <li>",
"      Similar observations were made in an analysis from the VALIANT trial of 14,527 patients with an acute MI (one-third with a NSTEMI) complicated by heart failure, left ventricular dysfunction, or both [",
"      <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/74\">",
"       74",
"      </a>",
"      ]. The glomerular filtration rate (GFR) was estimated using the Modification of Diet in Renal Disease (MDRD) equation. At three years, the mortality rates for patients with a GFR of &ge;75, 60 to 74.9, 45 to 59.9, and &lt;45",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2 were 14.1, 20.5, 28.9, and 45.5 percent. After adjustment for other risk factors, the risk of death or nonfatal cardiovascular complications increased significantly with declining GFR (hazard ratio 1.10 for each 10-unit decrease in GFR below 81.0",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A potential limitation of these studies is that only baseline serum creatine values were used. The formulas used for calculation of the creatinine clearance and the estimated GFR require stable values over time, which might not be present in patients with ACS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=see_link\">",
"     \"Assessment of kidney function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to renal dysfunction, the blood urea nitrogen (BUN) may be an independent risk factor for mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?25/9/25754/abstract/76\">",
"     76",
"    </a>",
"    ]. A possible mechanism is that an elevated BUN reflects renal hypoperfusion due to a low cardiac output. Renal hypoperfusion leads to enhanced tubular sodium and urea reabsorption, raising the BUN out of proportion to any reduction in GFR. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=see_link\">",
"     \"Assessment of kidney function\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Obstructive sleep apnea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstructive sleep apnea (OSA) has been associated with myocardial infarction and may be a marker for worse cardiovascular outcomes. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18169?source=see_link\">",
"     \"Cardiovascular effects of obstructive sleep apnea\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2836996\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following are the strongest predictors of adverse outcomes after unstable angina or non-ST elevation myocardial infarction:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The worse the unstable angina (ie, higher risk profile does worse--Braunwald Classification) (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Type of unstable angina'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Elevations in serum troponins are associated with a graded adverse effect early, mid-term, and long-term prognosis in men and women with a non-ST elevation MI. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Serum biomarkers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Overt heart failure or severe left ventricular dysfunction (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Heart failure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Renal failure (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Decreased renal function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Bleeding/anemia",
"      </span>",
"      (with or without PCI). (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Anemia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/1\">",
"      Canto JG, Kiefe CI, Rogers WJ, et al. Number of coronary heart disease risk factors and mortality in patients with first myocardial infarction. JAMA 2011; 306:2120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/2\">",
"      Goldberg RJ, McCormick D, Gurwitz JH, et al. Age-related trends in short- and long-term survival after acute myocardial infarction: a 20-year population-based perspective (1975-1995). Am J Cardiol 1998; 82:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/3\">",
"      Stone PH, Thompson B, Anderson HV, et al. Influence of race, sex, and age on management of unstable angina and non-Q-wave myocardial infarction: The TIMI III registry. JAMA 1996; 275:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstr",
"1ff8",
"act/4\">",
"      Braunwald E. Unstable angina. A classification. Circulation 1989; 80:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/5\">",
"      van Miltenburg-van Zijl AJ, Simoons ML, Veerhoek RJ, Bossuyt PM. Incidence and follow-up of Braunwald subgroups in unstable angina pectoris. J Am Coll Cardiol 1995; 25:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/6\">",
"      Calvin JE, Klein LW, VandenBerg BJ, et al. Risk stratification in unstable angina. Prospective validation of the Braunwald classification. JAMA 1995; 273:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/7\">",
"      Dangas G, Mehran R, Wallenstein S, et al. Correlation of angiographic morphology and clinical presentation in unstable angina. J Am Coll Cardiol 1997; 29:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/8\">",
"      Braunwald E, Jones RH, Mark DB, et al. Diagnosing and managing unstable angina. Agency for Health Care Policy and Research. Circulation 1994; 90:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/9\">",
"      Hamm CW, Braunwald E. A classification of unstable angina revisited. Circulation 2000; 102:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/10\">",
"      Becker RC, Burns M, Gore JM, et al. Early assessment and in-hospital management of patients with acute myocardial infarction at increased risk for adverse outcomes: a nationwide perspective of current clinical practice. The National Registry of Myocardial Infarction (NRMI-2) Participants. Am Heart J 1998; 135:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/11\">",
"      Killip T 3rd, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol 1967; 20:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/12\">",
"      Steg PG, Dabbous OH, Feldman LJ, et al. Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE). Circulation 2004; 109:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/13\">",
"      Khot UN, Jia G, Moliterno DJ, et al. Prognostic importance of physical examination for heart failure in non-ST-elevation acute coronary syndromes: the enduring value of Killip classification. JAMA 2003; 290:2174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/14\">",
"      Al-Khatib SM, Granger CB, Huang Y, et al. Sustained ventricular arrhythmias among patients with acute coronary syndromes with no ST-segment elevation: incidence, predictors, and outcomes. Circulation 2002; 106:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/15\">",
"      Piccini JP, White JA, Mehta RH, et al. Sustained ventricular tachycardia and ventricular fibrillation complicating non-ST-segment-elevation acute coronary syndromes. Circulation 2012; 126:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/16\">",
"      Al-Khatib SM, Pieper KS, Lee KL, et al. Atrial fibrillation and mortality among patients with acute coronary syndromes without ST-segment elevation: results from the PURSUIT trial. Am J Cardiol 2001; 88:A7, 76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/17\">",
"      Po&ccedil;i D, Hartford M, Karlsson T, et al. Role of the CHADS2 score in acute coronary syndromes: risk of subsequent death or stroke in patients with and without atrial fibrillation. Chest 2012; 141:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/18\">",
"      Boersma E, Pieper KS, Steyerberg EW, et al. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation 2000; 101:2557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/19\">",
"      Damman P, Holmvang L, Tijssen JG, et al. Usefulness of the admission electrocardiogram to predict long-term outcomes after non-ST-elevation acute coronary syndrome (from the FRISC II, ICTUS, and RITA-3 [FIR] Trials). Am J Cardiol 2012; 109:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/20\">",
"      Savonitto S, Ardissino D, Granger CB, et al. Prognostic value of the admission electrocardiogram in acute coronary syndromes. JAMA 1999; 281:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/21\">",
"      Haim M, Hod H, Reisin L, et al. Comparison of short- and long-term prognosis in patients with anterior wall versus inferior or lateral wall non-Q-wave acute myocardial infarction. Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT) Study Group. Am J Cardiol 1997; 79:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/22\">",
"      Kao W, Khaja F, Goldstein S, Gheorghiade M. Cardiac event rate after non-Q-wave acute myocardial infarction and the significance of its anterior location. Am J Cardiol 1989; 64:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/23\">",
"      Stone PH, Raabe DS, Jaffe AS, et al. Prognostic significance of location and type of myocardial infarction: independent adverse outcome associated with anterior location. J Am Coll Cardiol 1988; 11:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/24\">",
"      Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA 2000; 284:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/25\">",
"      Akkerhuis KM, Klootwijk PA, Lindeboom W, et al. Recurrent ischaemia during continuous multilead ST-segment monitoring identifies patients with acute coronary syndromes at high risk of adverse cardiac events; meta-analysis of three studies involving 995 patients. Eur Heart J 2001; 22:1997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/26\">",
"      Brilakis ES, Mavrogiorgos NC, Kopecky SL, et al.",
"1ff8",
" Usefulness of QRS duration in the absence of bundle branch block as an early predictor of survival in non-ST elevation acute myocardial infarction. Am J Cardiol 2002; 89:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/27\">",
"      Thygesen K, Alpert JS, White HD, Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J 2007; 28:2525.",
"     </a>",
"    </li>",
"    <li>",
"     Anderson J, Adams C, Antman E, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, American College or Physicians, Society for Academic Emergency Medicine, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2007; 50:e1 www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/29\">",
"      Ricciardi MJ, Wu E, Davidson CJ, et al. Visualization of discrete microinfarction after percutaneous coronary intervention associated with mild creatine kinase-MB elevation. Circulation 2001; 103:2780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/30\">",
"      Lindahl B, Diderholm E, Lagerqvist B, et al. Mechanisms behind the prognostic value of troponin T in unstable coronary artery disease: a FRISC II substudy. J Am Coll Cardiol 2001; 38:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/31\">",
"      James SK, Armstrong P, Barnathan E, et al. Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy. J Am Coll Cardiol 2003; 41:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/32\">",
"      Alexander JH, Sparapani RA, Mahaffey KW, et al. Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation. PURSUIT Steering Committee. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. JAMA 2000; 283:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/33\">",
"      Savonitto S, Granger CB, Ardissino D, et al. The prognostic value of creatine kinase elevations extends across the whole spectrum of acute coronary syndromes. J Am Coll Cardiol 2002; 39:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/34\">",
"      de Lemos JA, Morrow DA, Gibson CM, et al. The prognostic value of serum myoglobin in patients with non-ST-segment elevation acute coronary syndromes. Results from the TIMI 11B and TACTICS-TIMI 18 studies. J Am Coll Cardiol 2002; 40:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/35\">",
"      de Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001; 345:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/36\">",
"      Richards AM, Nicholls MG, Espiner EA, et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 2003; 107:2786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/37\">",
"      Tapanainen JM, Lindgren KS, M&auml;kikallio TH, et al. Natriuretic peptides as predictors of non-sudden and sudden cardiac death after acute myocardial infarction in the beta-blocking era. J Am Coll Cardiol 2004; 43:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/38\">",
"      Mega JL, Morrow DA, De Lemos JA, et al. B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy. J Am Coll Cardiol 2004; 44:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/39\">",
"      Morrow DA, de Lemos JA, Blazing MA, et al. Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. JAMA 2005; 294:2866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/40\">",
"      Blankenberg S, McQueen MJ, Smieja M, et al. Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2006; 114:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/41\">",
"      Kistorp C. Risk stratification in secondary prevention: advances in multimarker profiles, or back to basics? Circulation 2006; 114:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/42\">",
"      James SK, Lindahl B, Siegbahn A, et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation 2003; 108:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/43\">",
"      Jernberg T, Stridsberg M, Venge P, Lindahl B. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol 2002; 40:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/44\">",
"      Omland T, Persson A, Ng L, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 2002; 106:2913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/45\">",
"      Jernberg T, Lindahl B, Siegbahn A, et al. N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease. J Am Coll Cardiol 2003; 42:1909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/46\">",
"      Bazzino O, Fuselli JJ, Bot",
"1ff8",
"to F, et al. Relative value of N-terminal probrain natriuretic peptide, TIMI risk score, ACC/AHA prognostic classification and other risk markers in patients with non-ST-elevation acute coronary syndromes. Eur Heart J 2004; 25:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/47\">",
"      Heeschen C, Hamm CW, Mitrovic V, et al. N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation 2004; 110:3206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/48\">",
"      Lindahl B, Lindb&auml;ck J, Jernberg T, et al. Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: a Fragmin and fast Revascularisation during In Stability in Coronary artery disease (FRISC)-II substudy. J Am Coll Cardiol 2005; 45:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/49\">",
"      Toss H, Lindahl B, Siegbahn A, Wallentin L. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. Circulation 1997; 96:4204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/50\">",
"      Lindahl B, Toss H, Siegbahn A, et al. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med 2000; 343:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/51\">",
"      Biasucci LM, Liuzzo G, Grillo RL, et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 1999; 99:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/52\">",
"      Glatz JF, Kleine AH, van Nieuwenhoven FA, et al. Fatty-acid-binding protein as a plasma marker for the estimation of myocardial infarct size in humans. Br Heart J 1994; 71:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/53\">",
"      Seino Y, Ogata K, Takano T, et al. Use of a whole blood rapid panel test for heart-type fatty acid-binding protein in patients with acute chest pain: comparison with rapid troponin T and myoglobin tests. Am J Med 2003; 115:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/54\">",
"      O'Donoghue M, de Lemos JA, Morrow DA, et al. Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes. Circulation 2006; 114:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/55\">",
"      Wiviott SD, Cannon CP, Morrow DA, et al. Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction 18) substudy. Circulation 2004; 109:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/56\">",
"      Newby LK, Storrow AB, Gibler WB, et al. Bedside multimarker testing for risk stratification in chest pain units: The chest pain evaluation by creatine kinase-MB, myoglobin, and troponin I (CHECKMATE) study. Circulation 2001; 103:1832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/57\">",
"      Sabatine MS, Morrow DA, de Lemos JA, et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 2002; 105:1760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/58\">",
"      Goyal A, Spertus JA, Gosch K, et al. Serum potassium levels and mortality in acute myocardial infarction. JAMA 2012; 307:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/59\">",
"      Donahoe SM, Stewart GC, McCabe CH, et al. Diabetes and mortality following acute coronary syndromes. JAMA 2007; 298:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/60\">",
"      Narins CR, Zareba W, Moss AJ, et al. Relationship between intermittent claudication, inflammation, thrombosis, and recurrent cardiac events among survivors of myocardial infarction. Arch Intern Med 2004; 164:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/61\">",
"      Cotter G, Cannon CP, McCabe CH, et al. Prior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syndromes: are we doing enough? Results from the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study. Am Heart J 2003; 145:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/62\">",
"      Januzzi JL Jr, Buros J, Cannon CP, Tactics TIMI 18 Investigators. Peripheral arterial disease, acute coronary syndromes, and early invasive management: the TACTICS TIMI 18 trial. Clin Cardiol 2005; 28:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/63\">",
"      Madjid M, Awan I, Willerson JT, Casscells SW. Leukocyte count and coronary heart disease: implications for risk assessment. J Am Coll Cardiol 2004; 44:1945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/64\">",
"      Barron HV, Harr SD, Radford MJ, et al. The association between white blood cell count and acute myocardial infarction mortality in patients &gt; or =65 years of age: findings from the cooperative cardiovascular project. J Am Coll Cardiol 2001; 38:1654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/65\">",
"      Cannon CP, McCabe CH, Wilcox RG, et al. Association of white blood cell count with increased mortality in acute myocardial infarction and unstable angina pectoris. OPUS-TIMI 16 Investigators. Am J Cardiol 2001; 87:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/66\">",
"      Sabatine MS, Morrow DA, Cannon CP, et al. Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes: a TACTICS-TIMI 18 (Treat Angina with Ag",
"1ff8",
"grastat and determine Cost of Therapy with an Invasive or Conservative Strategy- Thrombolysis in Myocardial Infarction 18 trial)substudy. J Am Coll Cardiol 2002; 40:1761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/67\">",
"      Yen MH, Bhatt DL, Chew DP, et al. Association between admission white blood cell count and one-year mortality in patients with acute coronary syndromes. Am J Med 2003; 115:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/68\">",
"      Grau AJ, Boddy AW, Dukovic DA, et al. Leukocyte count as an independent predictor of recurrent ischemic events. Stroke 2004; 35:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/69\">",
"      Sabatine MS, Morrow DA, Giugliano RP, et al. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation 2005; 111:2042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/70\">",
"      Aronson D, Suleiman M, Agmon Y, et al. Changes in haemoglobin levels during hospital course and long-term outcome after acute myocardial infarction. Eur Heart J 2007; 28:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/71\">",
"      Eikelboom JW, Mehta SR, Anand SS, et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006; 114:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/72\">",
"      Wang TY, Xiao L, Alexander KP, et al. Antiplatelet therapy use after discharge among acute myocardial infarction patients with in-hospital bleeding. Circulation 2008; 118:2139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/73\">",
"      Al Suwaidi J, Reddan DN, Williams K, et al. Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation 2002; 106:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/74\">",
"      Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/75\">",
"      Freeman RV, Mehta RH, Al Badr W, et al. Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors. J Am Coll Cardiol 2003; 41:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/9/25754/abstract/76\">",
"      Kirtane AJ, Leder DM, Waikar SS, et al. Serum blood urea nitrogen as an independent marker of subsequent mortality among patients with acute coronary syndromes and normal to mildly reduced glomerular filtration rates. J Am Coll Cardiol 2005; 45:1781.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 77 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-218.28.111.102-322217C268-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_9_25754=[""].join("\n");
var outline_f25_9_25754=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2836996\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RISK PREDICTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8883788\">",
"      Number of CHD risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Older age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Type of unstable angina",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Heart failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Killip class",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Sustained ventricular arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ECG features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - ST segment depression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5702489\">",
"      - Left bundle branch block",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Infarct location",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Continuous ST segment monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - QRS duration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Serum biomarkers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Serum troponins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Serum CK-MB",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Serum myoglobin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Plasma BNP and N-pro-BNP",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - C-reactive protein",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Heart-type fatty acid binding protein",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Markers in women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Multimarker approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H57154531\">",
"      Incomplete revascularization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H458463926\">",
"      Serum potassium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Glycemic control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Claudication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      White blood cell count",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Major bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Decreased renal function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Obstructive sleep apnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2836996\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/77\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div 1ff8=\"CARD/77|FIG\" class=\"openRelatedGraphics\" id>",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/44/16078\" title=\"figure 1\">",
"      Troponin predicts outcome in unstable angina",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/53/14174\" title=\"figure 2A\">",
"      Higher BNP predicts death in non ST ACS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/43/12990\" title=\"figure 2B\">",
"      Higher BNP level predicts adverse events after non ST ACS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/59/24509\" title=\"figure 3\">",
"      Patients with diabetes have worse outcomes non ST elevation ACS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/77|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/46/22251\" title=\"table 1\">",
"      Classification unstable angina",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/60/7117\" title=\"table 2\">",
"      Risk of death or MI in UA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/59/4027\" title=\"table 3\">",
"      Killip classification of acute MI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?5/34/5665?source=related_link\" title=\"calculator 1\">",
"      Calculator: Thrombolysis in Myocardial Infarction (TIMI) score for unstable angina or non ST elevation myocardial infarction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=related_link\">",
"      Antiplatelet agents in acute non-ST elevation acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/28/28101?source=related_link\">",
"      Biomarkers of cardiac injury other than troponins and creatine kinase",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/0/27658?source=related_link\">",
"      C-reactive protein in cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18169?source=related_link\">",
"      Cardiovascular effects of obstructive sleep apnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=related_link\">",
"      Chronic kidney disease and coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28505?source=related_link\">",
"      Classification of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=related_link\">",
"      Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/11/4282?source=related_link\">",
"      Conduction abnormalities after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=related_link\">",
"      Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=related_link\">",
"      Criteria for the diagnosis of acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/26/4521?source=related_link\">",
"      Electrocardiogram in the prognosis of myocardial infarction or unstable angina",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44567?source=related_link\">",
"      Glycemic control for acute myocardial infarction in patients with and without diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=related_link\">",
"      Initial management of blood glucose in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=related_link\">",
"      Natriuretic peptide measurement in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=related_link\">",
"      Overview of the acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=related_link\">",
"      Overview of the risk equivalents and established risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/0/29703?source=related_link\">",
"      Risk factors and epidemiology of coronary artery disease in end-stage renal disease (dialysis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/43/2746?source=related_link\">",
"      Risk stratification after unstable angina or non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/35/4665?source=related_link\">",
"      Silent myocardial ischemia: Prognosis and therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16615?source=related_link\">",
"      Supraventricular arrhythmias after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29193?source=related_link\">",
"      Sustained monomorphic ventricular tachycardia in patients with a prior myocardial infarction: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39530?source=related_link\">",
"      Troponins and creatine kinase as biomarkers of cardiac injury",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_9_25755="Clinical features of acute colonic and small bowel ischemia";
var content_f25_9_25755=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F62738&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F62738&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical features of acute colonic and small bowel ischemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Acute colonic ischemia",
"       </td>",
"       <td class=\"subtitle1\">",
"        Acute mesenteric ischemia involving small bowel",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        90 percent of patients over age 60 years",
"       </td>",
"       <td>",
"        Age varies with etiology of ischemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute precipitating cause is rare",
"       </td>",
"       <td>",
"        Acute precipitating cause is typical",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patients do not appear severely ill",
"       </td>",
"       <td>",
"        Patients appear severely ill",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mild abdominal pain, tenderness present",
"       </td>",
"       <td>",
"        Pain is usually severe, tenderness is not prominent early",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rectal bleeding, bloody diarrhea typical",
"       </td>",
"       <td>",
"        Bleeding uncommon until very late",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Colonoscopy is procedure of choice",
"       </td>",
"       <td>",
"        MRA or MDCT angiography may be considered as the initial diagnostic test, angiography is recommended if there is strong clinical suspicion",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MDCT: multidetector row computed tomography; MRA: magnetic resonance angiography.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Reinus JF, Brandt LJ, Boley SJ, Gastroenterol Clin North Am 1990; 19:319.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_9_25755=[""].join("\n");
var outline_f25_9_25755=null;
var title_f25_9_25756="Intraabdominal sepsis bacteria";
var content_f25_9_25756=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F79147&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F79147&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Bacteriology of intraabdominal sepsis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Cases studied",
"       </td>",
"       <td>",
"        759",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Bacteriology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aerobes only",
"       </td>",
"       <td>",
"        132 (17)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anaerobes only",
"       </td>",
"       <td>",
"        7 (1)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anaerobes plus aerobes",
"       </td>",
"       <td>",
"        620 (82)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Bacterial isolates",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of isolates&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Aerobes",
"       </td>",
"       <td>",
"        1256",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Escherichia coli",
"       </td>",
"       <td>",
"        306",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pseudomonas aeruginosa",
"       </td>",
"       <td>",
"        121",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Klebsiella",
"       </td>",
"       <td>",
"        119",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Other Gram negative bacilli",
"       </td>",
"       <td>",
"        270",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Enterococcus",
"       </td>",
"       <td>",
"        277",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Staphylococcus aureus",
"       </td>",
"       <td>",
"        111",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Other Gram positive cocci",
"       </td>",
"       <td>",
"        62",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Anaerobes",
"       </td>",
"       <td>",
"        1187",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bacteroides species",
"       </td>",
"       <td>",
"        443",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bacteroides fragilis",
"       </td>",
"       <td>",
"        133",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Clostridium species",
"       </td>",
"       <td>",
"        306",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Peptostreptococcus",
"       </td>",
"       <td>",
"        220",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fusobacterium",
"       </td>",
"       <td>",
"        35",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Miscellaneous",
"       </td>",
"       <td>",
"        116",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Number of isolates (percent).",
"     <br>",
"      &bull; Numbers of isolates are greater than numbers of cases since the majority of cases had more than one microorganism isolated.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from Stone, HH, et al. Arch Surg 1983.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_9_25756=[""].join("\n");
var outline_f25_9_25756=null;
var title_f25_9_25757="Typical fast food meals";
var content_f25_9_25757=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62971&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62971&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Content of typical fast food meals in energy (calories) and fat",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Menu item",
"       </td>",
"       <td class=\"subtitle1\">",
"        Energy, kcal",
"       </td>",
"       <td class=\"subtitle1\">",
"        Fat, g",
"       </td>",
"       <td class=\"subtitle1\">",
"        Fat, percent of energy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Menu #1: (McDonald's)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hamburger",
"       </td>",
"       <td>",
"        250",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        32",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Small fries",
"       </td>",
"       <td>",
"        230",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        43",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Baked apple pie",
"       </td>",
"       <td>",
"        260",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        45",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Soft drink (16 ounces)",
"       </td>",
"       <td>",
"        170",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Total",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         910",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         33",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         33",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Menu #2: (Kentucky Fried Chicken)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Extra crispy fried leg and thigh",
"       </td>",
"       <td>",
"        490",
"       </td>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        62",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mashed potatoes and gravy",
"       </td>",
"       <td>",
"        130",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        35",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Biscuit",
"       </td>",
"       <td>",
"        180",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Soft drink (16 ounces)",
"       </td>",
"       <td>",
"        180",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Total",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         980",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         47",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         43",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Menu #3: (McDonald's)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Big Mac hamburger",
"       </td>",
"       <td>",
"        540",
"       </td>",
"       <td>",
"        29",
"       </td>",
"       <td>",
"        48",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        French fries (large)",
"       </td>",
"       <td>",
"        500",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        45",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Baked apple pie",
"       </td>",
"       <td>",
"        260",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        45",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Soft drink (large: 32 oz)",
"       </td>",
"       <td>",
"        310",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Total",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         1610",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         67",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         37",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Menu #4: (Burger King)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Triple whopper hamburger",
"       </td>",
"       <td>",
"        1140",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        59",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        French fries (large)",
"       </td>",
"       <td>",
"        540",
"       </td>",
"       <td>",
"        27",
"       </td>",
"       <td>",
"        45",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Apple fries",
"       </td>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Soft drink (large: 42 oz)",
"       </td>",
"       <td>",
"        380",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Total",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         2130",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         103",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         44",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Wake Forest University Baptist Medical Center Drive thru Diet (available at www1.wfubmc.edu/Nurtition/Count+Your+Calories/dtd.htm). Additional data from:",
"     <a href=\"file://www.mcdonalds.com\" target=\"_blank\">",
"      www.mcdonalds.com",
"     </a>",
"     ;",
"     <a href=\"file://www.kentuckyfriedchicken.com\" target=\"_blank\">",
"      www.kentuckyfriedchicken.com",
"     </a>",
"     ; and",
"     <a href=\"file://www.burgerking.com\" target=\"_blank\">",
"      www.burgerking.com",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_9_25757=[""].join("\n");
var outline_f25_9_25757=null;
var title_f25_9_25758="Pulse oximetry light absorption";
var content_f25_9_25758=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F80895&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F80895&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Principles of pulse oximetry: light absorption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 389px; height: 223px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This schematic diagram illustrates light absorption through living tissue. Note that the AC signal is due to the pulsatile component of arterial blood, while the DC signal is comprised of all the nonpulsatile absorbers in the tissue: nonpulsatile arterial blood, venous and capillary blood, and all other tissues.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Ohmeda Pulse Oximeter Model 3700 Service Manual, 1986, p. 22.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_9_25758=[""].join("\n");
var outline_f25_9_25758=null;
var title_f25_9_25759="Education at initial visit";
var content_f25_9_25759=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F56749%7EPULM%2F63828%7EPULM%2F75688%7EPULM%2F64430&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=24\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F56749%7EPULM%2F63828%7EPULM%2F75688%7EPULM%2F64430&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=24\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Delivery of asthma education by clinicians during patient care visits: recommendations for initial visit",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Assessment questions",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Focus on:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Concerns",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Quality of life",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Expectations",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Goals of treatment",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Ask relevant questions from previous visit and also ask:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            \"What worries you most about your asthma?\"",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            \"What do you want to accomplish at this visit?\"",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            \"What do you want to be able to do that you can't do now because of your asthma?\"",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            \"What do you expect from treatment?\"",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            \"What medications have you tried?\"",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            \"What other questions do you have for me today?\"",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Information",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Teach in simple language:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            What is asthma?",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            A chronic lung disease. The airways are very sensitive. They become inflamed and narrow; breathing becomes difficult.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            Asthma treatments: two types of medicines are needed:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Long-term control: medications that prevent symptoms, often by reducing inflammation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Quick relief: short-acting bronchodilator relaxes muscles around airways",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Bring all medications to every appointment.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td colspan=\"1\" rowspan=\"2\">",
"            When to seek medical advice. Provide appropriate telephone number.",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Skills",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Teach and demonstrate:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Inhaler and spacer/holding chamber use. Check performance.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            Self-monitoring skills that are tied to an action plan:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Recognize intensity and frequency of asthma symptoms",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Review the signs of deterioration and the need to reevaluate therapy:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            Waking at night with asthma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            Increased medication use",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            Decreased activity tolerance",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Use of a simple, written self-management plan",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Delivery of asthma education by clinicians during patient care visits: recommendations for first followup visit (two to four weeks or sooner as needed)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Assessment questions",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Focus on:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Concerns",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Quality of life",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Expectations",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Goals of treatment",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Ask relevant questions from previous visit and also ask:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\" colspan=\"1\" rowspan=\"1\">",
"            \"What medications are you taking?\"",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            \"How and when are you taking them?\"",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            \"What problems have you had using your medications?\"",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            \"Please show me how you use your inhaled medications?\"",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Information",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Teach or review in simple language:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Use two types of medications. Remind patient to bring all medications and the peak flow meter to every appointment for review.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Self-evaluation of progress in asthma control using symptoms and peak flow as a guide.",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Skills",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Teach or review and demonstrate:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Use of a daily self-management plan. Review and adjust as needed.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Use of an action plan. Review and adjust as needed.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Peak flow monitoring and daily diary recording.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Correct inhaler and spacer/holding chamber technique.",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Delivery of asthma education by clinicians during patient care visits: recommendations for second followup visit",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Assessment questions",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Focus on:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Expectations of visit",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Goals of treatment",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Medications",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Quality of life",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Ask relevant questions from previous visit and also ask:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            \"Have you noticed anything in your home, work, or school that makes your asthma worse?\"",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            \"Describe for me how you know when to call your doctor or go to the hospital for asthma care.\"",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            \"What questions do you have about the action plan?\" \"Can we make it easier?\"",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            \"Are your medications causing you any problems?\"",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Information",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Teach or review in simple language:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            Relevant environmental control/avoidance strategies:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            How to identify home, work, or school exposures that can cause or worsen asthma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            How to control house-dust mites, animal exposure if applicable",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            How to avoid cigarette smoke (active and passive)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Review all medications.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            Review and interpret from daily diary:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Peak flow measures",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Symptom scores",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Skills",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Teach or review and demonstrate:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Inhaler/spacer/holding chamber technique.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Peak flow monitoring technique.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Use of daily self-management plan. Review and adjust as needed.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\" rowspan=\"5\">",
"            Review use of action plan. Confirm that patient knows what to do if asthma gets worse.",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Delivery of asthma education by clinicians during patient care visits: recommendations for all subsequent visits",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Assessment questions",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Focus on:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Expectations of visit",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Goals of treatment",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Medications",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Quality of life",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Ask relevant questions from previous visit and also ask:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            \"How have you tried to control things that make your asthma worse?\"",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            \"Please show me how you use your inhaled medication.\"",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Information",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Teach or review in simple language:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            Review and reinforce all:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Educational messages",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Environmental control strategeis at home, work, or school",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Medications",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            Review and interpret from daily diary:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Peak flow measures",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Symptom scores",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Skills",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Teach or review and demonstrate:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Inhaler/spacer/holding chamber techique.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Peak flow monitoring technique.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Use of daily self-management plan. Review and adjust as needed.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Review use of action plan. Confirm that patient knows what to do if",
"asthma gets worse. Periodically review and adjust written action plan.",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_9_25759=[""].join("\n");
var outline_f25_9_25759=null;
